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Abstract 
Pancreatic ductal adenocarcinoma (PDAC) is the most common epithelial, exocrine 
pancreatic malignancy. Gemcitabine, as the only chemotherapy clinically available for 
pancreatic cancer, proves effective only in 23.8% of patients. Recently, iron oxide-gold 
hybrid nanoparticles (HNPs) have received significant attention in cancer therapy, which 
exploit the surface chemistry and SPR of the gold with magnetic character of the iron 
oxide, offering imaging, heating and drug delivery potentials.  
In this work HNPs were synthesised using a multi-step coating process of iron oxide cores. 
Particles were characterised by different techniques, in terms of their size, zeta potential, 
morphology and their magnetic properties. Laser irradiation on HNPs was used in order to 
obtain optimal temperature increase, needed for drug release. It is postulated that 
nanoparticulate irradiation at lower temperatures can trigger drug release from the surface 
of the vehicle before cellular hyperthermia was initiated. Different bisnaphtalamide based 
anticancer drugs were conjugated onto the surface of the HNPs. Drug loading, stability and 
drug release studies were carried out. A pancreatic cancer targeting peptide (c(RGDfC)) 
was conjugated to the formulations to increase drug specific delivery and anticancer 
activity. In vitro biological studies were performed on two pancreatic cancer cell lines and 
a human monocyte cell line. 
Hybrid formulations (specially targeted formulation) have shown higher cytotoxicity 
compared with free drugs and gemcitabine on pancreatic cancer cells. Drug uptake pattern 
was dose responsive and time dependant on all cell lines, and hybrid formulations 
internalised at significantly higher concentrations than the free drugs. AFM topography 
images were in agreement with cellular uptake. Moreover, HNPs possessed 
thermoresponsive drug delivery potentials in vitro. 
This is the first time these novel drugs were conjugated to iron oxide-gold HNPs, which 
demonstrated the interesting potential of these nanoparticles to act as thermoresponsive 
drug carriers.  
Key words: Iron oxide-gold nanoparticles, Pancreatic cancer, Thermoresponsive drug 
delivery 
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1.1. Cancer 
 
Cancer is described as one of the most hazardous class of disease categorised by 
uncontrolled cell growth (Stewart and Wild, 2014) and the third leading cause of death 
(after heart disease and stroke) in developed countries as well as the second leading cause 
of death (after heart disease) in the United States (ACS, 2014). Studies have revealed that 
there were about 8.2 million deaths and 14.1 million patients living with cancer worldwide 
in the year 2012 (World Cancer Report, 2014). This complex genetic disease has the 
potential to invade or spread through the bloodstream and lymphocytic system to other 
parts of the body. The incidence rate for all cancers was higher in developed countries 
compared to developing countries. Moreover, the most common causes of cancer related 
deaths in the world are lung, liver, bowl, breast, prostate and pancreatic cancer 
(ACS, 2011).  
  
1.1.1.  Pancreatic cancer 
 
Pancreatic cancer is the twelfth most common cancer worldwide (same position with 
kidney cancer) with 338,000 new cases diagnosed in 2012 (Ferlay et al. 2013). It is also 
the tenth most common cancer in the UK, where about 8,800 people were diagnosed with 
pancreatic cancer; equals 24 people every day (Cancer Research UK, 2014).  
Pancreatic cancer symptoms include pain in the upper or middle abdomen and back, 
jaundice, unexplained weight loss, loss of appetite and fatigue. Unfortunately, pancreatic 
cancer cannot be detected at early stages and most patients with localised disease have no 
detectable symptoms or signs. Therefore, it is not diagnosed until late stages, when cancer 
has metastasised to other organs. This leads to poor prognosis and incidence equalling 
mortality (5 years survival rate). Pancreatic cancer is highly related to the age and the peak 
incidence of the disease takes place between 65-75 year age group (Lankisch et al. 2002). 
This type of cancer is divided into two main groups: Exocrine tumours, which are 
associated with enzyme producing cell and endocrine tumours, for hormone producing 
cells such as insulin, glucagon and somatostatin. 
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Exocrine pancreatic cancer is the most common form of pancreatic cancer (95 %), which 
can occur anywhere along the length of the pancreas (Thompson, 1988). But endocrine 
tumours are very rare and they grow more slowly than exocrine tumours 
(Tomassetti et al. 2005). The risk factors for both types of pancreatic cancers are smoking, 
drinking alcohol, carcinogens and chronic pancreatitis. 
 
1.1.1.1. Pancreatic ductal adenocarcinoma (PDAC) 
 
Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent epithelial, exocrine 
pancreatic cancer, which shows for more than 80 % of the malignant neoplasms of the 
pancreas (Alexakis et al. 2004). It is developed from cells lining the ducts that carry the 
digestive juices into the main pancreatic duct and then on into the duodenum. Clinical 
research has revealed slight improvement in the median overall survival of patients since 
20 years ago (Lockhart et al. 2005). 
PDAC influences more developed countries than other parts of the world with more than 
8000 cases diagnosed in the UK each year (Keane et al. 2014). Patients who do not receive 
any treatment usually live for of 3-5 months and 6-10 months for locally advanced disease 
(O'Sullivan and Kocher, 2007).  Over the past decade, gemcitabine alone or combined with 
fluoropyrimidine, fluorouracil (5FU) or erlotinibis has been the only chemotherapy 
available clinically for pancreatic cancer (Walker and Ko, 2014). Gemcitabine is a 
nucleoside analogue that mimics physiological nucleosides in terms of uptake and 
metabolism and is incorporated into newly synthesised DNA resulting in synthesis 
inhibition and chain termination. Unfortunately, this chemotherapeutic agent proves 
effective in only 23.8 % of patients with the only alternative being surgical removal of the 
localised tumour (Figure 1) (Cunha et al. 2005).  
Like many solid tumours PDAC has mass transport properties which are different from 
normal tissues (Neesse et al. 2011). Many physical barriers may affect efficient PDAC 
drug delivery which results from numerous pathological features.  These barriers are leaky 
and disorganised with non-functional vasculature (Farrell et al. 2009), characteristically 
dense stroma (Neesse et al. 2011) and deregulated cellular transport proteins 
(Farrell et al. 2009). The permeable vasculature of PDAC may result in high interstitial 
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fluid pressure (Frieboes et al. 2011), which inhibits the transition of drug from the 
vasculature to the extracellular section. The extracellular section of PDAC is normally a 
dense stromal, called desmoplastic, which has been demonstrated to affect drug delivery 
and reaction to gemcitabine in preclinical models (Neesse et al. 2011). Thus, there is a 
need to increase the efficacy of this treatment as well as exploring alternative therapies. 
 
 
 
Figure 1. Diagram showing the area to be removed for pylorus preserving pancreatic 
duodenectomy (Cancer Research UK, 2012). 
 
1.2. Nanotechnology in medicine 
 
The concept of nanotechnology was first considered by Richard Feynman, in his 1959 
lecture. By saying “There's plenty of room at the bottom”, he defined the value of 
employing individual atoms using larger machines to creating smaller machines 
(Feynman, 1959).  
Nanotechnology is derived from the Greek word, which means dwarf or one billionth. This 
is one of the fastest growing technologies of our time and is a multidisciplinary field, 
which includes chemistry, engineering, biology and medicine.  Moreover, it has become a 
versatile and promising platform for creating novel materials with enhanced properties and 
potential applications in cancer therapy. This technology has revolutionised healthcare and 
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medical therapies. Nanoparticles (NPs) are commonly smaller than hundred nanometres in 
size; therefore, they can represent many interactions with biological molecules on the 
surface of the cells as well as inside the cells. 
This technology suggests the possibility for constructing smart therapies capable of 
targeting specific cancers. The particles themselves may possess multifunctional properties 
that can be used for early detection, accurate diagnosis and personalised treatment 
(Cai and Chen, 2007). Although progress of therapies is still in the early phases, the use of 
NPs is becoming prevalent in diagnostic applications and will probably involve all areas of 
medicine in the future for the treatment of certain diseases such as cancer. Research into 
NPs is in its infancy for liver, upper gastrointestinal and pancreatic cancers, and their use is 
becoming increasingly popular as contrast media for radiological researches (Andrén-
Sandberg, 2012). However, more advanced technologies capable of active targeting are 
still in the early phases of evaluation for clinical use and small fraction of NP-based 
therapies are in the clinic. 
Nanomedicine platforms suggest many advantages for sensing, delivery and 
image-targeting agents. The first study in cancer therapy by nanomedicine goes back to 
1974, when Gregoria et al.  prepared liposomes as drug carriers for the first time 
(Gregoria et al. 1974). The size, shape, structure and chemical properties of engineered 
NPs open a vast range of technical applications and novel approaches in medical research 
(Yang et al. 2009). 
In nanomedicine, the most widely researched NPs are quantum dots (Cai et al. 2007), 
carbon nanotubes (Liu et al. 2007), magnetic NPs (Thorek et al. 2006), liposomes 
(Park et al. 2004), gold NPs (Huang et al. 2011a), polymeric (Thompson et al.2008), lipid 
and silver NPs (Ferrari, 2005; Grodzinski et al. 2006). 
Quantum dots have been used in detection and biological labelling because of their 
size-dependent fluorescence properties (Bruchez et al. 1998; Chan and Nie, 1998; 
Lee, 2001). Magnetic NPs are useful in cell sorting (Liberti et al. 2001), MRI 
(Lawaczeck et al. 1997; Meyers et al. 1963; Schleich et al. 2014), drug delivery 
(Goodwin et al. 1999; Joubert, 1997; Koppolu et al. 2012) and magnetic hyperthermia 
therapy (Andra et al. 1999; Hilger et al. 2000; Kruse et al. 2014). Polymeric and lipid and 
NPs have been investigated to encapsulate therapeutic agents in order to enhance drug 
safety, solubility, and delivery efficiency due to the enhanced permeability and retention 
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(EPR) effect of the cancerous tissues (Farokhzad and Langer 2006; Moses et al. 2003). 
Carbon-based NPs have been exploited for photothermal therapy (Kam et al. 2005) and 
drug delivery (Bekyarova et al. 2005; Bianco et al. 2005; Lin et al. 2004).  
 
1.2.1. Metallic nanoparticles 
 
Metallic NPs have received great attention for over a century and are now extensively 
utilised in biomedical sciences (Conde et al. 2012; Hu et al. 2009; Lin et al. 2014). 
Metallic NPs have shown unique and unusual chemical, physical and biological properties 
due to their quantum size, in comparison with other NPs. This capability allows them to be 
used in a range of biomedical applications (Kogan et al. 2007). Metallic NPs can be simply 
synthesised with a high level of control of their shape, size and composition 
(Kawamura et al. 2013). Two simple methods, bottom-up and the top-down techniques, 
have been suggested for the fabrication of metal NPs. Top-down technique uses traditional 
methods to guide the synthesis of nanoscale materials. The paradigm proper of its 
definition generally shows that in the top-down method it all starts from bulk piece of 
material, which is then gradually or step-by-step removed to form objects in nano scale. 
This approach for nanofabrication is the one first suggested by Feynman (Feynman, 1959). 
However, top-down techniques for nanofabrication have critical limit in the ability to 
miniaturise components. Therefore, several bottom-up techniques have been used to 
synthesise nanostructures one atom at a time, in the most efficient and precise way possible 
(Pattekari et al. 2011).  
Metals such as nickel and cobalt are extremely magnetic but also highly cytotoxic, which 
limits their biomedical applications (Denkhaus and Salnikow, 2002; Haynes et al. 2000). 
On the other hand, iron oxide, gold and silver have a long history of safe clinical use.  
Because of their inherent instability, surface engineering of these particles before 
introduction into biological environments is highly demanded (Auffan et al. 2009; 
Häfeli et al. 2009). The specific attention of this thesis is on the use of iron oxide and gold 
metallic hybrid nanostructures. 
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1.2.2. Iron oxide metallic nanoparticles 
 
In recent years magnetic iron oxide NPs (MNPs) have attracted considerable attention of 
the researchers due to their vast biomedical applications from utilising in the recovery of 
metal ions and dyes to drug delivery, hyperthermia and imaging (Figure 2) 
(Comoucka et al. 2010; Neuberger et al. 2005). Studies have highlighted MNPs offer the 
benefit of utilising both EPR effect (passive targeting) whilst also allowing for a direct, 
externally guided delivery to the tumour (active targeting) (Arruebo et al. 2007). 
 
  
Figure 2. Schematic diagram showing biomedical applications of iron oxide nanoparticles. 
 
Magnetic separation of iron oxide NPs (with a single magnet instead of centrifugation or 
precipitation) is a rapid and advantageous method with high efficacy and cost-
effectiveness. Superparamagnetic properties of MNPs allow them to interact with 
numerous biological molecules in different ways. They also have large surface area to 
volume ratios (because of their nano-size), wide choice of surface functionalisation and 
low surface charge at physiological pH. However, they tend to aggregate in aqueous 
solution and biological systems due to their inherent magnetic nature. This unwanted 
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behaviour possibly reduces the long term stability of formulations and results in large 
nanoparticle clusters that are not acceptable for biomedical applications (Chan, 2007). 
Furthermore, it has been well documented that iron oxide may degrade into free ions in 
physiological environments (Stroh et al. 2004). This degradation can enhance the 
production of free radical in cells which leads to cell damaging and finally cell death 
(Hoskins et al. 2012a; Hoskins et al. 2012c; Minotti and Aust, 1987).  
In order to eliminate the potential of degradation of iron oxide NPs, they are usually coated 
with materials such as poly (acrylic acid) PAA (Mak and Chen, 2005), Dextran 
(Ciobanu et al. 2012) and poly (ethyleneimine) (PEI) (Wang et al. 2009) or coatings such 
as silica (Santra et al. 2001), carbon (Mendes et al. 2014) or precious metals (e.g. gold or 
silver) (Mandal et al. 2005). 
As mentioned above, in order to increase biocompatibility, impart colloidal stability and 
avoid to uptake by the reticuloendothelial system (RES), iron oxide NPs can be coated 
with polymers such as polyethylene glycol (PEG) and polyacrylamide. During systemic 
administration, a significant quantity of NPs are non-specifically cleared from the blood by 
the mononuclear phagocytic system (MPS) (the liver, spleen, and lymph nodes) and the 
efficiency of this process depends on NPs` size and surface chemistry. Therefore, HNPs 
composed of multiple nanocomponents must be engineered to exhibit a long residence time 
in the bloodstream if in vivo circulation is needed to be effective. The polymeric coating 
also allows for addition of functional ligands, such as radioactive ions for PET imaging 
and fluorophores for fluorescent imaging.  
Furthermore, this functionalisation and modification of MNPs may improve their magnetic 
properties and affect their behaviour in vivo (Gupta and Gupta 2005; Tartaj et al. 2003). 
MNPs have been extensively explored as contrast enhancement agents in magnetic 
resonance imaging (MRI) applications due to their capacity to increase the proton 
relaxation of specific tissue. Investigations are also underway utilising them in MRI 
induced cellular hyperthermia (Wabler et al. 2014); such phenomenon can be observed 
when these particles are placed inside an altering magnetic field resulting in rapid fluxing 
between polarised and relaxed states which leads to localised heating of the NPs. 
Additionally, MNPs have been exploited widely as a nanomedicine platform for the 
targeted delivery of therapeutic agent through magnetic drug delivery 
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(Neuberger et al. 2005) and via the attachment of high-affinity ligands (Zhang et al. 2002; 
Torchilin, 2006). 
However, recent studies have emerged detailing the flaws of such flexible coatings for long 
term application, whereby core exposure leads to free radical cellular damage 
(Hoskins et al. 2012a; Hoskins et al. 2012c). Recent investigations have shown toxicity 
and cellular fate of polymer coated iron oxide NPs. As a result, most of them such as 
Feridex IV
®
 and Luminex
®
, which were exploited as contrast agents in clinic, have been 
removed from use in humans. Currently, designing highly rigid coatings which make 
nano-sized formulations biocompatible and keep the unique contrast ability of their 
predecessors is being sought.  
The main concerns in chemically fabricated hybrid assemblies include the numerous 
synthesis steps that may produce a vast range of structures with ill-controlled 
configurations. For example, coating step may not achieve successfully in synthesis 
process and instead of producing uniform HNPs, many different NPs in shape and size 
may be fabricated. Another problem is lack of understanding about the details of particle 
formation. This might be due, to a large extent, to the lack of adequate techniques to 
precisely control the shell structures of HNPs (Prabhu and Hudson, 2009; 
Chen et al. 2009).  
 
1.2.2.1. Super paramagnetic iron oxide nanoparticles (SPIONs) 
 
Iron oxide NPs are usually divided in two main groups (in terms of their size): super 
paramagnetic and ferromagnetic NPs. Nearly all of investigations in nanomedicine are 
based on super paramagnetic NPs (Neuberger et al. 2005) but few studies have also 
emphasised the potential of ferromagnetic NPs (Kita et al. 2010). 
The term superparamagnetism is referred to a form of magnetism, which appears in small 
(20 nm or less) ferromagnetic or ferrimagnetic NPs. The concept of SPIONs magnetism is 
mentioned in the mid-1950 s for the first time (Bean, 1956), which explains the capability 
of a ferrimagnetic or ferromagnetic particle to be magnetised with an external magnetic 
field and to completely lose this magnetisation when the magnetic field is removed 
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(Dunlop, 1973; Bate, 1980). Then, in 1970s, Freeman and colleagues proposed the use of 
magnetism in biomedicine (Freeman et al. 1960).   
Super paramagnetic iron oxide nanoparticles (SPIONs) are small synthetic α-Fe2O3 
(hematite), γ-Fe2O3 (maghemite) or Fe3O4 (magnetite) particles with a core diameter 
between 10-20 nm. Among this group only maghemite and magnetite can be used for 
biomedical applications. Moreover, mixed oxides of iron with transition metal ions such as 
manganese, cobalt, copper and nickel have superparamagnetic characteristics and also 
included in the SPIONs category. SPIONs are biocompatible, biodegradable and facilely 
tunable with rapid removal through extravasation and renal clearance. They have been 
shown to have high suspensibility, well reactive surface, consistent particle size 
distribution, and the possibility of further modifications (Kemshead and Ugelstad, 1985).  
SPIONs have been utilised as targeted magnetic resonance contrast agents for MRI, with 
advanced progression in diagnosis of diseases such as cancer in their early stages 
(Amstad et al. 2009). The nonspecific uptake of SPIONs in the mononuclear phagocyte 
system (MPS) or reticuloendothelial system (RES) after administration made it feasible to 
use in clinical diagnostic of  many organs.  
In drug delivery, targeted cancer therapy, in order to deliver radio therapeutics and 
chemotherapeutics, is the one of most considered areas (Bae and Park, 2011; 
Moghimi et al. 2001). Nevertheless, photothermal ablation (cell death by using local 
hyperthermia) (Zhigilei et al. 2009), peptides (Zuo et al. 2014), antibodies (Pathak and 
Benita, 2012) and gene delivery (Cheong et al. 2009) by SPIONs have received increasing 
attention recently (Yen et al. 2013).  
Over the past three decades, the synthesis of SPIONs by different synthetic routes has been 
well documented. SPIONs can be fabricated by physical approaches such as mechanical 
grinding and bio-mineralisation processes or through chemical methods such as 
co-precipitation methods, thermal decomposition methods, micro emulsion methods, 
flame-assisted methods, hydrothermal syntheses, polyol methods, sol-gel syntheses, 
sono-chemical reactions, electrochemical methods, etc (Chaudhuri et al. 2012; Wahajuddin 
and Arora, 2012). Compared with the physical methods and the bio-mineralisation 
processes, chemical methods, especially co-precipitation technique, are common methods 
to make iron oxide NPs for MRI application. Because, they represent high potential in 
controlling fundamental parameters, such as, size, size distribution, phase purity and 
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degree of crystallinity in MRI applications. For example, in co-precipitation technique, the 
size of the particles can be adjusted by base concentration, temperature, and presence of 
surfactants (Levy et al. 2002). 
SPIONs are one of the few particles injected into the human body which are simply 
incorporated into the body`s natural metabolism. In general, SPIONs can be removed from 
circulation prematurely by two pathways, which are taking by the RES (> 200 nm) or via 
renal clearance system (< 5.5 nm). Therefore, particles between 10-100 nm in diameter 
exhibit the highest circulation time (Gupta and Gupta, 2005) as their small surface area 
(compared with large SPIONs) reduces the area accessible for adsorption of RES proteins 
and they are still large enough to avoid renal filtration.  
In order to create stealthy NPs, the chemical nature of the particles` surface must be 
considered. For example, in terms of RES uptake, some studies propose that for SPIONs 
with less than 40 nm in diameter, surface properties of the particles are more important 
than their size. While a surface with negative charge enhances the attachment of plasma 
proteins that results higher uptake, positively charged surface may allow the SPIONs to 
attach to cells in a non-specific behaviour (Wahajuddin and Arora, 2012). As a result, 
hydrophilic and neutral surface are more ideal to reduce opsonisation and clearance 
(Köseoğlu et al. 2002). It has been proposed that pinocytosis was the main mechanism of 
SPIONs internalisation with tumour cells as SPIONs drug uptake was not plateau 
(Zhang et al. 2009a). Plateau would be expected in the case of receptor mediated 
endocytosis due to the decreased availability of free receptors overtime.  
AmionSPARK
®
 and Feraheme
®
 are two clinically available form of iron oxide NPs, which 
have been chemically modified to present a specific function (Chen, 2010). 
AminoSPARK
®
 is NIR fluorescent NPs consist of an iron oxide core with a biocompatible, 
amine-functionalised surface suitable for further chemistry and conjugation to a variety of 
amine reactive molecules. So far it has been used in laboratory for animal research. 
Feraheme
®
 or ferumoxytol is used to treat iron deficiency anaemia in people with chronic 
kidney disease.  
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1.2.2.2. Ferromagnetic iron oxide nanoparticles 
 
Ferromagnetic iron oxide nanoparticles have potential in biomedical applications. Their 
particle size can be controlled and a vast range of size can be fabricated (from a few 
nanometres up to tens of nanometres). The small size of ferromagnetic iron oxide NPs 
proves that they can enter to the living cells. As with SPIONs, these NPs may be coated 
with biomolecules, which allow them to bind to or interact with other molecules for 
creating a controllable addressing or tagging tool (Pankhurst et al. 2003). Furthermore, 
ferromagnetic NPs are under Coulomb’s law, which indicates that they can be affected by 
external magnetic fields, where energy can be shifted from the exciting fields to the 
nanoparticle. As a result, ferromagnetic iron oxide NPs can be synthesised to resonantly 
react with a time-changing magnetic field. For example, particles can be prepared for 
heating purposes, which can be used as hyperthermia agents; transferring toxic amounts of 
thermal energy to desirable area such as tumours; or as radiotherapy and chemotherapy 
improvement agents, which applies moderate warming to be more efficient on cancer 
therapy.   
They also present greater magnetic potential than their SPION counterparts, which is 
desirable for external magnetic guidance and enhanced contrast-ability. Ferromagnetic iron 
oxide preparations, combined with MRI, have the potential to revolutionise a number of 
investigative and treatment procedures. This would be attained by the combination of the 
benefits delivered by iron oxide NPs together with MRI, which leads to superior and safer 
imaging alternatives (Gneveckow et al. 2005; Hilger et al. 2005; Rudolf et al. 2006).  
Ferromagnetic iron oxide NPs are usually fabricated by co-precipitation methods 
(Kandpal et al. 2014).  As same as SPIONs, their shape, size and crystallinity can be 
designed based on reaction conditions. Although SPIONs are less magnetic, they are still 
more preferred than ferromagnetic iron oxide NPs, which is related to the relative 
instability of ferromagnetic NPs and difficulties in suspending due to their aggregation. 
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1.2.2.3. Iron oxide for MRI 
 
Liver tumour was the first cancer clinically diagnosed by iron oxide imaging agent 
(Saini et al. 1987). Recently, multi-functional iron oxide NPs are considered to be used for 
measuring tumour volumes and improving the delineation of brain tumour boundaries 
(Mehdorn et al. 2011; Senft et al. 2010; Willems et al. 2006). There are several examples 
of SPIONs in experimental study or first phase of clinical trials (Vu-Quang et al. 2012; 
Wang et al. 2014a; Wang et al. 2014b). Many formulations have already been used in 
clinic for medical imaging and therapeutic applications. For example, Lumirem
®
 has been 
used for bowel imaging (Wang et al. 2001). Also, using Feridex IV
®
 for spleen and liver 
imaging (Bonnemain, 1998), Combidex
®
 for lymph node metastases imaging 
(Harisinghani et al. 2003), and Ferumoxytol
®
 for iron replacement therapy has been 
reported (Provenzano et al. 2009). Although designing this new class of diagnosing agents 
has been a huge achievement in modern nanomedicine, the theoretical models of iron oxide 
NPs and the electron structure of the complex compounds with diagnosing molecules are 
not well described. 
MRI has been used for in vivo cell tracking due to its great spatial resolution. This can be 
achieved by changing the proton relaxation time, when hydrogen protons align and come 
back to their initial state. MR image is generated by two independent processes, longitude 
relaxation (T1 recovery) and transverse relaxation (T2 decay). SPIONs can change the 
relaxation time extensively through transferring their magnetic relaxation to the 
surrounding nuclei. As a result, significant delay of the signals between contrasted and 
non-contrasted areas can be monitored (Figure 3).  
Investigations are also underway utilising SPIONs in clinic to visualise cell migration, in 
order to monitor cellular therapies with MRI. The detection threshold for SPION-labelled 
cells is affected by magnetic field strength and acquisition parameters. One of the problems 
using MRI is that it needs high concentrations of contrast agents due to its low sensitivity. 
A high concentration of iron oxide enhances toxicity, which is highly concerned in 
biomedical applications. Fabricating aggregated particles may be an alternative method to 
enhance the sensitivity. Aggregated forms have stronger magnetic field, thus high 
concentration of iron oxide NPs is not necessarily needed (Bystrejewski et al. 2007).  
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Figure 3. Standard MR image of a healthy canine brain by T2 imaging agent presenting difference 
in contrast between various areas (Malekigorji et al. 2014). 
 
In an interesting study, Wu and co-workers explored MR imaging of human pancreatic 
cancer xenograft labelled with SPIONs in nude mice (Wu et al. 2012). Tumour xenografts 
were induced in nude mice through the injection of human pancreatic cancer cells labelled 
with SPIONs. The unlabelled cancer cells served as a control. MR imaging was achieved 
by a 1.5 T MR scanner for the tumour xenograft at the first, second and third week after the 
injection. They revealed that the tumour xenograft was induced in 100 % nude mice on 
MR imaging for both groups in the first week after the injection. In the SPION category, 
the tumours presented homogeneous hypo intensity on T₁ - and T₂ -weighted and FIESTA 
images 1 week after injection. Two and three weeks after injection, the centre of the 
tumours was still hypo intense on all the above sequences. The tumour periphery is intense 
on T₁ -weighted, and hyper intense on T₂ -weighted and FIESTA images. The tumours in 
the control group were homogeneously hypo intense or is intense on T₁ -weighted, and 
hyper intense on T₂ -weighted and FIESTA images in the first, second and third week after 
the injection. The signal to-noise ratio and size of the tumour centre in the group injected 
with the SPIONs decreased in all T₁ - and T₂ -weighted images and FIESTA. These 
outcomes emphasise that human pancreatic cancer cells labelled with SPIONs can induce 
tumour xenograft in nude mice and MRI can display the kinetics of SPIONs distribution in 
tumour xenografts (Wu et al. 2012). 
15 
 
1.2.2.4. Iron oxide for magnetic hyperthermia 
 
Magnetic thermotherapy of cancers is a fourth treatment technique, after surgery, 
radiotherapy, and chemotherapy in the world. This novel technique can be utilised on its 
own or in combination with chemotherapy and/or radiotherapy. Iron oxide NPs have the 
capacity to produce heat when exposed to strong magnetic fields (Rosensweig, 2002); the 
magnetic moments of the iron oxide NPs completely or partially align in the direction of 
the field, upon usage of an electromagnetic field. At a unique frequency to the NPs, the 
magnetic moments delay behind the field can cause a delay in the magnetic response. 
Therefore, the magnetic moments do not follow the same line throughout the reversal of 
orientation of the used magnetic field. A hysteresis loop is produced that is evident when 
the reversal is hindered and related energy loss is dissipated in the form of heat energy 
(Figure 4).  
Magnetic moment can alter unsystematically in single domain materials through thermal 
fluctuation at high temperatures. But the thermal energy is decreased at lower temperatures 
leading to a blocking of the magnetic moments. This is identified as the blocking 
temperature which is related to the shape and size of NP. Small NPs have smaller volumes, 
thus they represent a lower energy barrier and lower blocking temperature. Magnetic 
crystal suspensions of iron oxide NPs deposit the energy of alternating magnetic fields and 
release this energy as heat, which triggers hyperthermic stress in cancer cells 
(Kossatz et al. 2014). In targeted magnetic hyperthermia treatment of cancers, MNPs act as 
thermal seeds under an alternating magnetic field (Figure 5) (Gneveckow et al. 2005; 
Hergt et al. 2006; Hilger et al. 2005). Increasing temperature more than 40 °C improves 
the radiation effect and causes thermoablation of the cancer cells. This heating is supposed 
to induce enhanced vibrational, translational and rotational motion of molecules in the 
cells. Moreover, heating has the ability to increase metabolism and transition (structural 
transformation from an ordered to a disordered state) of cellular structures, such as 
proteins, DNA and RNA (Hilger and Kaiser, 2012).  
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Figure 4. Hysteresis loop of iron oxide NPs. The area of the hysteresis loop represents the energy 
dissipated during a magnetisation cycle (Hervault and Thanh, 2014). 
 
 
 
Figure 5.  Schematic illustration of hyperthermia treatment of cancers inside an altering magnetic 
field. 
 
Recently, Kossatz et al. studied the therapeutic outcomes of magnetic hyperthermia 
therapy with SPIONs on pancreatic cancer (BxPC-3) xenografts in mice in vivo. Iron oxide 
NPs were injected into the pancreatic tumour before applying cumulative heating to 43 ˚C. 
Histological study of magnetic hyperthermia treated tumour tissue revealed changes in cell 
viability (apoptosis and necrosis) and demonstrated a reduced cell proliferation, in 
MNPs 
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comparison with the control cells. This study emphasises the capability of iron oxide NPs 
for magnetic hyperthermia application in pancreatic cancer therapy (Kossatz et al. 2014).   
In another interesting piece of research, Basel and co-workers injected MNPs into mouse 
monocyte macrophage like (RAW264.7) cells. These cells are well-known for their tumour 
homing activity. In order to develop a murine xenograft model of disseminated peritoneal 
pancreatic cancer, they injected Pan 02 cells intraperitoneally (IP). After tumour growth, 
monocyte/macrophage like cells (loaded with MNPs) were injected IP and let to transfer 
into the tumour. After three days, the mice were located in an alternating magnetic field for 
20 min to induce hyperthermia. This treatment procedure was performed three times. A 
survival study showed that this treatment considerably enhanced survival in this murine 
pancreatic cancer model and the average post-tumour insertion life expectancy improved to 
31 %. Therefore, this technology is really promising method in actively delivering NPs for 
local hyperthermia therapy of cancer (Basel et al. 2012). 
However, there are still inconsistencies between experimental results and predictions of the 
amount of heat produced by the MNPs based on the current simple models, which has been 
a main problem to optimise the design of magnetic particles for clinical application 
(Manfred et al. 2010). 
 
1.2.2.5. Iron oxide nanoparticles as vehicles for chemotherapy 
 
Iron oxide NPs have been highly studied for their potential as drug delivery means for 
chemotherapeutic applications (Hedgire et al. 2014; Jain et al. 2005; Yallapu et al. 2013). 
Incorporating cytotoxic agents with NPs has shown to passively target pancreatic 
adenocarcinomas and enhance drug efficacy (Hoskins et al. 2010). This is supposed to be 
due to the accumulation of drug by EPR effect, which leads to deeper tissue penetration. 
This localised delivery, in combination with the rapid diagnosis and treatment leads to an 
interesting approach with excellent potentials to act as a selective treatment with lowered 
dosages, therefore reducing side effects and improves clinical results for patients suffering 
from pancreatic cancer. 
Therapeutic agents, such as drugs, proteins, peptides and nucleic acids, can be incorporated 
in the iron oxide NPs by either conjugating on the surface of particles or trapping within 
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the NPs themselves. Many chemical strategies have been used for the conjugation of 
targeting, therapeutic and imaging agents with NPs surfaces. These can be categorised into 
covalent linkage methods, such as direct NP conjugation, covalent linker chemistry 
(conjugation of biomolecules to the surface of NPs by a linker) and click chemistry 
(biocompatible reactions intended primarily to join substrates of choice with specific 
biomolecules); and physical interactions, which are electrostatic, hydrophilic/hydrophobic 
interactions (forces between molecules or atomic groups do not arise from a covalent 
bond). Functional groups of the NPs` coating, ligands and physicochemical properties of 
them can directly affect the choice of chemistry. The main goal is to incorporate the 
therapeutic, targeting or imaging agent without changing its functionality. Functionality in 
such formulations is imposed by the nature of the ligand (e.g. conformation of 
biomolecules) and the method by which it is conjugated. For example, if an antibody is 
attached to the NPs` surface but its detection site is covered by proteins, it may lose its 
ability to bind or reach to its site of action. Surface modification of NPs with 
biocompatible materials such as polyethylene glycol (PEG) can reduce the adsorption of 
plasma proteins and avoid the formation of protein corona (Gref et al. 2000).  
The surface of iron oxide NPs has been amended with anticancer drugs such as 
doxorubicin (Dox) (Kievit et al. 2011), Catechin-dextran (Vittorio et al. 2014) and 
Paclitaxel (Hwu et al. 2009). Catechin-dextran conjugated Endorem NPs (dextran coated 
iron oxide NPs) enhance the intracellular concentration of the drug, in comparison with the 
drug alone. Inside a magnetic field, this nano-sized formulation caused apoptosis in 98 % 
of human pancreatic cancer cell line (MIA PaCa-2). The authors proposed that the 
attachment of catechin-dextran with Endorem improves the anticancer activity of the drug 
and offers a novel way of targeted drug delivery to cancerous cells with the help of 
magnetic fields in vitro. It is suggested that this remote control drug delivery of the 
catechin-dextran by a magnetic field makes it a potential agent in cancer therapy 
(Vittorio et al. 2014). 
Sometimes the surface of iron oxide NPs, as a chemotherapeutic carrier, contains a 
targeting ligand that can find the receptors overexpressed on the external surface of tumour 
cells (Kievit and Zhang, 2011). As an example, Lee et al. (Lee et al. 2013) fabricated 
urokinase plasminogen activator receptor (uPAR)-targeted magnetic iron oxide NPs 
delivering gemcitabine as a chemotherapeutic agent for targeted delivery into 
uPAR-expressing tumour and stromal cells. This novel assembly was designed by grafting 
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iron oxide NPs with the amino-terminal fragment peptide of the receptor-binding domain 
of uPA (naturally occurring ligand of gemcitabine and uPAR, through a lysosomal 
cleavable tetrapeptide linker). These multifunctional NPs were synthesised not only to 
induce intracellular release of gemcitabine following receptor-mediated endocytosis into 
cancer cells, but also to offer contrast enhancement property in MRI of cancers. The data 
confirmed the lysosomal enzyme- and pH-dependent release of gemcitabine, which 
preserves the drug from enzymatic degradation and offering imaging capability. 
 
1.2.3.  Gold Nanoparticles  
 
Among the category of metallic NPs, gold NPs (AuNPs) deserve close examination and 
discussion due to their biocompatibility, non-toxic properties, simple and fast preparation, 
ease of bioconjugation, physical, chemical, optical and electronic properties and the 
increasing number of publications in the literature for medical applications, from imaging 
and diagnosing to drug delivery and photothermal therapy (Li et al. 2010; 
Mikami et al. 2013).  
There are many sub-types of AuNPs based on the size, shape, and physical properties, such 
as nanosphere, nanoshells, nanocages and nanorods (Figure 6). Each type has its own 
unique physical properties. The specific architecture is determined the synthetic route and 
chemical precursors used. The earliest studies of gold nanoparticles go back to gold 
nanospheres (although not exactly spherical in a strict sense) (Zsigmondy, 1926).  
 
 
 
 
 
Figure 6. Schematic illustration of different types of gold nanoparticle.  
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Gold nanospheres between 2 nm and 100 nm in diameter can be synthesised by wet 
chemical method, which is controlled reduction of an aqueous chloroauric acid (HAuCl4) 
solution with different reducing agents under varying conditions (Cai et al. 2008). Particles 
around 2 nm in diameter demonstrate distinctive chemical and physical properties, with 
interesting biomedical applications (Qian et al. 2008). AuNPs have been investigated for 
imaging (Zhang et al. 2009b), cancer therapy (Jain et al. 2012), and drug delivery 
(khan et al. 2014) in recent years. They also have been used for photothermal therapy and 
tumour ablation as one of the hottest areas (diagnosis, surgery and medicine) in current 
research due their enhanced optical properties (Iancu, 2013) (Figure 7). The capability to 
react as nanoheaters makes these particles  potential agents in theranostics, which was 
presented by Loo et al. for the first time (for gold nanoshells) (Loo et al. 2004), 
Lapotko et al. (for gold nanospheres) (Lapotko et al. 2006), and Hleb et al. (for gold 
nanorods) (Hleb et al. 2008).   
 
 
 
               
 
Figure 7. Applications of gold nanoparticles.  
 
Multiple studies have highlighted AuNPs use as surface-enhanced Raman Scattering 
(SERS) substrates to investigate components in living cells (Li et al. 2014; 
Quaresma et al. 2014). In surface-enhanced Raman scattering (SERS), the Raman signals 
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can be enhanced by many orders of magnitude when the probed molecules are attached or 
in very close vicinity to noble metal nanostructures with their high local optical fields. 
SERS spectroscopy can offer the local chemical composition of biomolecules at very low 
concentrations, and detect the slight changes of the structure at sub-cellular level. 
Moreover, SERS spectroscopy can be exploited in physiological environment without 
fixation. AuNPs are able to evaluate the interaction of many chemotherapeutic agents with 
their pharmacological destinations, such as DNA, within living cancer cells (Alliain and 
Vo-Dinh, 2002; Alliain et al. 2002; Culha et al. 2003). Other studies contain cancer gene 
detection (Rivera et al. 2010) and cancer protein biomarker detection (Kosaka et al. 2014).  
In addition to good synthetic control, gold is extremely biocompatible. This means that it 
does little to no harm when coming into contact with the human organism. In vitro studies 
suggest that AuNPs do not cause cytotoxicity in human cells (Mie, 1908). This study 
iterates the findings of many other studies previously described. Thus, Medical devices 
such as insulin pumps and peacemakers use gold because of both biocompatibility and 
reliability in electronic devices.  
 
1.2.3.1. Light-scattering of gold nanoparticles 
 
Recent medical applications of colloidal gold, particularly cancer diagnostics and 
photothermal therapy, have initiated generally from their intensely enhanced optical 
properties. When particles are exposed to light, many processes can happen: the incoming 
light might be adsorbed and/or scattered at the same frequency as the incoming light (Mie 
scattering (scattering of an electromagnetic plane wave by a homogeneous sphere) or 
Rayleigh scattering (elastic scattering of light by particles that is much smaller than the 
wavelength of the radiation)), the adsorbed light might be re-emitted (i.e., fluorescence) or 
the local electromagnetic field of the incoming light can be enhanced; thus increasing any 
spectroscopic signals from the molecules at the surface of particles, which is called 
surface-enhanced spectroscopy; such as surface-enhanced Raman scattering (Mie, 1908). 
For AuNPs, all these processes are powerfully enhanced due to the unique interaction of 
light with the free electrons in the metal particles. When AuNPs are irradiated, conduction-
band electrons at the surface of the particle start to oscillate due to the electron field of the 
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light (Sokolov et al. 2003). This coherent oscillation of the metal free electrons in 
resonance with the electromagnetic field is called the surface plasmon resonance (SPR). 
The SPR absorption related to the dielectric constant of the metal, the particle shape and 
size and the surrounding medium (Jensen et al. 1999). For small particles (< 25 nm), the 
absorption cross-section directly depends on the particle size and can be measured by Mie 
theory (Mie, 1908). SPR applications include evaluation of macromolecules in biological 
environments, equilibrium measurements (affinity and enthalpy), kinetic measurements 
and analysis of mutant proteins. 
For AuNPs, the resonance takes place in the visible spectral area at around 520 nm, which 
is confirmed by the deep red colour of the NPs in solution. The high-scattering 
cross-section of AuNPs, with their high photostability (comparing with organic dyes), 
create a powerful tool for imaging guided drug delivery systems. The use of this 
light-scattering property for cellular imaging, particularly cancer imaging, has progressed 
recently (Gu et al. 2015; Ilovitsh et al. 2015).  
AuNPs are used in optical labelling of the cancer biomarkers due to the strong scattering of 
them. Gold NPs of 30-100 nm diameters scatter strongly and can be distinguished easily by 
eye. Also the scattering from a gold nanoparticle (60 nm) is much higher than the emission 
of a fluorescence molecule (Jain et al. 2006). The drawback of light-scattering imaging is 
the interfering of scattered light from tissue (Huang et al. 2011a). Therefore, for highly 
scattering tissue using fluorescence-based imaging techniques can be helpful. While 
clinical investigations of MNPs have presented great potential in imaging, the use of 
AuNPs in light-scattering imaging or photon luminescence imaging is still in the first stage 
in the laboratories. Moreover, the light scattering imaging using AuNPs is simple 
(a conventional light microscope prepared with a dark field condenser is the only tool 
needed for the gold imaging system), in comparison with the requirements of MRI.  
 
1.2.3.2. Tumour ablation using gold nanoparticles 
 
To kill cancerous cells, researchers have focussed on exploiting the SPR effect of AuNPs 
as an alternative method to standard surgical therapies (especially for patients with 
contraindications), which results in cellular hyperthermia leading to tumour ablation 
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(Kodiha et al. 2015; Lee et al. 2014). The advantages of using thermal ablation are 
reduced morbidity and mortality compared with standard surgical resection and the ability 
to treat nonsurgical patients.  
Photothermal ablation is a minimally invasive therapy, where a focussed laser beam of a 
specific wavelength (relating to the SPR of the NPs) is irradiated onto the nanoparticulates. 
Photothermal sensitizers are able to convert the adsorbed light from laser irradiation into 
heat. Therefore, NPs experience temperature increase (above 42 °C), which can be used to 
cause irreversible damage to the carcinoma. 
Gold holds great potential as a pivotal material key to fighting cancer in future smart 
therapies. For light scattering and absorption it has been well documented that gold 
nanoshells and nanocages are preferential in biomedical application due to their SPR 
occurring at highly red-shifted wavelengths within the biological near infrared window. 
This window is a narrow range of wavelengths where light is highly transmittable through 
biological tissue. Hence, this leads to a highly localised therapy which causes minimal 
trauma to healthy tissue (Fiedler et al. 2001; Vogl et al. 2004; Weissleder et al. 2001). 
Pitsilldes et al. first explained in 2003 the application of gold nanoparticle for 
photothermal therapy of lymphocytes in vitro using immunoconjugates coupled with a 
nanosecond Nd (Pitsillides et al. 2003). In this study laser induced solvent bubbles around 
the particles produced enough mechanical stress to cause cell death. Zharov and colleagues 
subsequently proposed the factors that influence the killing energy (thermal energy which 
causes cell death), for example particle size and the number of pulses per second, as well 
as the dynamics of the thermal events around the particles. These factors are crucial in 
order to realise the killing efficiency and mechanism involved. Additionally, nanorods 
(when the shape of gold NPs change from spheres to rods) (Popp et al. 2014), nanoshells 
(composed of a silica core around 100 nm and a thin shell of gold) (Gao et al. 2015), and 
nanocages (a type of hollow and porous gold nanostructures, which are formed by a 
galvanic replacement reaction between silver nanocubes and auric acid in aqueous 
solution) (Kessentini and Barchiesi, 2013) (Figure 6) have all been reported to be used as a 
nanoheater in biomedicine.  
Puvanakrishnan demonstrated the feasibility of using the real-time narrow band imaging 
system of AuNPs to image breast and pancreatic tumour margins, intraoperatively. He also 
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showed the feasibility of performing image-guided therapy of pancreatic tumour margins, 
potentially guiding photo-thermal ablation of tumours (Puvanakrishnan, 2011). 
In another study, Glazer et al. demonstrated a new cancer therapy by applying intracellular 
hyperthermia of AuNPs in a radio frequency field. This therapy is based on the specificity 
of the targeting antibody. Despite systemic treatment and whole-body radio frequency field 
exposure, healthy tissues were without toxicity. Pancreatic cancer cells showed higher 
apoptosis and cell viability reduced after treatment with cetuximab-conjugated AuNPs and 
radio frequency field exposure (Glazer et al. 2010). 
 
1.2.3.3. Gold nanoparticles in drug delivery 
 
AuNPs can be exploited to deliver drugs and imaging agents that have poor 
pharmacokinetics (Kim et al. 2009; Zhang et al. 2011). These nanoparticulates are able to 
deliver compounds, which are susceptible to enzymatic degradation, such as vaccines as 
well as those that have low intracellular penetration, for example siRNA (Lee et al. 2011b; 
Lu et al. 2010). AuNPs have the potential to be functionalised by active ligands, due to 
their large surface area, at densities (1.0 × 10
6
 µm
−2
) (Bard and Faulkner, 2001), which are 
100 times higher than that achievable with conventional liposomes (Torchilin et al. 2001). 
This property allows the researchers to optimise AuNPs binding affinity for a specific 
disease type, stage or patient. Gold nanostructures can also engage multiple, adjacent 
receptor sites, due to their comparability in size to the distances between cell-surface 
targets, resulting higher selectivity in their uptake (Jiang et al. 2008).  
Receptor mediated endocytosis (RME) has been proposed as the primary mechanism of 
AuNPs cellular entry (Shukla et al. 2005).  AuNPs in around 1 nm in size can cross the cell 
membrane and nucleus to interact with DNA. In contrast, particles between 20-50 nm 
show excellent penetration in to cells without any cytotoxic effect (Gao et al. 2011). 
Due to the optical and electronic properties of AuNPs, these particles recently have been 
used in thermorespomsive drug delivery as they can produce enough heat upon laser 
irradiation, which can be applied as a trigger for therapeutic agents to be released in their 
site of action (Dreaden et al, 2011) (Figure 8).  
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Figure 8. Laser driven anticancer drug delivery based on gold nanoparticles (Dong et al. 2013). 
 
AuNPs can conjugate to other molecules by physical (electrostatic) interactions 
(Rayavarapu et al. 2007) and covalent interactions. The nature of AuNPs surface chemistry 
can help for easy and controlled attachment of different molecules particularly those with 
thiol functionalities (Lee et al. 2010). Moreover, conjugation with proteins (Aubin-Tam, 
2013), carboxylic acid (DeLong et al. 2010) aptamers (Zhang et al. 2013) and disulfides 
(Letsinger et al. 2000) have been also reported.  
 
1.3. Hybrid nanoparticles 
 
Hybrid NPs (HNPs) consist of two or more types of material, such as liposomes, quantum 
dots, metals, mesoporous silica and polymers. In general, the term “hybrid” mostly used if 
the inorganic units are in situ by using sol-gel chemistry. The introduction of multifaceted 
hybrid system has the potential to improve upon the biocompatibility and stability 
encapsulation efficiency of non-hybrid system. For example, polymer-lipid HNPs have 
been demonstrated to enhance size or suspension stability of NPs in biological 
environments by controlling the molar ratio between lipid and polymer components 
(Wang et al. 2013). Moreover, it has been well demonstrated that by coating the surface of 
quantum dots with a lipid layer, biocompatibility was increased (Wang et al. 2012).  By 
using this technology both organic and inorganic phases are formed together through the 
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simultaneous polymerisation of organic monomer and sol-gel precursors of the inorganic 
domains (Ochi and Takahashi, 2001).  
Depending on the strength or level of interactions, two types of hybrid materials can be 
classified. Type 1, “non-covalent” hybrid materials, develop weak interactions between the 
two phases (organic and inorganic phases consist of interactions due to van der Waals, 
electrostatic and hydrogen bonding forces), whereas, type 2 hybrid materials show strong 
chemical interaction between the two materials phases to increase the phase coupling. The 
structural components of the HNPs are mainly classified based on the therapeutic function 
they deliver. For example, structural nano components such as polymers, liposome, 
mesoporous silica, micelle or viruses can mainly carry a drug cargo, while structural 
nanocomponent such as a gold nanoparticle or a carbon nanotube are useful for 
photoablation therapy (Sailor and Park, 2012).  
Controlled drug release from hybrid nanostructure is the next challenge after encapsulating 
or conjugating the imaging and therapeutic agents onto the hybrid structure. It has been 
well documented that degradation and diffusion are the key factors for drug release process 
(Morales et al. 2012).  
Hybrid nanostructures (NPs which consist of two or more types of material) can eliminate 
some of the problems required to overcome multidrug resistance due to their 
multi-functionality. Typically, by adding different functional ligands to a single module 
one can tackle a problem from different angles at the same time. For example, Zhang and 
colleagues fabricated novel nanostructured lipid-dextran sulfate hybrid carriers (NLDCs) 
for sustained delivery of water-soluble cationic mitoxantrone hydrochloride (MTO) and 
overcoming multidrug resistance. In vivo pharmacokinetics in rats after intravenous 
administration showed that MTO-loaded NLDCs (MTO-NLDCs) had longer half-life than 
free MTO. In the biodistribution study, NLDCs significantly improved the MTO levels in 
plasma, spleen, and brain, and reduced the distribution of MTO in heart and kidney. In 
comparison with free drug, MTO-NLDCs efficiently increased cytotoxicity through the 
higher accumulation of the drug in breast cancer resistance protein (BCRP)-overexpressing 
MCF-7/MX cells. MTO-NLDCs accumulated into the resistant cancer cells by the 
clathrin-mediated endocytosis pathway, which escaped the efflux induced by BCRP 
transporter and thereby overcame the multidrug resistance of MCF-7/MX cells 
(Zhang et al. 2012). 
27 
 
The idea of encapsulating imaging agents and susceptible drugs in order to avoid 
premature metabolism has been the focus of many investigations (Morales et al. 2012; 
Zhang et al. 2008). NPs that carry biomolecules as a cargo can release their payloads if 
they became unprotected. The release of imaging agent can be triggered by enzymatic 
degradation, changing the pH and temperature at the designated area.   
The potential of HNPs to transport more than one SPION makes them easier to be seen by 
MRI, which leads to earlier detection of smaller tumours. The fact that this type of drug 
delivery vehicle can transfer very different cargos such as a fluorescence NP, a magnetic 
NP, quantum dot, and a small drug is really promising for the future of drug delivery. 
 
1.4. Nanoparticles in biological environment 
 
The suspension stability (dispersion ability of particulate solid to remain in a liquid matrix 
solution indefinitely) of NPs in physiological environment is one of the most crucial issues 
for their usage in biomedicine. This depends on the chemical and physical structure of the 
NPs and the surface charge of the particles.  
In a complex environment NPs aggregation is a common phenomenon, which usually 
results in irreversible inter-particular adherence and leads to the formation of large and 
irregularly shaped clusters (Rausch et al. 2010). Therefore, understanding the factors that 
affect NPs colloidal stability and aggregation when introduced into biological environment 
is crucial to design safe and effective formulations for clinical use. NPs colloidal stability 
will control their pharmacokinetics, bio-distribution, and systemic toxicity in vivo 
(Nel et al. 2006). As an example, Aoki and co-workers revealed in an in vivo toxicity 
experiment that the cause of morbidity of Wistar rats administered at high doses 
intravenously nano-hydroxyapatite was NPs aggregation and subsequent capillary 
blockage in the lungs (Aoki et al. 2000). Moreover, researcher have revealed that NPs 
which are stable in blood have a prolonged circulation half-life in the body, and are less 
likely to be rapidly cleared by the body’s reticuloendothelial system (RES) 
(Gref et al. 2000). Therefore, a fundamental understanding of NPs aggregation is required 
to rationally design NPs whereby it can be understood how they may behave at molecular, 
cellular, and systemic levels within biological systems. 
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Surface modification of NPs is one of the most preferred methods to improve colloidal 
stability (Albanese and Chan, 2011). Thus, it is important to have a good understanding of 
the mechanisms governing NP stability, and to apply these methodologies in biomedical 
applications. Modification techniques designed to improve colloidal stability in complex 
biological environments are electrostatic, steric, or electrosteric stabilisation 
(Jiang et al. 2010). 
While characterisations of NPs such as surface area, surface charge and crystallinity have 
been increasingly investigated (Rivera et al. 2010), a deep recognition of the basic 
mechanisms such as interactions between NPs and proteins and their colloidal reaction in 
different physiological media is required (Warheit et al. 2008). When NPs enter into the 
biological environment, proteins and other biological molecules compete to attach to the 
surface of particles, which results in the creation of a protein corona (Figure 9). This 
phenomenon significantly describes the biological characteristics of the NPs and covering 
its original surface properties. The biophysical properties of this complex can be different 
from original formulated NPs. As a result, the biological properties and bio- distribution of 
the NPs are critically affected by the particle-protein complexes.  
 
 
 
 
 
 
 
 
Figure 9. Schematic illustration of protein corona (NPs-Protein complex) created around an iron 
oxide nanoparticle in biological environment. 
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1.5. Theranostics in nanomedicine 
 
The term “theranostics” used for first time in the literature in 2002 (Funkhouser, 2002). 
Theranostics combines diagnosis of disease with the therapeutic capability to treat the 
disease in one platform. This dual therapy could potentially lead to reduced treatments 
times and better patient prognosis (Sumer and Gao, 2009).  
This novel technology is mainly used in cancer therapy and nanomedicine. In cancer 
therapy, it is important to detect and treat the tumour before it expands into different part 
of the organism, as well as image the tumour before, during and after treatment. Since 
theranostics combines two separate functions, diagnosis and therapy, it is necessary to have 
sufficient accumulation of agent within the diseased area. This can be achieved via EPR 
effect, which is first termed by Matsumura and Maeda in 1986 (Matsumura and Maeda, 
1986), resulting in deeper drug penetration (Figure 10). This is associated with the 
damaged and leaky tumour vasculature due to the rapid angiogenesis related to tumour 
growth. Inside the tumour, the particles are hindered from returning to systemic blood 
circulation due to the poorly developed lymphatic drainage system presented by most 
tumours. Additionally, the use of targeting ligands has been studied to increase the 
accumulation of the NPs in the tumour tissue (Yu et al. 2012).  
 
 
 
 
Figure 10. Schematic diagram of the enhanced permeability and retention effect. 
 
In drug delivery technique the size of NPs plays an important role, which has to be large 
enough to avoid filtration via kidneys and small enough to prevent the capture by the liver 
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and spleen (Moghimi et al. 2001). NPs less than 100 nm in size can enter into the highly 
permeable blood capillaries which provided by the rapidly growing tumours (EPR effect) 
(Barenholz, 2012). This however does not happen in healthy tissue as the blood vessels are 
well developed and nonporous. Moreover, formulation with suitable NPs may increase 
physicochemical properties such as aqueous solubility, which can enhance therapeutic 
efficiency. 
Nano-sized formulations of chemotherapeutic drugs have demonstrated to passively target 
pancreatic adenocarcinomas and increased drug efficacy (Yoshida et al. 2012). This is 
related to the accumulation by EPR effect, which leads to deeper drug penetration. One 
potential problem of using the EPR effect to target tumour is that macromolecule have 
accumulated in inflamed areas in a similar trend which is undesirable for cancer drug 
delivery (Vasir et al. 2008). Many different nanoparticulates have been used for 
theranosthic purposes, which are summarised in Table 1. Some NPs such as AuNPs, MNPs 
or carbon nanotubes have inherent diagnostic/therapeutic properties.  
Targeted drug delivery is more advantageous than conventional drug therapy as in targeted 
drug delivery only a desirable area in the body is affected, which can minimise the side 
effects caused by conventional drug therapy. The purpose of drug chemotherapy is to 
transport a drug to the targeted area and treat the disease without affecting surrounding 
healthy tissue. Strong carrier-drug interactions might enhance the loading capacity and 
reduce the release rate of drug from the carrier; thus, choosing proper carrier-drug 
interactions is critical in design and preparation of nanocarriers for drug delivery. 
A successful drug delivery carrier protects the drug from degradation or metabolism transit 
in the physiological environment. It is also essential to minimise the rate of drug release 
during transportation. Upon reaching the tumour tissue and entering the diseased cell, the 
system should release its payload quickly; thus promoting cell mortality. After delivering 
the drug at the target site, the carrier needs to be easy expelled from the body. Toxicity 
must be considered and reduced to avoid adverse effects in the organism 
(Poste and Kirsh, 1983).  
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Table 1. Different theranostic materials in biomedical applications. 
Contrast agent Drug used Applications References 
Manganese oxide siRNA RNA delivery and MRI Bae et al. 2011 
Gold Doxorubicin Diagnosis, stimulus responsive 
drug release and photothermal 
therapy 
Chen et al. 2013  
Huang et al. 2011b 
Iron oxide siRNA, doxorubicin, 
docetaxel 
Targeting, MRI and therapy Lee et al. 2009 
Yang et al. 2010 
Ling et al. 2011  
Silica Pyropheophorbide 
(HPPH), doxorubicin 
Drug carrier, CT and x-ray 
imaging and photodynamic 
therapy 
Huang et al. 2011b 
Roy et al. 2003 
Park et al. 2009 
 
Carbon nanotubes DNA plasmid, 
doxorubicin,  paclitaxel 
Diagnosis, DNA and drug 
delivery, self photolumines-cent 
and photothermal property 
Pantarotto et al. 2004 
Liu et al. 2008 
Robinson et al. 2010b 
Quantum dots Doxorubicin, 
methotrexate 
Imaging, therapy and sensing Savla et al. 2011 
Yuan et al. 2009 
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1.6. Iron oxide-gold hybrid nanoparticles 
 
Functionalised iron oxides NPs (iron oxide as the core) with inorganic compounds are 
divided into five groups (Figure 11): mosaic, dumbbell, core-shell, shell-core and 
shell-core-shell (Wu et al. 2008).  
 
Figure 11. Schematic functionalised iron oxide nanoparticle (iron oxide assumed as the core). 
 
Matrix-dispersed iron oxide NPs can be fabricated by a variety of different states and 
increase the size of naked iron oxide NPs. The mosaic assembly are usually synthesised in 
the hollow silica spheres with iron oxide NPs and the shell-core structure can be produced 
through individual iron oxides that are attached with their inner layer. Shell-core-shell 
structure can be formed via layer-by-layer strategy, which might overcome some 
limitations of iron oxide NPs such as degradation (producing free radicals, which lead to 
cell damage and cell death), aggregation (making clusters, which are undesirable for 
biomedical applications) and precipitation (reducing colloidal stability) (Jeong et al. 2007; 
Lyon et al. 2004; Yu et al. 2008). The outer shell can be a polymer, metal NPs and 
quantum dots, but the inner shell may be the same or different functional materials.  This 
type of nano-composite is estimated to highly increase the range of application of iron 
oxide NPs. Dumbbell structure is usually fabricated by epitaxial growth of iron oxide on 
the inorganic compound. 
Core-shell structural iron oxide hybrid NPs are remarkably promising materials. Coatings 
can stabilise magnetic NPs, which improve dispersion and biocompatibility, and the 
surface can be functionalised by different molecules for various applications. As 
mentioned above, iron oxide alone in physiological media is unstable. Moreover, 
limitations have been reported with the use of flexible polymer coatings, whereby core 
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exposure leads to free radical cellular damage. As a result, imaging agents (polymer coated 
iron oxide NPs) such as Feridex IV
®
 and Luminex
®
 have been removed from use in 
humans (Hoskins et al. 2012a; Hoskins et al. 2012c). To overcome these limitations, they 
are usually coated with materials such as silica, polymers or gold, which has allowed the 
synthesis and design of NPs of sophisticated structure and function for biomedical 
applications. Iron oxide-gold as hybrid nanoparticles (HNPs) (Figure 12) have recently 
been the focus of many investigations (Hoskins et al. 2012b; Seied Sajadi et al. 2014; 
Štarha et al. 2015) and are becoming increasingly applicable in biomedicine. 
 
 
 
Figure 12. Schematic diagram of gold-iron oxide core-shell nanoparticle presenting electrostatic 
charges within each layer. 
 
Gold surfaces have the affinity to bind with thiol groups (-SH) by dative covalent linkages 
(a kind of 2-center, 2-electron covalent bond in which the two electrons derive from the 
same atom), which means they can be easily modified to confer different functional groups 
(Figure 13). In particular, it accelerates the attachment of biomolecules with intrinsic 
self-assembly properties onto the surface of NPs. For instance, Wei et al. fabricated a 
reversible self-assembly of α-cyclodextrins capped AuNPs to vesicles, mediated by a guest 
(azobenzene) conjugated to the double hydrophilic block copolymers 
poly-isopropylacrylamide and poly dimethyl acrylamide. This assembly mechanism occurs 
in pure water under the stimulus of temperature. A possible mechanism is via the thermal 
responsive coil-to-globule transition of the poly-isopropylacrylamide block 
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(Wei et al. 2012). This shows novel approach for designing magnetic NPs with 
well-controlled and functional complexes (Robinson et al. 2010a). 
By using hybrid structure of iron oxide/gold core-shell a multifunctional system can be 
designed which exploits the surface chemistry of the gold whilst retaining the magnetic 
character of the iron oxide, allowing for biologically sound drug delivery and imaging. 
This leads to a rigid nanoparticle structure which eliminates the potential of degradation of 
the iron oxide core into toxic free radicals. Hence, the overall system is more 
biocompatible.  
Iglesias-Silva and colleagues used microemulsion method to synthesis iron oxide NPs 
(9 ± 2 nm) following by coating with gold. For gold coating, HAuCl4 was reduced by 
glucose using a range of molar ratios (1:1 – 1:8) of HAuCl4/glucose. The complete 
core-shell NPs were characterised via UV spectroscopy, TEM (Transmission electron 
microscopy), magnetometry measurements and x-ray powder diffraction (XRD) analysis. 
These characterisation tests of the NPs show that the initial nuclei were completely coated 
by the metal, and the ratio of reducing agent affected shells size. Moreover, magnetic 
properties demonstrated a large reduce of the magnetisation for the coated NPs in 
comparison with the uncoated ones (Iglesias-Silva et al. 2010). 
 
Figure 13. Schematic diagram of functionalising iron oxide-gold hybrid nanoparticles by Au-S 
chemistry. 
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Recently, Maleki et al. prepared gold coated iron oxide NPs. They used modified 
water-in-oil inverse nano-emulsion method to fabricate stable iron oxide NPs with high 
saturation magnetisation (Maleki et al. 2015). To achieve mono-dispersed iron oxide 
particles, molar ratio of iron salts, the concentration of ammonium hydroxide as reducing 
agent, and molar ratio of water to surfactant were optimised. The biocompatibility of the 
iron oxide NPs was tested by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT) assay, which disclosed that the produced NPs were non-toxic. The surface 
of iron oxide NPs was functionalised through conformal coating of the NPs with a thin 
shell of gold (∼4 nm) via chemical reduction of attached gold salts at the surface of the 
iron oxide NPs. The final iron oxide core shell NPs show strong plasmon resonance. 
Results from physical and chemical characterisation of the changes in surface plasmon 
resonance, optical band particle size, core-shell surface composition, phase components, 
and magnetic properties proved the formation of iron oxide gold NPs.  
Lin and colleague explained for the first time that gold shell did not degrade the magnetic 
properties of their iron oxide NPs (Lin et al. 2001). In another study doxorubicin was 
loaded onto gold-coated iron oxide NPs, which showed the same retention of magnetism of 
naked iron oxide NPs and a sustained release of the drug (Kayal and Ramanujan, 2010). 
Moreover, iron oxide and gold have been applied in drug delivery systems and imaging to 
form multifunctional particles. These studies confirmed the attachment of a variety of 
molecules to the NPs and sustained drug release outlines. As an example, in one study 
FePt-Au NPs were synthesised, which possessed multifunctional capabilities including 
catalytic growth effects, magnetic resonance (MR) contrast effects, optical signal 
enhancing properties with high colloidal stability and biocompatibility. Biological 
detection capabilities were validated through evaluating the particles in the patterned 
biochip based detection of avidin−biotin and in molecular MR imaging of neuroblastoma 
cells (Choi et al. 2006). In another interesting study, Xu and colleagues fabricated 
dumbbell-like iron oxide-gold NPs and coupled with Herceptin and a platin complex. The 
platin-gold-iron oxide-Herceptin complex as a target-specific nanocarrier was capable to 
deliver platin into Her2-positive breast cancer cells (Sk-Br3) with strong therapeutic 
effects (Xu et al. 2009). Moreover, literature has revealed that the oxidised maghemite 
form preferentially binds gold compared with the magnetite form and is more stable and 
biocompatible form of iron oxide (Lyon et al. 2004).   
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Iron oxide gold NPs have been used as a drug carrier to deliver chemotherapeutic agents 
into the tumour tissue. For example, Wagstaff and colleagues have synthesised cisplatin 
conjugated iron oxide gold NPs. To do this, Iron oxide core was synthesised by 
co-precipitation method following by gold reducing onto the surface. Cisplatin was 
conjugated to the NPs by a thiolated polyethylene glycol (PEG) linker. Characterisation of 
the particles was performed by scanning transmission electron microscopy, inductively 
coupled plasma mass spectrometry, dynamic light scattering, UV-Vis spectrophotometry, 
and electron probe microanalysis. They found that iron oxide NPs have low inherent 
cytotoxicity on ovarian cancer cell lines (A2780 and A2780/cp70) and cisplatin conjugated 
formulations are up to 110-fold more cytotoxic than the drug alone. This might be due to 
the differences in uptake mechanism as free drug internalises through cells` pores/ 
channels and particles are taken up by endocytosis, thus higher proliferation rate in 
cancerous cells resulted in greater cytotoxicity of conjugated cisplatin, in comparison with 
free cisplatin. Interestingly, they demonstrated that this nano-sized formulation could be 
accumulated in specific regions by using an external magnetic field, which showed cell 
growth inhibition area for the treated cells by novel formulation. This is mainly due to the 
higher accumulation of hybrid formulation in cells placed in magnetised area, which leads 
to higher internalisation and cytotoxicity of novel formulation compared to the cells treated 
without external magnetic field (Wagstaff et al. 2012). 
Some studies have been focusing on the treatment of pancreatic cancer. Recently, 
Barnett et al. studied the attachment of 6-thioguanine (6-TG) onto iron oxide-gold HNPs 
(Barnett et al. 2013a). In this study, 6-TG was successfully conjugated onto the HNP 
surface and incubated with human pancreatic cancer cells (BxPC-3). A 10-fold decrease in 
half maximal inhibitory concentration (IC50) and enhanced cellular uptake was reported 
with the 6-TG-conjugated HNPs in comparison with free drug. From the measurement of 
the SPR band of AuNPs, iron oxide-gold particles reportedly possessed SPR bands in the 
range of 535-750 nm depending on the core size and Au shell thickness. This band is 
characteristic of the optical properties of gold nano-structures, in contrast to the largely 
silent feature in the visible region for Fe3O4 particles. The observed SPR band showed a 
red shift in comparison with AuNPs. Interestingly, the core-shell NPs with a thicker Au 
shell displayed a smaller red shift than those with thinner Au shells. This finding is in fact 
consistent with theoretical calculation of the Fe3O4-Au core-shell morphology based on 
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Mie theory, suggesting that the optical properties are affected by the chemical nature of the 
oxide core (Wang et al. 2008). 
Recently, Guo et al. investigated the Photothermal ablation of human pancreatic cancer 
cell line (PANC-1) with hybrid iron-oxide core gold-shell nanoparticles. They showed that 
GoldMag
®
 (30 nm diameter, 50 μgmL-1) nanoparticles were capable of cellular 
internalisation and temperature elevation after near infrared irradiation (7.9 Wcm
-1
, 5 min). 
The temperature elevation achieved was as high as 79.51 ˚C which resulted in only 2.3 % 
cellular proliferation after 24 h compared with 47.0 % in the non-irradiated control 
(Guo et al. 2013). 
Use of HNPs for thermo-responsive drug delivery is now a major focus. This technology 
benefits from magnetic properties reduced toxicities and the ability to target the drug 
release using focussed laser irradiation.  
 
1.7. Bisnaphthalimide based anticancer agents 
 
In order to find more efficient anticancer agents, using small molecules which have the 
affinity to bind to deoxyribonucleic acid (DNA) and demonstrating anticancer activities 
has been the focus of scientific interest recently (Gurova et al. 2009; 
Mohammadi et al. 2015; Wootton et al. 2015). Amongst these, bisnaphthalimide 
derivatives with photophysical properties have exhibited exciting potential as 
chemotherapeutic agents, which is due to their interactions with DNA by intercalation of 
the chromophore unit between the base pairs of the DNA double helix. Bisnaphthalimides 
consist of two chromophore units (naphthalimido rings), which are linked together through 
a linker chain. The linker should contain no less than one or two amine groups as amino 
group has been verified as a crucial part for cytotoxic activity (Figure 14A) 
(Brana et al. 1993). Many compounds with different substitutions in the chromophore and 
different length of the linker chain have been designed and synthesised (Brana et al. 1993).  
DNA intercalators are held in place between the base pairs by van der Waal’s interactions, 
thus creating a stable complex. As a result, the DNA becomes partially unwound and 
lengthens, which leads to the inhibition of DNA replication and transcription (Figure 14B). 
Bisnaphthalamide based drugs also inhibit topoisomerase II action (responsible for double 
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stranded breaks in DNA, catalyses DNA unwinding, and controls the processes required to 
untangle and unknot double stranded DNA), resulting in cell death. In addition, 
topoisomerase II has a key role in DNA replication and transcription, and also aids 
chromosomal organisation prior to mitosis (Banerjee et al. 2013; Barron et al. 2010).   
 
 
  
 
Figure 14. A) Basic bisnaphthalimide chemical structure and B) Schematic interaction between a 
bisnaphthalamide based drug and DNA (Karimi Goftar et al. 2014). 
A 
B 
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Brana and colleagues designed and synthesised a new symmetrical bis-intercalating series 
of bisnaphthalimides in the 1980s (Brana et al, 1980). These chemicals can be synthesised 
by nucleophilic reaction of 1,8-naphthalic anhydride with the corresponding 
alkyltetraamine. In contradiction of naphthalimides, bisnaphthalimides` structure increases 
DNA binding capacity, therefore, enhances their chemotherapeutic capability (Brana and 
Ramos, 2001).  
Even though bisnaphthalimide series have considerable cytotoxicity, they have very 
limited solubility in aqueous solvents; thus, exploring alternative carrier to deliver them 
inside the tumour is essential (Brana et al. 1995). Poorly water-soluble anticancer agents 
normally have a tendency to distribute and accumulate in the peripheral tissues. Due to the 
nature of most chemotherapeutic agents, this will translate into significant systemic toxic 
effects. It was demonstrated that once an anticancer agent is conjugated with a nanocarrier, 
its biodistribution and pharmacokinetics will be dictated by the properties of the carriers 
rather than the drug molecules themselves (Chen et al. 2001). This gives researchers a new 
way to make poorly water-soluble anticancer drugs work better without the need to modify 
them. 
 
1.8. Gemcitabine 
 
Gemcitabine (2,2-difluorodeoxycytidine) as a novel nucleoside analogue, is an 
chemotherapeutic agent, which has been used for the treatment of many different type of 
tumour, such as pancreatic, ovarian, non-small-cell-lung, breast and bladder cancers. This 
cytotoxic agent can affect DNA replication in rapidly dividing cells, such as cancer cells. 
However, prior its action, gemcitabine must be activated by deoxycytidine kinase and other 
intracellular kinases. These enzymes can phosphorylate gemcitabine to produce 
gemcitabine diphosphate and triphosphate, which are the active forms of gemcitabine. 
Gemcitabine triphosphate incorporate into DNA throughout S-phase of cell cycle, which 
influences the termination of DNA synthesis and lead to single-strand breaks and finally 
cell apoptosis (Tiefenthaler et al. 2003; Veltkamp et al. 2008).  
Patients with advanced or metastatic pancreatic cancer may be treated with gemcitabine as 
a first line treatment. However, it proves effective in 23.8 % of patients with the only 
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alternative being surgical removal of the localised tumour (Cunha et al. 2005). Moreover, 
it was demonstrated that elderly patients (with unresectable pancreatic cancer) were 
suffered from haematological and non-haematological adverse effects of gemcitabine 
(Takeuchi et al. 2004). In this thesis, all of the biological investigations will be compared 
with gemcitabine as a reference chemotherapeutic agent.   
 
1.9. Aims 
 
HNPs have interesting potential for theranostics; however, due to their relative age little 
literature is available. Hence this study exploited the use of the combined magnetic and 
optical properties in the thermoresponsive delivery of novel bisnaphthalamide based drugs 
in the treatment of pancreatic cancer. This was realised via nanoparticulate irradiation at 
lower temperatures which triggered drug release from the surface of the vehicle before 
cellular hyperthermia was initiated.  
This research is based on the design, synthesis and characterisation of hybrid iron 
oxide-gold core-shell nanostructures, which possess strong magnetism and surface 
plasmon resonance (SPR) and consists of three parts: 1) synthesis and characterisation of 
HNPs, 2) drug loading (bisnaphthalimide based drugs) and characterisation of new 
formulations, and 3) biological investigations of novel formulations. Here, the drug loading 
is achieved via charge-charge interactions between the positively charged drug compound 
and negatively charged HNPs. It is postulated that these electrostatic interactions can be 
broken at high temperatures (Figure 15). Electrostatic bonds are weaker than covalent 
bonds. These bonds have bond energy (the energy required to break a bond) of only about 
20 kJmol
-1
, while covalent O-H bond has a bond energy of 460 kJmol
-1
. By temperature 
increase, the vibration of electrostatic bonds results in breaking the interactions between 
differently charged molecules. The amount of energy required to break this interaction is 
supplied by laser irradiation (gold reacts as a nanoheater upon laser irradiation). 
Statistical independent sample t.test (parametric test) was used throughout of the thesis to 
compare means of two independent groups within the Microsoft Excel software package.   
This is the first time that drugs (bisnaphthalamide based drugs) conjugated to the surface of 
HNPs by charge-charge interactions, which possess thermoresponsive delivery potentials. 
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Moreover, this system is capable to be used in image guided heat triggered drug delivery in 
cancer diagnosis and therapy.  
 
 
Figure 15. Schematic diagram of thermoresponsive drug delivery of HNP-Drug upon laser 
irradiation. 
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Chapter Two 
Synthesis and 
characterisation of 
iron oxide-gold 
core-shell hybrid 
nanoparticles 
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2.1. Introduction 
 
Iron oxide-gold hybrid nanoparticles (HNPs) have recently been the focus of a number of 
investigations and are becoming increasingly applicable in biomedicine 
(Hoskins et al. 2012b; Hoskins et al. 2012c; Seied Sajadi et al. 2014; Štarha et al. 2015). 
By using both iron oxide (Fe3O4) and gold (Au) within one drug delivery vehicle, a 
multifaceted and stable system can be fabricated (Barnett et al. 2013; Barnett et al. 2012). 
This exploits the surface chemistry and SPR of the gold coating whilst maintaining the 
magnetic character of the iron oxide core, offering imaging, heating and drug carrier 
potentials. Moreover, the presence of the gold shell surrounding the magnetic core makes it 
possible to functionalise the nanoparticles (NPs) with thiolated (-SH) molecules by 
exploiting the well described Au-S chemistry (Robinson et al. 2010a).  
 
The binding energy of thiolates to the gold surfaces is experimentally determined by 
high-resolution x-ray photoelectron spectroscopy (Castner et al. 1996) and 
temperature-programmed desorption (Nuzzo et al, 1987) to be about 160 kJ/mol. X-ray 
absorption experiments (Roper et al. 2004) and early interpretation of photoelectron 
diffraction (Kondoh et al. 2003) suggested that the sulfur binds to the atop position of the 
Au surface. 
 
While there are a number of strategies reported for the synthesis and fabrication of 
Fe3O4-Au NPs such as reverse micelle method and iterative seeding method 
(Carpenter et al. 1999; Cho et al. 2005; Lin et al. 2001; Lyon et al. 2004), they all 
highlight the importance of bottom-up synthesis and processing. One strategy involves 
sequential formation of the iron oxide core and Au shell, which was used for the synthesis 
of highly-monodisperse Fe3O4-Au NPs (Goon et al. 2009). This approach can produce iron 
oxide gold NPs in a core size range of 5-15 nm with a shell thickness range of 0.5-2.0 nm.  
Another strategy is thermally activated processing of iron oxide NPs and AuNPs as 
precursors in a mixed solution. This strategy expands the method of thermally-induced 
homo-interparticle coalescence of metal NPs (Schadt et al. 2006).  
Goon and co-workers described the synthesis of Fe3O4-Au core-shell HNPs with an 
intermediate polymer, which separates the two entities (Goon et al. 2009). Incorporation of 
an organic intermediate layer between the Fe3O4 NPs and Au shell is proposed to avoid 
gold migration into the Fe3O4 core and enhance the saturation magnetisation and 
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relaxivity (Smolensky et al. 2011). Gold coating of the polymer coated Fe3O4 NPs can be 
fabricated by firstly attaching gold seeds (by electrostatic interactions between positively 
charged polymer and negatively charged gold NPs) to the nanoparticle surface, which is 
followed by subsequent reduction of Au onto the surface, in order to achieve a complete 
Au coat (Goon et al. 2009; Zhang et al. 2011). Moreover, this seeding technique is suitable 
method to achieve a higher degree of control over the Au shell thickness (around 10 nm). 
The shell thickness is an important factor as it affects the SPR of gold. Decreasing the 
thickness of the gold shell from 20 to 5 nm leads to SPR red shift (Goon et al. 2009; Zhang 
et al. 2011).  
In another study, Barnett et al. synthesised Fe3O4-Au core-shell HNPs with the core 
diameter of 70 nm, using a polymer intermediate (PEI). These particles finally were 
PEGylated with PEG-thiol through dative covalent bonding between the thiol groups (-SH) 
on the polymer and the gold shell of the NPs. Particles were characterised by Fourier 
Transform infrared spectroscopy (FTIR) and transmission electron microscopy (TEM). 
The stability of HNPs was tested for six months and the size of particles, zeta potential, 
magnetic coercivity, T2 relaxivity and nano-heating potentials were analysed to verify 
whether, any physical changes or degradation had happened since first measurement. The 
stability of particles was also tested in physiological conditions in vitro over a two week 
period. Therefore, HNPs were suspended in deionised water, placed inside the dialysis 
membrane and located into conical flasks containing 200 mL RPMI cell culture media (in 
sink condition). Media was pH adjusted to pH 7.2 and 4.5 to mimic blood and lysosomal 
physiological conditions, respectively. The hybrid formulation was subsequently analysed 
for Fe and Au content by inductively coupled plasma-optical emission spectroscopy 
(ICP-OES). The metal concentration in HNP formulation was calculated to be in a 3:1 ratio 
for Fe:Au (wt:wt). FTIR spectroscopy proved the presence of characteristic peaks 
attributed to the PEG coating. After six months, there were not any surface modification, 
morphology or diameter changes, confirmed by TEM, for the formulation. Zeta potential 
measurements also confirmed that the gold shell did not degrade or change during the 
stability test. Magnetic coercivity (Hc), determined by superconducting quantum 
interference device (SQUID) measurement, appeared to decrease after six months, showing 
that the magnetic properties of HNPs were modified over time. Physiological stability test 
showed an increase in Au content outside the dialysis chamber, which is indicative of 
particle degradation. No measureable degradation was observed for Fe, which is 
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reasonable, given, the rigid nature of the gold coating. The ΔT values (change in 
temperature) achieved upon laser irradiation appeared to be stable after six months, 
compared to the initial study (Barnett et al. 2013a).  
This work describes the synthesis and characterisation of HNPs using the techniques Goon 
and colleagues reported for HNP assembly (Goon et al. 2009). This method is able to 
synthesis HNPs with the ability to engineer the coverage of gold on the magnetite particle 
surface, which utilises PEI for the dual functions of attaching gold nano-seeds onto 
magnetite particles as well as preventing the formation of large aggregates. Moreover, this 
seeding gives a higher degree of control over the Au shell thickness. Characterisation of 
the HNPs will be carried out using a number of analytical and microscopy techniques 
including, ICP-OES, UV/Visible spectroscopy, photon correlation spectroscopy, T2 
relaxivity measurement using magnetic resonance imaging, superconducting quantum 
interference analysis, x-ray diffraction analysis, laser irradiation and TEM. These methods 
are described below in relation to our work. 
 
2.1.1. Inductively coupled plasma-optical emission spectroscopy  
 
Inductively coupled plasma-optical emission spectroscopy (ICP/OES) is one of the most 
commonly used techniques in metal content analysis. The technique is related to the 
spontaneous emission of photons from ions and atoms that have been excited in a radio 
frequency discharge to identify, and quantify the elements present (Fassel and 
Kniesley, 1974). Solid samples need acid digestion or extraction before injection, 
therefore, the analytes will be presented in a solution but gas and liquid samples can be 
injected straight into the instrument (Mermet, 2005).  
The ICP-OES is composed of two systems: the ICP and the optical spectrometer 
(Figure 16). Argon gas is mainly used to create the plasma which is directed by a torch 
consisting of three concentric tubes made of quartz. The sample solution is transformed to 
an aerosol and placed into the central channel of the plasma.  The aerosol is rapidly 
vaporised at the centre of ICP due to the extremely high temperature (nearly 10000 K), 
where it is liberated as free atoms in the gaseous state. Required energy for promoting 
atoms to excited states is achieved by additional collisional excitation within the plasma 
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imparts. After excited state, atoms will relax to the ground state through the emission of a 
photon, which have specific energies. This energy can be identified via the quantised 
energy level structure for the atoms or ions. Therefore, the wavelength of the photons 
determines the elements from which they originated. Moreover, the concentration of the 
element in the sample can be calculated by the total number of photons (Hou and 
Jones, 2000).  
By using ICP, the presence of gold and iron in our formulation can be confirmed; the 
concentration of them can be analysed and also the ratio of Fe:Au can be determined.  
 
 
Figure 16. Schematic diagram of inductively coupled plasma-optical emission spectroscopy. 
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2.1.2. X-Ray Diffraction 
 
X-ray diffraction (XRD) is a unique technique in determination of crystallinity of a 
compound and mainly applied to analyse solid substances in forensic science. In some 
cases, it is the only technique to achieve further differentiation of substances under 
laboratory environments. This method can analyse minute contact traces, smears, tiny 
sample areas, or small sample quantities, as well as large amounts of substances. XRD is 
generally worked by diffractometers, which is a piece of equipment to place samples and 
detector (Figure 17).  
XRD method is based on constructive interference of a crystalline sample and 
monochromatic x-rays. The x-rays are produced via cathode ray tube and filtered to 
generate monochromatic radiation. The interaction of the incident rays with the sample 
results constructive interference when conditions obey Bragg’s Law (Equation 1).  This 
law correlates to the wavelength of electromagnetic radiation (λ) to the diffraction angle 
(θ) and the lattice spacing in a crystalline sample (d).  
nλ = 2d sin θ                                                                    (1) 
This distinctive x-ray diffraction pattern produced in a characteristic XRD analysis offers a 
unique “fingerprint” of the crystals in the sample, which allows recognising the crystalline 
form of sample by comparing with the standard reference patterns. 
This technique allows us to compare the PXRD pattern of the fabricated Fe3O4 NPs with 
the reference sample of Fe3O4. Moreover, the purity of samples can be determined.  
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Figure 17. Schematic illustration of XRD technique. 
 
2.1.3. UV/Visible spectroscopy 
 
UV/Vis spectroscopy is routinely used in analytical chemistry for both qualitative and 
quantitative determination of different molecules (Deeney and Sinclair, 1997). Many 
analytes absorb light in the ultraviolet-visible spectral region, which causes objects to 
appear coloured. When light is adsorbed by a material, outer electrons are promoted from 
their ground states to excited states. This promotion of electrons to different energy levels 
leads to electromagnetic radiation in the visible part of the spectrum or in the ultraviolet 
region. The electrons are held strongly in single bonds, making them difficult to excite but 
the electrons involved in double and triple bonds are held less tightly and can be a lot more 
exited. This phenomenon can be used to produce well-defined absorption spectra (Deeney 
and Sinclair, 1997). UV/Vis spectrometer consists of a source of radiation of appropriate 
wavelengths, equipment for isolating light to a single wavelength and getting it to the 
sample (monochromator and optical geometry), a container for introducing the test sample 
into the light beam and finally a detector to measure the light intensity (Figure 18).  
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Figure 18. Schematic diagram of a UV/Vis spectrometer. 
 
Each chemical has a unique spectral characteristic due to the location of the electrons with 
respect to the nucleus. In order to calculate the concentration of analytes a relationship 
must be created to achieve quantitative information. The fraction of light that passes 
through the sample (T) can be calculated by these equations: 
 
T = I / I0                                                                                                 (2)                                                  
                                          % T= T × 100                                                            (3) 
I is the intensity of light, which passes through the sample solution and I0 is the intensity of 
the light that passes through the solvent. Percent transmittance (% T) is the transmittance 
fraction multiplied by 100 (Equation 3). A more convenient quantity in analysing is the 
absorbance or the negative log of transmittance (Equation 4). 
                                         A = – log T                                                                    (4) 
 
The Beer-Lambert law explains that the absorbance of a solution is directly related to the 
concentration of the absorbing molecules in the solution (Equation 5) (Bouguer, 1729). 
Therefore, UV/Vis spectroscopy can be used to verify the concentration of the absorber in 
a solution. In this equation, ε is a molar absorptivity constant which based on both 
substance and wavelength, L is the length of the path travelled by light through the sample 
and c is the concentration. This linear equation between concentration and absorbance lets 
researchers to use spectroscopy for quantitative measurements of samples. A calibration 
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curve can be made by preparing standard solutions and the concentration of an unknown 
solution can be calculated by linear regression. 
                                      
 Abs = log10  I / I0 =   ε L C                                                           (5) 
 
This test is useful for the determination of coating process in HNPs synthesis as each 
particle (naked iron oxide, seeded or coated particles) has a different UV spectrum. UV/ 
Vis spectroscopy also shows us the presence of gold and help us to measure the gold 
surface plasmon wavelength.  
 
2.1.4. Photon correlation spectroscopy 
 
Photon correlation spectroscopy (PCS) or dynamic light scattering (DLS) has been a useful 
light-scattering method for investigating the properties of solutions and suspensions of 
small particles, macromolecules and polymers (Berne, 2000). This technology is absolute, 
non-destructive and non-invasive. When small particles are exposed to the incoming light, 
the light will scatter in all directions. If the light supply is a laser (coherent and 
monochromatic), the scattering intensity randomly moves and vibrates over time. This 
oscillation is because of the fact that the small particles in solutions are experiencing 
Brownian motion, and thus the distance between the light scatters in the solution is 
continually fluctuating with time, leading to the development of a moving pattern. This 
random motion is modelled by the Stokes-Einstein equation. Below the equation is given 
in the form most often used for particle size analysis (Equation 6).  
 
Where: 
- Dh is the hydrodynamic diameter (particle size) 
- Dt is the translational diffusion coefficient (found by dynamic light scattering) 
(6) 
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- kB is Boltzmann’s constant  
- T is thermodynamic temperature  
- η is dynamic viscosity  
This moving pattern is used to deduce particle size as the movement of smaller particles is 
faster than larger or heavier ones and scatter less light (Figure 19). The scattered light then 
undergoes destructive or constructive interference via the surrounding small particles, and 
within this intensity changing, data presents the time scale of movement of the scatters. 
The dynamic data of the particles is originated by an auto-correlation of the intensity trace 
recorded throughout the procedure. 
 
 
 
 
 
 
 
 
Figure 19. Schematic diagram of light scattering of two samples (small and large particles). 
 
This technique is an indirect size measurement method as the measured quantity (the 
auto-correlation of fluctuations of the scattered light intensity) must undergo further 
mathematical processing to extract the quantity of interest (e.g. the particle size distribution 
or the diffusion coefficient distribution). Therefore, the actual size of the particles may 
differ from the one obtained by PCS (especially for aggregated NPs). Moreover, the size 
measurement gained is slightly larger than that of the actual sample particle size due to the 
Smaller particles 
Larger particles 
Laser 
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formation of a hydration layer surrounding the particles from the solvent (Sibilia, 1996). 
This method is very suitable for macromolecules as it can measure sample sizes from 3 nm 
to 3 µm (Sibilia, 1996). 
PCS has been used to measure the size of different particles such as polymers, micelles, 
carbohydrates, proteins and other NPs. The mean effective diameter of the particles can be 
verified in monodisperse systems. This quantity depends on the size of surface structures, 
the particles` core size, the concentration of the particles, and the type of ions in the 
solution. PCS can also be equipped to determine the diffusion coefficient of the particles 
and the surface charge (zeta potential) of them in suspensions. PCS software usually shows 
the particle population (polydispersity index (PDI)) at different diameters. Therefore, in a 
mono-disperse system, software displays only one population (PDI = 0), but in a 
poly-disperse system, multiple particle populations are displayed (0 < PDI < 1). Moreover, 
PCS can be exploited for stability tests by periodical measurements of samples, which can 
determine aggregation and changing hydrodynamic radius of the particles over time.  
Using PCS in our study can help us to determine the size of particles during the synthesis 
process, which can confirm the coating steps.  
 
2.1.5. Transmission electron microscopy 
 
The transmission electron microscope (TEM) is a very useful instrument that can be 
exploited to study the aggregation structure of a sample (Sibilia, 1996). TEM has been 
used to image nanomaterials, measuring of particle and/or grain size, size distribution, and 
morphology. The equipment passes a beam of electrons through a thin layer of sample 
resulting in interactions (Sibilia, 1996). These interactions produce a high resolution image 
of the aggregation architecture. Therefore, samples of less than 1 µm in size can be imaged 
by this technology (Sibilia, 1996). The quality of images depends on the contrast of the 
sample relative to the background. Samples are usually made by drying NPs on a copper 
grid, which is covered with a thin layer of carbon. Chemicals with high electron densities 
can be easily imaged compared with amorphous carbon. This involves most metals 
(e.g. aluminium, copper, gold and silver), metal oxides (e.g. 52uperpara oxide, silica, 
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titanium oxide), and other NPs such as carbon nanotubes, polymer NPs, quantum dots, and 
MNPs.  
TEM help us to visualise our naked and coated particles and measure the size of the 
particles accurately as aggregation of particles cannot interfere the size measurement in 
this method.    
 
2.1.6. Zeta potential measurement 
 
Suspended NPs usually possess surface charge because of the chemistry at the particle 
surface. Counter ions can be attracted to the charged surface; thus, NPs will be surrounded 
by a cloud of counter ions. These counter ions are related to the particle close to the 
particle surface. As a result, this immobile layer of counter ions accumulates near to the 
surface of particle, which is termed the stern layer. Outside of this layer (toward to the 
centre of particles) the concentration of counter ions falls consistently, and because of the 
higher mobility of ions within this layer, it is usually called diffuse layer. Zeta potential 
defines the electrostatic potential between the stern and diffuse layer.  
Zeta potential measurement is a standard technique to understand the stability of colloidal 
dispersions. The magnitude of the zeta potential shows the degree of electrostatic repulsion 
between adjacent, similarly charged particles in a formulation. For molecules and particles 
that are small enough, a high zeta potential will confer stability, i.e., the solution or 
dispersion will resist aggregation. When the potential is small, attractive forces may exceed 
this repulsion and the dispersion may break and flocculate. So, colloids with high zeta 
potential (negative or positive) are electrically stabilised, while colloids with low zeta 
potentials tend to coagulate or flocculate. 
Zeta potential measurement can also be used to evaluate synthesis process. Low zeta 
potential demonstrates that the particles possess a weak surface charge; therefore, repulsive 
forces between particles in that suspension are weak. These particles will aggregate more, 
which leads to low stability. In contrast, high surface charge represents strong repulsive 
forces between particles, resulting less aggregation, and higher stability. 
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Zeta potential measurement can help us to determine the surface charge of the particles 
during the synthesis process, which can confirm the coating steps. 
 
2.1.7. Magnetic resonance imaging and T2 relaxivity measurement 
 
Magnetic resonance imaging (MRI), as a non-invasive imaging technique, offers 
anatomical imaging system via measuring proton relaxation time of water and soft tissues 
(structure and function) in biological environments (Britton, 2010). MR images are 
obtained by manipulating the magnetic orientations of the hydrogen nuclei. Super 
paramagnetic materials possess a property called spin (rotation of the nucleus around its 
own axis), which can help the nucleus produces a magnetic field. This spin is returned to 
its resting state by two mechanisms, spin-lattice relaxation (T1) and spin-spin relaxation 
(T2). T1 or longitudinal relaxation is returning of magnetisation in longitude and T2 is 
returning of the transverse magnetisation. The enhanced transverse relaxivity (decreased T2 
signal) is detected as a darker area in an MRI scan (Figuerola et al. 2010). MR contrast 
agents are formulations injected intravenously in order to increase, or produce, differences 
in signal intensity between tissues in the MR image.  
This technique allows us to compare the magnetic property of our fabricated iron oxide 
NPs with commercial superparamagnetic NPs, Feridex
®
. 
 
2.1.8. Superconducting quantum interference  
 
Superconducting quantum interference device (SQUID) sensors are highly sensitive 
devices to detect and localise superparamagnetic iron oxide NPs (SPIONs). They are 
sensitive detectors of time-varying magnetic fields. This time-varying magnetic field is 
produced by moving the sample relative to the pick-up coil of the sensor and an external 
field is utilised to retain the sample magnetisation. Relaxometry can detect NPs in a 
stationary sample and the time-varying magnetic field is generated via magnetising the 
NPs by a pulsed DC field following by removing the magnetic field, which allows the NP 
magnetisation to relax.  
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In this system, the SQUID sensors are switched on after a short delay before measuring the 
decaying field of the magnetised particles. This delay is needed to let transient fields, 
produced in conductive elements of the measuring system through the pulsed field, to 
decline appropriately, in order to organise process of the SQUIDs in their most sensitive 
range.  
SQUID allows us to determine saturation magnetisation of our HNPs vs. applied field 
hysteresis loop. 
 
2.1.9. Laser irradiation  
 
When a laser is irradiated to a sample surface, the surface reflects a proportion of the 
energy, which highly depends on the material and the laser wavelength 
(Zhigilei et al. 2009). The adsorbed energy is transmitted from optical photons to electrons 
and subsequently to the lattice, resulting diffusion of the energy into the material 
(Liu, 2005). Extremely high energy pulses might result in photochemical reactions that 
detach atoms and molecules from the surface. The rest of the energy distributes into the 
material through heat transfer. These include the sequential excitation and relaxation of the 
metal electrons, its interaction with the lattice, i.e. the phonon-phonon thermalisation and 
the electron-phonon relaxation (Liu, 2005; Zhigilei et al. 2009). The heating effect can be 
applied for thermoresponsive drug delivery and photothermal ablation without affecting 
the surrounding healthy tissues.  
By irradiating HNPs with a laser beam, the ability of particles to produce enough heat 
needed for drug release process can be examined.  
 
2.1.10. Aims and objectives 
 
The aim of this study is to synthesise hybrid iron oxide-gold core-shell NPs and 
characterise them in order to ensure the correct structures were fabricated. Chemical and 
physical characterisation will be carried out by ICP-OES, UV/Visible spectroscopy, photon 
correlation spectroscopy, zeta potential measurement, T2 relaxivity measurement, 
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superconducting quantum interference analysis, x-ray diffraction analysis, laser irradiation 
and transmission electron microscopy. These techniques will be used to confirm the size, 
shape, surface charge, crystallinity, magnetic properties and the capability of HNPs to act 
as nano-heaters, ultimately indicating their use as drug carriers. 
 
2.2. Materials and Methods 
2.2.1. Materials used 
 
Table 2. Materials used in synthesis and characterisation of HNPs.  
Materials Suppliers 
Sodium hydroxide Fisher Scientific Co., UK 
Potassium nitrate Sigma-Aldrich Co., UK 
Iron sulphate ACROS Organics Co., USA 
Sulphuric acid Sigma-Aldrich Co., UK 
Poly(ethyleneimine) (PEI) (ave. Mw=2 kDa) Sigma-Aldrich Co., UK 
Poly(ethyleneimine) (PEI) (ave. Mw=750 kDa) Sigma-Aldrich Co., UK 
Chloroauric acid Sigma-Aldrich Co., UK 
Sodium borohydride ACROS Organics Co., USA  
Hydroxyl amine Sigma-Aldrich Co., UK 
Hydroxyl amine Sigma-Aldrich Co., UK 
Hydrochloric acid Sigma-Aldrich Co., UK 
Nitric Acid Sigma-Aldrich Co., UK 
Iron III standard  Sigma-Aldrich Co., UK 
Iron oxide standard Sigma-Aldrich Co., UK 
Gold standard Sigma-Aldrich Co., UK 
Chloroform Sigma-Aldrich Co., UK 
Formvar Agar Scientific Co., UK 
Ethanol Sigma-Aldrich Co., UK 
Copper grid Agar Scientific Co., UK 
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2.2.2. Methods 
2.2.2.1. Synthesis of iron oxide nanoparticles 
 
This work describes the synthesis and characterisation of HNPs using the techniques Goon 
and colleagues reported for HNP assembly (Goon et al. 2009). Iron oxide core was 
synthesised through co-precipitation method. Initially, 1.03 g sodium hydroxide and 1.82 g 
potassium nitrate were added to 180 mL deionised water and nitrogen was bubbled over at 
90 °C for 1 h. The above solution was added to a mixture of iron sulphate (3.89 g) and 
sulphuric acid (20 mL, 0.01 M) and stirred at 90 °C under nitrogen gas for 24 h 
(Figure 20). The supernatant was removed after using a strong permanent magnet on the 
outside of a glass vial containing the iron oxide NPs to separate the magnetic material from 
the solvent. This magnetic fraction was washed 6 times and immediately re-suspended in 
15 ml deionised water (the concentration of Fe was determined after gold coating step). 
Characterisation of iron oxide core was carried out within 1 week after synthesis of the 
particles.   
 
  
Figure 20. Schematic reaction on of synthesising iron oxide nanoparticles. 
 
Reaction mixture 
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The concentration of the particles was determined using ICP-OES and zeta potential 
measurement was used to monitor their surface charge. The size of the particles was 
measured using photon correlation spectroscopy and transmission electron microscopy. 
2.2.2.2. Polymer coating of iron oxide nanoparticles 
 
Poly(ethylenimine) (PEI) was used to coat the surface of the iron oxide (Fe3O4) NPs 
(Figure 21) by electrostatic interaction between the negatively charged iron oxide and the 
cationic PEI. PEI used for the dual functions of attaching gold nano-seeds onto magnetite 
particles as well as preventing the formation of large aggregates. In this stage, 5 mL of 
Fe3O4 solution was added to a 50 mL solution of PEI in water (MW 750,000, 5 mgmL
-1
) 
and sonicated using a probe sonicator (Soniprep 150 plus, MSE Co, MSS150.CX4.5) for 
0.5 h. Particles were separated from the free PEI in solution using a high powered magnet 
and washed 6 times with deionised water. The final particles were re-suspended in 5 ml 
deionised water. 
 
 
 
 
 
 
 
Figure 21. Schematic diagram of PEI coating on iron oxide nanoparticles. 
 
The surface charge of the particles was monitored via zeta potential measurement. By this 
method, the presence of polymer around the iron oxide core can be confirmed since upon 
the PEI coating, the negative zeta potential of Fe3O4 core must shift from the negative 
value toward the positive charge due to the presence of PEI coating. 
 
Fe Fe 
Polymer coating 
PEI  
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2.2.2.3. Gold seeding process 
 
In order to fabricate gold seed NPs, chloroauric acid (HAuCl4, 4 %, 375 μL) and sodium 
carbonate (Na2CO3, 500 μL, 0.2 M) were diluted to 100 mL of ice cold water. This 
solution was stirred for 10 min before the addition of sodium borohydride (NaBH4, 
0.5 mgmL
-1, 5 mL). At this time the solution turned a deep red colour and was stirred for 
another 10 min (Figure 22). 
  
                                                                                     
Figure 22. Colour changing of gold solution (5 mL) from yellow to deep red after reduction.     
 
Gold seeding was achieved by electrostatic interaction of negatively charged gold NPs 
with cationic PEI coating (Figure 23). Fe3O4-PEI (2 mL) was added to the gold-seed 
solution (90 mL) previously prepared. The mixture was stirred at room temperature for 2 h. 
The magnetic particles were magnetically separated from solution and washed 6 times with 
deionised water. These particles stabilised by stirring in a solution of 1 mgmL
-1 
PEI 
(MW 2000) for 10 min. Finally, the particles were washed extensively with deionised 
water and re-suspended in 5 mL deionised water. 
 
 
 
 
 
 
 
 
Figure 23. Schematic diagram of gold seeding process. 
Reduction HAuCl4 Au nanoparticles 
Fe Fe 
Gold seeding 
 
PEI coating 
PEI (High MW) 
PEI (Low MW) 
Gold seed 
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The gold seeding and PEI coating were monitored by zeta potential measurement in each 
step. This can show that whether the seeding and coating processes achieved as gold and 
PEI have negative and positive charge, respectively. These synthesis steps also monitored 
by UV/Vis spectroscopy as the presence of gold seeds in the formulation must change the 
Fe3O4-PEI spectrum due to the surface plasmon resonance of gold.  
 
2.2.2.4. Gold coating process 
 
In order to achieve a complete shell, gold was reduced onto the particle surface. To do this, 
particles were stirred with 110 mL sodium hydroxide (0.01 M) at 60 °C and 0.5 mL of 1 % 
HAuCl4 was added followed by hydroxyl amine (NH2OH·HCl, 0.75 mL, 0.2 M). Two 
consecutive iterative reductions were carried out by addition of 1 % HAuCl4 (0.5 mL) and 
0.2 M NH2OH·HCl (0.25 mL) with 10 min intervals. Final HNPs re-suspended in 5 ml of 
water after washing extensively and magnetically separating. Zeta potential and UV/Vis 
spectroscopy was recorded to investigate any changing in surface charge and UV/Vis 
spectrum upon the complete coating.  
 
2.2.2.5. Characterisation of hybrid nanoparticles   
2.2.2.5.1. Inductively coupled plasma-optical emission spectroscopy 
 
Metal content of the HNPs was determined using inductively coupled plasma-optical 
emission spectroscopy (ICP-OES, Optima 7000V DV, PerkinElmer, Wokingham, UK). An 
acid digestion was carried out on the samples using a concentrated nitric acid: hydrochloric 
acid (1:1) solution with heating up to 100 °C (1:10 sample: acid). The samples were diluted 
(1:10) with deionised water prior to analysis. A calibration was run using iron and gold 
standard solutions 10-0.05 ppm (R
2
 = 0.9999) (Barnett et al. 2013a). The concentration of 
HNPs used for all subsequent experiments indicates the concentration of Fe. 
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2.2.2.5.2. Powder x-ray diffraction (PXRD) 
 
Iron oxide NPs in solution were sent for powder x-ray diffraction (PXRD) to the Lennard 
Jones Laboratories, Keele University. PXRD was carried out to verify the crystal structure 
of the fabricated Fe3O4 NPs (Hoskins et al. 2012b). PXRD patterns have been achieved by 
a Bruker D8 Advance x-ray diffractometer with these parameters (Norrish and Taylor, 
1962): 
1) A flat disc sample holder from 10˚ to 70˚ (2Ɵ) 
2) Cu Kα radiation 
3) A 0.04˚ (2 Ɵ) step size 
4) A data collection time of 7s per step 
 
The result compared to reference sample of Fe3O4. 
 
2.2.2.5.3. UV/Visible spectroscopy 
 
UV Peak absorbance of iron oxide NPs, gold seeds and HNPs in deionised water was 
measured using a Shimadzu UV-Vis spectrometer (UV-2600 UV–Vis (NIR) with an 
ISR-2600 Plus Integrated sphere, Shimadzu, Germany). Aqueous samples were analysed in 
quartz cuvettes, absorbance scans were carried out between 300-800 nm 
(Hoskins et al. 2012b). All measurements were run in triplicate at room temperature 
(25 °C) and recorded as average values. 
 
2.2.2.5.4. Photon correlation spectroscopy and zeta potential 
measurement 
 
Hydrodynamic diameters and zeta potential measurements were carried out using a photon 
correlation spectrometer (PCS, Zetasizer Nano-ZS, Malvern Instruments, UK). Samples 
were diluted in deionised water to make 1 mgmL
-1
 of HNPs and sonicated for 30 s before 
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measuring the size and surface charge of the particles at 25 °C.  1 mL of samples was 
placed in screw-top glass vials and hydrodynamic radius, PDI and zeta potential of samples 
were measured during the synthesis process (Hoskins et al. 2012b).  
 
2.2.2.5.5. TEM imaging 
 
Transmission electron microscopy (TEM) was used to visualise the particles. Formvar
®
, 
known as polyvinyl formal appears to be the most widely used support film for TEM grids. 
In order to make Formvar
®
 coated copper grids, commercially available copper grids 
(200 mesh, Agar Scientific Co, UK) were washed in chloroform in small beaker and 
transferred onto filter paper to dry. A glass slide was polished and wiped with lint-free 
cloth and then submerged (3/4 of height) 2 times in Formvar
®
 solution (0.5 mgmL
-1
). The 
slide was immediately removed from solution and air dried. The edges of the slide were 
scored with a sharp, ethanol-cleaned razor blade. The film was removed from the slide by 
floating it onto a water pool. The copper grids were laid (face down) on the film in the 
regions that are of the proper thickness and without wrinkles. Then the film with grids was 
picked up by covering them with a glass slide. The glass slide containing coated copper 
grids was air dried overnight. Samples were pipetted onto formvar coated copper grids 
(2 μL) and dried under a heat lamp for 4 h. The samples on the grids were directly imaged 
using a JEOL JEM-12 microscope with ANAlysis software (JEOL, Japan) 
(Barnett et al. 2013a). 
 
2.2.2.5.6. Magnetic resonance relaxivity measurements 
 
The HNPs were dispersed in agar as described below and sent to the University of Dundee 
for magnetic resonance imaging. Magnetic relaxivity of the HNPs was measured by a 1.5 T 
MRI scanner (Signa G=HDx, GE, USA) by means of GE’s receive only HD 8-channel 
head coil. Feridex
®
 (superparamagnetic NPs coated with dextran) and HNPs were 
dispersed in 2 % agar, with the concentration between 0.05 µgmL
-1
 and 50 µgmL
-1
, and 
placed on plastic vials. Inversion Recovery Spin-Echo (IRSE) sequences has been applied, 
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in order to measure T1 and T2 relaxation times, respectively, on a single coronal slice 
intersecting the gel with NPs. The parameters for IRSE imaging were as described below:  
1) Time repeating (TR) = 15s 
2) Echo time (TE) = 9ms 
3) Field of view (FOV) =  20 cm 
4) Acquisition matrix = 128 × 128 
5) Band width (BW) = 15.63 kHz 
6) Slice thickness = 8 mm 
7) Number of excitations (NEX) = 1 
8) Inversion time (TI) = 100, 200, 400, 600, 800, 1000, 1200, 1400, 1600, 1800, 2000 
and 2200 ms. 
  
These parameters were applied as mentioned with 10, 20, 30, 50, 70, 100, 120, 150, 200, 
250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850 and 900 ms. Areas of 
interest were chosen in each sample over the image set and then Ti(i=1&2) values were 
determined by the 3-parameter non-linear least squares fit of the mean signal intensities vs. 
time (TI and TE respectively) data. The related relaxivities were calculated (ri in Mm
-1
S
-1
) 
through the gradient of the linear least squares fit of the relaxation rates (Ri=1/Ti) vs. 
concentration of Fe (mM) (Hoskins et al. 2012b). 
 
2.2.2.5.7. Superconducting quantum interference device analysis 
 
Iron oxide NPs were sent in solution to the University of Warwick for superconducting 
quantum interference device (SQUID) analysis as described below. Magnetic 
characterisation of NPs was performed by a Quantum Design MPMS-XL SQUID 
magnetometer. In this method, cooling (FCC) curves, field-cooled-warming (FCW) and 
zero-field-cooled warming (ZFCW) were determined in a field H = 8 kA/m, between 10 
and 280 K. Magnetisation vs. applied field hysteresis loops were measured at 250 K in 
applied fields up to 4 MA/m. For the ZFC curves, the samples were first cooled to the 
basal temperature (10 K) without applied field. Next, a field was applied and the variation 
of magnetisation was measured by increasing the temperature up to T = 250 K 
(Barnett et al. 2013a). 
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2.2.2.5.8. Laser irradiation  
 
HNPs were evenly suspended in a 2 % agar solution at concentrations of 50 μgmL-1 and 
100 μgmL-1. The dispersed HNPs in agar were allowed to cool to form gels in 35 mm 
diameter plastic petri dishes. Samples were stored in the fridge until analysis and allowed 
to equilibrate at room (25 °C) and human body temperature (37 °C) before irradiation. 
Samples were exposed to continuous wave laser beam (1000 V, 6 Hz) emitted by a solid 
state laser system (Ng:YAG pulsed 1064 nm).  
Many of the reports to date have been carried out using a 532 nm green light source for 
laser irradiation of gold (Woods, 2010). However, light of this wavelength unfortunately 
does not pass through biological tissues. Instead it becomes adsorbed and this leads to heat 
discharge of NPs as well as the biological tissue rather than sole heating of NPs. The broad 
UV peak of HNPs (Figure 27) covers a large array of wavelengths in which laser 
irradiation would become adsorbed resulting in heating effects in the HNPs. It can be seen 
from the spectra that 532 nm does experience some absorbance which clarifies increasing 
of thermal energy described in the literature for gold nano-shells after irradiation 
(Figure 27) (Woods, 2010). It has been well documented that heating will occur at any 
point in the spectra where absorbance occurs due to the presence of gold 
(Curtis et al. 2015). Towards the red end of the spectra at 1064 nm it was detected that 
comparable absorbance to 532 nm occurs. Thus, it is assumed that laser irradiation at 1064 
nm should cause localised heating of the HNPs without heating of biological tissues. 
Moreover, laser systems using 1064 nm pulsed sources are widely used both in the 
cosmetic industry for tattoo removal and hair removal and also in clinical settings for 
ophthalmic treatment (Tanaka et al. 2011). Thus, these systems are rather cheap, portable 
and penetrate biological tissues with no adverse effect. Other researches about heating of 
NPs via SPR utilisation have revealed that using pulsed laser irradiation is more efficient 
than continuous laser irradiation (Lukianova-Hleb, 2013). 
In this study ultrafine thermocouples were used to monitor thermal change (inside and 
outside of the beam) in the gel (0.076 mm diameter, T-type, PFA coated, Omega, UK) 
coupled with a thermocouple logger (TC08 Pico Technology, UK). This transformed the 
voltage change to the real-time change in temperature. The gel samples were placed in the 
laser beam and irradiated by the beam for 60 s, which were timed by a stopwatch 
(Figure 24). A sample of 2 % agar (without NPs) was exploited to measure the temperature 
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change as a control sample. Changing temperature in the samples was calculated by 
Equation 7 and all statistical analyses were carried out using t.test analysis within the 
Microsoft Excel software package.   
                                    Δ T = (Tfinal– Tinitial) − TΔ control                                               (7) 
 
Further studies incorporated HNPs into fresh raw chicken tissue which used to mimic that 
of human. The HNPs were dispersed using a fine needle into the tissue at a concentration 
of 100 μgmL-1. This sample was exposed to the same laser beam as mentioned above, for 
60 s at room temperature. Any thermal change resulting in tissue damage would be 
visually evident due to whitening of the tissue, as a result of cooking. 
 
 
 
Figure 24. Laser irradiation of HNPs sample dispersed in agar gel. 
 
Laser irradiation of HNPs in agar gel was previously used by Curtis et al. HNPs 
(500 μgmL−1, 50 μgmL−1 5 μgmL−1 and 0 μgmL−1) were dispersed into a 2% agar phantom 
in 35 mm petri dishes and samples were irradiated by a laser beam at 1064 nm using a 
ML-LASER-YB5 Q-switched Nd:YAG Laser Treatment System. The gels were exposed 
to laser irradiation for 60 s and their cooling profile monitored by T-type thermocouples 
over 120 s. Temperature change was also measured using an thermal imaging Camera. 
Laser beam 
HNPs dispersed in agar gel 
A pair of 
thermocouples 
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Data showed that HNPs experienced heating of up to 40°C with a total area of heat 
dissipation up to 132.73 mm
2
 from the 1 mm diameter irradiation point after 60 s 
(Curtis et al. 2015).  
 
2.3. Results 
2.3.1. Photon correlation spectroscopy and zeta potential 
measurement 
 
The Fe3O4 particles were successfully synthesised and coated with PEI and gold (the ratio 
of Fe:Au was 4:1) which has a percentage yield of 86 %. The fabrication of these 
structures was monitored closely through zeta potential measurement. The Fe3O4 possessed 
a negative surface charge of ˗ 24.9 mV due to the surface sulphate associations from the 
synthetic procedure (Hoskins et al. 2012a) (Table  3). Subsequently the zeta potential 
shifted to + 47.5 mV after coating of the Fe3O4 core with PEI. This increase is due to the 
presence of the positively charged primary amine groups in the PEI backbone; hence 
indicating that coating was successful. The Fe3O4-PEI-Auseed and Fe3O4-PEI-Aucoat NPs 
represented a decrease in surface charge, which is due to the negatively charged gold 
atoms (+ 33.9 mV and ˗ 4.3 mV, respectively). The hydrodynamic radius of Fe3O4 core, 
Fe3O4-PEI and HNPs (1 mgmL
-1
) was 1100 nm, 300 nm and 891 nm, respectively 
(Table 3). A large diameter was obtained due to the inherent magnetic properties of the 
iron oxide cores. However, Fe3O4-PEI had the smallest particle size in this group which 
could be due to the polymer coating that decreased the aggregation of the particles. After 
gold coating the apparent size increased probably due to the tendency of gold nanoparticles 
which are unfunctionalised to aggregate in solution. 
PDI index of particles showed that they possess homogeneous distribution within the 
formulation as PDI of Fe3O4, Fe3O4-PEI and HNPs was less than 0.3. PDI of 
Fe3O4-PEI-Auseed was around 0.394, which could be due to the presence of small fraction 
of free gold seeds in formulation (Table 3).   
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Table 3. Photon correlation spectroscopy showing hydrodynamic radius, polydispersity index and 
zeta potential of particles measured at 1 mgmL
-1 
in deionised water (n=3, ave ± SD). 
Particle Hydrodynamic 
Radius nm ± SD 
Polydispersity 
Index ± SD 
Zeta Potential 
mV ± SD 
Fe3O4 1100±24.21 0.22±0.06 − 24.92±1.88 
Fe3O4-PEI 300±11.75 0.27±0.03 + 47.56±3.72 
Fe3O4-PEI-Auseed 433±8.83 0.39±0.06 + 33.94±4.48 
Fe3O4-PEI-Aucoat 
(HNP) 
891±35.81 0.24±0.11 − 4.34±0.03 
 
 
2.3.2. TEM imaging 
 
TEM imaging represented a precise view of the Fe3O4 shape and size, which was 
approximately 30 nm (n = 20, SD = ± 4.23) (Figure 25A). Gold NPs (2 nm) (Figure 25B) 
were fabricated and seeded on to the surface of Fe3O4 NPs by charge-charge interactions, 
which changed the shape of particles to a unique ‘bobbly’ surface (Figure 25C).  The TEM 
images of the fully coated HNPs displayed a small increase in particle size to around 40 nm 
(n = 20, SD = ± 6.61) (Figure 25D).  
 
68 
 
             
  
 
Figure 25. Size and shape estimations of NPs analysed by TEM: A) Fe3O4 nanoparticles, B) Gold 
nano-seeds, C) Fe3O4-Auseed and D) HNPs. 
 
2.3.3. Inductively coupled plasma-optical emission spectroscopy 
 
ICP was used to deduce the concentration based on the total iron and gold content of the 
NPs. The concentration of iron and gold in formulation (calculate from the standard curves 
(Appendix, Figure 1)) were 2.65 ± 0.15 mgmL
-1 
(R
2
 = 0.999) and 0.68 ± 0.004 mgmL
-1 
(R
2
 = 0.998), respectively (calculated from the standard calibration equation). The ratio of 
Fe:Au in formulation was approximately 4 : 1. This ratio was in line with other studies of 
HNPs for biological applications (Barnett et al. 2013a; Hoskins et al. 2012b). ICP analysis 
200 nm 
A B 
100 nm 
200 nm 200 nm 
C D 
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for Fe and Au was run 6 times for three different batches of HNPs showing that the 
standard deviations and means are reliable and the synthesis protocol is reproducible. 
 
2.3.4. Powder x-ray diffraction analysis  
 
Both synthesised Fe3O4 NPs and reference sample of Fe3O4 (Sigma-Aldrich Co., UK ) 
were analysed by PXRD test.  PXRD pattern of fabricated Fe3O4 NPs was compared with 
the reference sample of Fe3O4 (Figure 26). The diffraction peaks of synthesised sample 
(Figure 26A) are closely matched with the reference sample (Figure 26B), showing that 
our particles have a cubic crystal system (Itoh et al. 2003). Moreover, no specific peaks of 
impurities were detected. The small extra peaks observed in fabricated iron oxide sample 
are associated with signal/noise ratio.   
 
 
 
Figure 26. Powder x-ray diffraction of A) Fabricated Fe3O4 NPs compared to B) reference sample 
of Fe3O4. 
 
2.3.5. UV/Visible spectroscopy 
 
Colloidal gold NPs can absorb light and transform it into localised heat (photo-thermal 
therapy). UV-visible spectroscopy was used to obtain absorption spectra of the particles 
(Figure 27) in order to determine the wavelength at which the maximum absorbance 
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occurred (λmax). λmax value is used as an indication of the wavelength at which the SPR 
effect will be optimal. The scan of PEI-coated iron oxide cores showed featureless spectra, 
which indicated that no SPR occurred. This was expected since the particles did not consist 
of any gold. The gold seed solution possessed a λmax of 480 nm, which was red shifted after 
seeding to the Fe3O4-PEI surface to 520 nm. After reducing gold onto the surface of 
particles (completing the coating process) a shift to 610 nm was achieved; this indicates 
that the gold coating was successful. However, this peak was rather broad, which might be 
due to the interaction between solute and solvent or gold shell and PEI polymer. The shift 
is mainly due to differences of size between gold nano-seed (2 nm) and HNPs (40 nm) as 
increasing the size of solid gold nanospheres shifts their absorption spectrum toward more 
penetrating red light (Hainfeld et al. 2014).  
 
 
 
Figure 27. UV–Vis absorbance spectra of A) Fe3O4-PEI, Au seeds, Fe3O4-PEI-Auseeds and 
Fe3O4-PEI-Aucoat (HNPs) and B) Second derivative peak of Fe3O4-PEI-Auseeds. 
A 
B 
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2.3.6. T2 MR relaxivity measurment of HNPs  
 
Transverse relaxation (T2) of HNPs and Feridex
®
 as a function of concentration of Fe in 
mM were obtained (Figure 28). The transverse relaxivities (r2) was measured with the 
gradient of the straight lines fitted to those data.  
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Transverse relaxation (T2) rate of A) HNPs and B) Feridex
®
 as a function of 
concentration of Fe. The dotted line represents the linear fit to the experimental data.  
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For both samples, the relaxation rates (1/Ti) with the highest concentration of iron 
(1.79 mM) had to be omitted due to the large deviation from the linear fit to the rest of the 
data, which could be because of the agglomeration of highly concentrated and/or the larger 
error presented in the calculation of the T2 for that specific sample attributed to the very 
low signal-to-noise ratio of the MR images achieved at longer TE. 
The transverse relaxivity of Fe3O4 NPs was 260.20 mM
-1 s-1 (Figure 28A), which was 
slightly higher than the relaxivity of previously clinically used Feridex
®
 
(240.37 mM-1 s -1) (p > 0.05) (Figure 28B).  
 
2.3.7. Magnetic characterisation of hybrid nanoparticles 
 
The saturation magnetisation vs. applied field hysteresis loop (Figure 29A) of the HNPs 
was collected at 250 K. The saturation magnetisation and magnetic coercivity parameters 
at T = 250 K are indicative that the Fe3O4 core of the HNPs was highly crystalline and 
magnetically ordered at room temperature. The zero field cooled / field cooled curve 
(Figure 29B) indicates features characteristic of ferromagnetic NP. The absence of a 
maximum in this data shows that the ordering temperature is above room temperature. 
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Figure 29. Magnetisation data of HNPs: A) M(T) curves determined in zero-field cooled warming 
(AFCW) and field-cooling mode, B) M(H) curves collected at 250 K between - 4 and 4 MA/m and 
C) M(H) curves measured at 250 K. 
 
2.3.8. Laser irradiation 
 
Incorporation of the unique properties of HNPs into thermally responsive carrier has great 
potential for future biomedical applications (thermoresponsive drug delivery). In this kind 
of treatment the surrounding normal tissues would not experience temperature increase, 
which may lead to unwanted damage (Zijlstra and Orrit, 2011). This is because the laser 
beam only focuses on the treated area and the temperature will not increase outside the 
laser beam (confirmed in our results below). To explore the potential of the HNPs as 
nano-heaters, HNPs (50 μgmL-1 and 100 μgmL-1) were dispersed in agar gel and irradiated 
with continuous wave laser (Ng:YAG pulsed 1064 nm, 1000 V, 6 Hz) for 60 s.  
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The agar phantom was utilised to mimic physiological tissue. HNPs showed a time and 
concentration dependent heating effect and a localised heating of the sample was observed 
in the region exposed to laser radiation via thermocouple measurement (Figure 30). The 
first thermocouple was fixed at the centre of the gel (inside the laser focal point) and the 
second thermocouple was placed on the edge of the phantom sample, 14 mm away from 
the laser focal point. 
  
 
Figure 30. Diagram showing the heating effect of HNPs dispersed in 2 % agar gel upon laser 
irradiation in room and body temperature. All statistical analyses were carried out using t.test 
analysis within the Microsoft Excel software package.   
 
After laser irradiation for 60 s, changing temperature in agar gel without HNPs  as a 
reference sample and outside of the laser focal point (for samples containing HNPs) were 
negligible, showing that heating only took place for HNPs in the region exposed to the 
laser radiation.  
Data demonstrated the change in temperature (ΔT) of the agar gels containing the HNPs 
(50 μgmL-1 and 100 μgmL-1) at 22 °C and 37 °C. ΔT was calculated by any temperature 
change during laser irradiation, compared with the control sample (Equation 6).  
24
29
34
39
44
49
0 20 40 60 80
Te
m
p
er
at
u
re
 (
˚C
) 
Time (s) 
In beam 100 ug/mL (22 °C)
Outside beam (22 °C)
In beam 50 ug/mL (22 °C)
In beam 100 ug/mL (37 °C)
Outside the beam (37 °C)
In beam 50 ug/mL (37 °C)
75 
 
At concentrations of 50 μgmL-1 at room temperature, ΔT was 5.57 °C ± 1.43 after 60 s 
laser irradiation, which was significantly higher than the temperature increase achieved 
outside the beam (p < 0.05) (Figure 30). A small time dependant increase in temperature 
was recorded upon longer laser exposure, which was insignificant (p > 0.05). At 
100 μgmL-1, ΔT significantly increased (p < 0.05) after 60 s (ΔT was 7.70 °C ± 0.80), 
comparing with the temperature changes outside the beam. Negatively skewed distribution 
of temperature increase was achieved for both concentrations (Appendix, Figure 2).   The 
experiment was repeated at 37 °C and around the same ΔT was achieved for samples at 
this temperature (p < 0.05) (Figure 30).   
In order to see visual heating effect of HNPs, 100 μgmL-1 of HNPs was injected into a raw 
chicken breast in vitro and exposed to the laser irradiation for 60 s, at room temperature 
(Figure 31). A control sample of raw chicken breast (without HNPs) was irradiated and 
imaged before and after irradiation (Figures 31A and 31B). After laser irradiation, the 
control sample did not change in case of colour and no heating effect was observed, 
confirming our previous studies on agar gel discussed before. However, the colour of the 
samples containing nano-formulation did change subtly as a result of temperature increase 
caused by HNPs (although it is not distinctive in the image) (Figures 31C and 31D). 
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Figure 31. In vitro laser irradition of  raw chicken breast:  A) Control sample before irradiation, 
B) Control sample after irradiation, C) Sample containing HNPs before laser irradiation and 
D) Sample containing HNPs after laser irradition. 
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2.4. Discussion  
 
Hybrid iron oxide-gold NPs were successfully synthesised. The formation of Fe3O4 core 
and/or the hybrid structure were characterised by T2 MR relaxivity measurement, powder 
x-ray diffraction analysis, magnetic characterisation, ICP-OES, UV/Visible spectroscopy, 
PCS and TEM microscopy.  
Both Powder x-ray diffraction analysis and magnetic characterisation confirmed that 
typical crystalline structure of Fe3O4 was achieved (by comparing with the control sample) 
(Figures 26 and 29). In general, UV/Vis spectroscopy and zeta potential measurement 
indicated that fully coated HNPs were synthesised (Figure 27 and Table 3, respectively). 
Naked iron oxide core was successfully coated with poly(ethylenimine) as an intermediate 
layer, which was proved by zeta potential measurements (Table 3). Changing the zeta 
potential from negative charge for iron oxide to positive value after coating with PEI is a 
suitable indication that polymer coating process was successful. Gold seeding was attained 
with 2 nm gold NPs and complete gold shell was achieved by consecutive gold reduction 
onto the surface of NPs. The gold shell thickness was around 10 nm, which can be 
increased or decreased to study the optimal physical properties for different purposes 
(Huang et al. 2011a; Pissuwan et al. 2006; Zijlstra and Orrit, 2011). Each stage in the 
synthesis process was examined with UV/Visible spectroscopy (Figure 27), TEM 
(Figure 25), and zeta potential measurement (Table 3).  
Fe3O4-PEI-Auseed particles had a lower positive zeta potential compared to Fe3O4-PEI and 
zeta potential shifted to negative range upon the complete gold coating. These shifts 
toward the negative value is due to the presence of gold, which possess negative charge, 
and can confirm that gold seeding and gold coating have been achieved during the 
synthesis process (Table 3). UV/Visible spectroscopy was carried out in order to identify 
the presence of colloidal gold in these constructs. The λmax, measured via UV/Visible 
spectroscopy, red shifted from 480 nm (gold NPs λmax) to 520 nm and 610 nm, after gold 
seeding and gold coating, respectively (Figure 27). This result again indicates that 
complete coating was achieved. Earlier investigations on gold nano-shells have described 
that the λmax can be red shifted toward the infrared region (800-1200 nm) 
(Pissuwan et al. 2006). However, fabricated HNPs in this study did not show such large 
shift. The spectrum achieved was very broad and covered from 500-700 nm. This wide 
absorbance peak, without high shifting toward the infrared region could be because of the 
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synthesis method, the presence of PEI polymer layer between the gold shell and iron oxide 
core and the size variations of shell thickness and/or final particles diameter. However, the 
UV/Visible spectrum of HNPs was in line with other studies (λmax between 500-600 nm) 
(Curtis et al. 2015; Goon et al. 2009; Smolensky et al. 2011; Wang et al. 2005a; Wang et 
al. 2005b).  
The inherent magnetic nature of iron oxide core resulted in particle aggregation in solution, 
which was reflected in the large hydrodynamic radius observed using PCS. Therefore, the 
size estimation from the PCS was higher than the size found using TEM and large particle 
size was observed in each synthesis step. Previous studies on HNPs showed large 
hydrodynamic radius caused by magnetic aggregation (Hoskins et al. 2012b). However, 
after polymer coating, particle size decreased, which can indicate that coated particles tend 
to aggregate less than naked iron oxide NPs; thus the PEI intermediate layer acted as a 
stabiliser (Table 3). Gold seeding and gold coating onto the Fe3O4-PEI also affected the 
particles size and larger diameter has been obtained upon the seeding and coating process 
(Table 3). These results from the PCS were not in agreement with the TEM data, because 
findings from the TEM microscopy showed that naked Fe3O4 seemed to be monodisperse 
and approximately 30 nm in size (Figure 25A).  
The electron micrograph (Figure 25) showed that the iron oxide core is formed, seeded and 
coated with gold NPs. A slight increase in particles size was observed after complete gold 
coating to the surface of iron oxide NPs.  Therefore, it is estimated that the shell thickness 
is around 10 nm. Shell thickness has a direct impact on SPR and heating properties. It was 
suggested that reducing the thickness of the Au shell from 20 nm to 5 nm results in SPR 
red shift about 300 nm, which is related to the enhanced coupling between the outer and 
inner shell surface plasmons for the particles with thinner shell (Prodan et al. 2003). 
The results revealed that fabricated HNPs had an r2 (260.2 mM
-1 s-1) fairly similar with 
previously clinically administered Feridex
®
 (240.37 mM-1 s-1) (Lee et al. 2011) (Figure 28). 
Previously, Smolensky and colleagues proposed that gold shell at the surface of iron oxide 
NPs leads to quenched contrast ability (Smolensky et al. 2011). 
The findings suggest that the magnetic characteristics of the HNPs after gold coating 
process are in agreement with clinical standards and therefore have the capacity to use as 
contrast agents. These results in addition to the laser irradiation finding emphasise that the 
unique physical characteristics of the magnetic iron oxide NP and gold nano-shell, which 
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possesses SPR effect, are preserved by an intermediate polymer layer (PEI) that separates 
the core and shell.  
Few investigations have been performed for the heating effects of iron oxide-gold HNPs. 
Previously Hirsh and colleagues fabricated HNPs (Hirsch et al. 2003). They injected their 
HNPs into a tumour tissue in mice, which was exposed to laser irradiation (820 nm, 
4 Wcm
-2, 5 mm spot diameter) for around 6 min. The result demonstrated that irradiation 
of this novel particles inside the tumours increased the temperature to 37.4 °C after 4-6 min 
irradiation. Hirsh reported that this temperature increase was above the threshold 
temperature at which irreversible tissue damage occurs. In another study, Barnett et al. 
dispersed HNPs in 2 % agar gel and the samples were exposed to laser irradiation at 
532 nm by a Q-switched Nd:YAG laser (10 ns pulse duration, 10 pulses s
-1
). They reported 
that increasing the thickness of gold coating onto the iron oxide-PEI NPs resulted in 
reducing particles` ability to act as nano-heaters and decreased their magnetic properties, 
which is related to the enhanced coupling between the outer and inner shell surface 
plasmons for the particles with thinner shell (Barnett et al. 2012).  
Synthesised HNPs demonstrated to act as nano-heaters upon the laser irradiation at 
1064 nm, which was time and concentration dependant (Figure 30). In concentration of 
100  μgmL-1 at 37 °C , the temperature of the particles increased up to 44.5 °C, which is 
enough for our therapeutic agent to be released inside the tumour cells (will be described in 
Chapter Three). Moreover, the increased temperature only occurred in laser irradiated area, 
which means that this technique will not affect or damage surrounding healthy tissues. 
Laser experiment was performed with HNPs dispersed in an agar phantom, although this 
was an in vitro assay, the agar was used to mimic in vivo tissue conditions. However, in 
order to achieve higher ΔT, optimisation of synthesis process for HNPs is needed as the 
maximum achieved ΔT was less than 8 degrees. Additionally, the visual heating effect of 
HNPs has been confirmed by in vitro injection of particles into the raw chicken breast by 
applying laser irradiation (Figure 31).  
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2.5. Conclusion 
 
Novel hybrid iron oxide-gold core-shell NPs have been successfully synthesised and 
characterised by various techniques such as FTIR, PCS, UV–vis absorption, TEM, and 
PXRD, which all confirmed the formation of hybrid structure of the particles. Iron oxide 
NPs of core diameter 30 nm and gold coat (using the seeding method) were synthesised 
with a poly(ethylenimine) intermediate layer. The size of HNPs by TEM was 
approximately 40 nm. HNPs possessed a maximal absorbance at 610 nm. After laser 
irradiation in agar phantom a ΔT of 7.70 °C ± 0.80 was achieved after only 60 s exposure 
(100 μgmL-1). The HNPs appeared to decrease T2 values in line with previously clinically 
used MRI contrast agent Feridex
®
. Therefore, this study showed the potential of these 
HNPs as dual function MRI contrast agents and thermal switches in heat triggered drug 
delivery for thermo-responsive drug delivery. 
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Chapter Three  
Drug conjugations 
and characterisation 
of new formulations 
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3.1. Introduction 
 
NPs are usually described as aggregates or solid particles, which possess the core diameter 
between 10-1000 nm. This irreversible aggregation is the main indication of physical 
stability of NPs. The principle factors that influence the effect of aggregation are type of 
NPs, duration and temperature of storage, zeta potential and the presence of electrolytes. 
To prevent NPs from sticking together and setting out of suspension, NPs must be 
stabilised.  
There are two main strategies to induce stability for NPs in suspension: electrostatic 
repulsion and steric hindrance. By electrostatic repulsion, the charged surface of two NPs 
repels each other, resulting in a stable suspension. Steric stabilisation can be achieved by 
the sorption of none-ionic molecules (usually large ones) onto the surface of NPs. The 
surface-grafted molecules have a tail that is soluble in the surrounding solvent, and an 
anchor unit that is ideally non-soluble. These molecules keep NPs away from each other, 
reducing the effects of attractive van der Waals forces.  
In nanoparticulate drug delivery systems, the therapeutic or diagnostic agent can be 
encapsulated in or conjugated directly onto the NPs` surface. Recently, iron oxide-gold 
nanoparticles coated with hydrophilic polymer poly(ethylene glycol) (PEG) have been 
identified as long-circulating NPs which have potentials as drug delivery systems. The 
presence of the PEG coating makes the NPs becoming ‘stealth’ like resulting in longer 
systemic circulation compared with conventional therapies (Bhadra et al. 2002; 
Jokerst et al. 2011).  
Aqueous based formulations are desirable for administration of therapies into biological 
environments. However, many formulations experience long term stability issues. As such, 
it is common for NP formulations to be freeze dried and stored as solid powders before use 
to enhance their shelf life. Often, aggregation of NPs or drug release occurs on storage and 
hence the need for such freeze drying processes.  
The aggregation plays a pivotal role in their fate in aqueous environment. Many factors in 
human bodies such as pH and ionic composition can affect the interactions of nano-sized 
particles in biological environments (Guzman et al. 2006). Aggregated forms of NPs are 
usually poly-dispersed in solutions and their sizes may increase further when the pH 
reaches to the zero point of charge (pHzpc) (the pH where the concentration of protonated 
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and deprotonated surface groups are equal). Another important issue for understanding 
particles` behaviour is whether the dried NPs can disperse in a similar manner to the native 
solution upon reconstitution with water or biological media.  
Moreover, release of therapeutic agents at their designated site of action in order to achieve 
targeting of the drug is one of the main concerns in designing NPs. To take full advantage 
of high specific NPs, there should be no drug release until HNPs reach target site; thus 
reducing adverse effects (Zeng et al. 2011). This can be achieved by designing a 
sophisticated drug delivery system which protects particles from early release and has to be 
triggered by an external stimulus (e.g. temperature or pH changes) to release the cargo at 
the final destination.    
Measurement of drug release from formulations can be achieved using various methods 
including ultracentrifugation and ultrafiltration. More recently the use of dialysis tubing 
has grown dramatically (Johnston et al. 2006; Modi and Anderson, 2013). This entails 
trapping the formulation inside visking membrane of known pore size and exhaustively 
dialysing against water. As drug is released from the formulation, it permeates through the 
membrane into the surrounding media where it can be extracted and measured as a 
function of time. In comparison with the ultracentrifugation and ultrafiltration techniques, 
using the dialysis method means there is no need to set up an additional step of separating 
NPs from the free drug during the study. The external pressure utilised to separate NPs in 
other techniques may disturb the equilibrium, and partial separation can result in major 
errors (Wallace et al. 2012). Some of the advantages of using dialysis membrane for 
measuring drug release are one or more of the following: (1) assessing the effect of 
formulation factors and manufacturing methods on the drug product, (2) routine 
assessment of quality control to support batch release, (3) substantiating product label 
claims, and (4) establishing an in vitro in vivo correlation (IVIVC). 
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3.1.1. Bisnaphthalimide based drug 
 
In 1993, Brana et al. suggested bisnaphthalimides as potent chemotherapeutic agents. The 
bistertiary derivatives of this substance are identified to possess great antitumor activity in 
both murine and human cancerous cells (Brana et al. 2001). Due to the planar aromatic 
moiety, these chemicals intercalate within the DNA by the major groove 
(Sami et al. 2000). Although mitonafide and amonafide as monomeric 3-nitro- and 
3-amino-substituted compounds, respectively did not present sufficient anti-tumour 
activity in clinical trials (Taylor et al. 2002), elinafide and bisnafide as bissecondary 
analogues, (Figure 32), have shown remarkable in vitro anti-tumour activity. However, 
transferring elinafide to clinical trials for the treatment of solid tumours was not successful, 
because it showed a high toxicity without any marked therapeutic benefit 
(Brana et al. 2001). 
 
 
 
Figure 32. Chemical structure of the bisnaphthalimide based anti-cancers, elinafide and bisnafide. 
 
 
Previous studies have evaluated the in vitro and in vivo pancreatic anticancer activity of a 
nano-sized formulation based on novel poly(allylamine) grafted with 5 % mole cholesteryl 
pendant groups (Ch5-PAA). Novel anticancer drug, bis(naphtalimido propyl) diamino 
octane (BNIPDaoct) (Figure 33) was loaded into Ch5-PAA polymeric self-assemblies. 
BNIPDaoct compounds are not soluble in aqueous solutions, thus toxic solvents such as 
dimethyl sulfoxide (DMSO) have been used to solubilise this drug. Ch5-PAA novel 
formulation was able to increase aqueous solubility of BNIPDaoct, which enhanced its 
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anticancer activity and efficacy. Ch5 showed the capability of solubilising 0.3 mgmL
-1 
of 
BNIPDaoct in water (free drug was insoluble in water) with 1:1 initial drug:polymer mass 
ratio (concentration of the polymer was 1 mgmL
-1
).  
As previously described in Chapter One (Section 1.5), NPs are able to improve 
penetration/ internalisation of drugs into cancerous cells by EPR effect. Therefore, instead 
of active targeting, Ch5-PAA formulation accumulated passively in pancreatic cancer cells 
driven by EPR effect. This new formulation showed similar tumour reduction efficacy as 
the commercial drug, gemcitabine and an 8-fold reduction in concentration of free 
BNIPDaoct for the same cytotoxic result was achieved. The optimal formulations of Ch5 
loaded with BNIPDaoct were tested for their cytotoxicity in vitro on Caco-2 and HEK293 
cells. All formulations were capable of lowering the IC50 values when compared with the 
free drug, therefore enhancing their therapeutic effect. In vivo oral administration of Ch5 
formulations demonstrated significant decrease of the tumour growth when treated on 
tumour bearing nude mice over a 4 week period (Hoskins et al. 2010).  
BNIPDaoct possesses a chain with 14 carbons and two amine groups (eight carbons are 
between amines) between the bisnaphthalamide aromatic moieties (Figure 33). Many 
different compounds can be designed through changing this chain. For example, by 
increasing the number of carbon the hydrophobicity of the compound would increase, 
which makes it easier for the drug to cross the hydrophobic cell membrane. Moreover, by 
increasing the number of amine group, the drug would be more positively charged. This 
might able the drug to conjugate with the negatively charged NPs and since this interaction 
is not as robust as covalent bonding; the drug can be released by a trigger (temperature or 
pH changing) in a designated area.  
    
 
Figure 33. Chemical structure of bisnaphtalimido propyl diamino octane (BNIPDaoct). 
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This work will investigate the potential of using HNPs as thermally triggered drug carriers 
for pancreatic cancer. This novel technology will exploit the use of gold surface of the 
HNPs for the conjugation and delivery of novel chemotherapeutic drugs based on the 
bisnaphthalamide series. Four different bisnaphthalamide derivatives will be used in this 
study (Figure 34).  
 
 
 
 
 
 
Figure 34. Chemical structure of A) BNIDi, B) BNIPd, C) BNIPDSpm and D) BNIPds 
A 
C 
B 
D 
(BNIDi) 
(BNIPd) 
(BNIPDSpm) 
(BNIPds) 
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The first drug is bis(naphthalimido)-1,20-diaminoicosane (BNIDi) which possesses a 
chain, 20 carbons long between the bisnaphthalime moieties (Figure 34A). The second one 
is bis(naphthalimido)-1,12-diaminododecane (BNIPd) which possesses a chain of similar 
length, however two of the carbons was replaced with two amine groups (Figure 34B). The 
third derivative chain, bis(naphthalimidopropyl) spermine (BNIPDSpm), is of similar 
length with four substituted amines (Figure 34C) and finally, bis(naphthamimidopropyl)-
3,3`-(butane-1,4-diylbis(sulfanediyl))bis(propan-1-amine) (BNIPds) is comprised of a 
chain of the same length which has two amine groups as well as two additional thiol 
groups (Figure 34D). These compounds have been selected for binding onto the HNPs in 
order to investigate the potential of electrostatic interaction of drugs and HNPs as stimuli 
responsive systems for drug release. It was assumed that BNIDi would not conjugate onto 
the surface of the HNPs due to the absence of any charge or driving force for attachment. 
However, it was postulated that the drugs with positive amine groups (BNIPd and 
BNIPDSpm) would possess the ability to conjugate onto the negative surface of HNPs via 
weak van der Waal’s interactions. The final drug BNIPds has been added as a control as 
the thiol groups in the drug structure facilitate the attachment to the gold surface of HNPs 
by dative covalent bond (Au-S chemistry).  
These novel formulations were characterised by different analytic instruments such as 
photon correlation spectroscopy (PSC), Fourier Transform Infrared Spectroscopy (FTIR), 
fluorescence spectroscopy (due to the presence of aromatic rings in bisnaphthalamide 
derivatives) and reverse phase high performance liquid chromatography (RP-HPLC) (with 
fluorescence detector). The loading concentration of each drug has been optimised and 
formulations were tested for their stability and drug release profiles.   
Drug release study at various temperatures in water or culturing medium (in order to 
simulate physiological conditions) will be performed. It is suspected that the release 
pattern of the drugs with stronger interactions with HNPs, such as BNIPDSpm and BNIPds 
will be slower than formulation containing BNIPd which has only two amines in its 
structure. It is important to investigate the drug release pattern at different temperatures 
because the aim of this study is to trigger the release of drug in pancreatic cancer cells by 
laser irradiations. As described in Chapter Two (Section 2.3.8), these particles produced 
temperature increase up to 44 ºC upon the laser irradiation for 60 s. Therefore, it is crucial 
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to explore how much drug will be released from the formulations at different temperatures 
including 44 ºC.  
 
3.1.2. Fourier Transform Infrared spectroscopy 
 
FTIR is a sensitive and highly diverse molecular spectroscopy method and chemical 
analysis technique, which can identify organic chemicals in a whole range of applications 
in pharmaceutical industries related to drug discovery and structural elucidation.  
The term “Fourier transform” comes from the fact that a mathematical process is needed to 
translate the raw data into the actual spectrum.  Infrared (IR) spectroscopy has been used to 
identify unknown materials, recognise the quality/consistency of a sample, determine the 
amount of components in a mixture and identify the functional groups in a chemical 
compound (Griffiths and de Hasseth, 2007).  Samples in any state can be analysed using 
this technique including solid, liquid and gaseous phase samples (Sibilia, 1996).  
Each molecule has its own particular frequency resulting from the internal vibrations in the 
chemical bonds of the functional groups, which is used in IR spectroscopy (Banwell and 
McCash, 1994; Schwedt and Haderlie, 1997; Sibilia, 1996). IR spectroscopy works by 
passing infrared radiation (500-4000 cm
-1
) through a sample. This radiation is adsorbed at 
frequencies related to the compound vibrational frequency and the remaining frequencies 
are transmitted (Sibilia, 1996; Stuart et al. 1996). Each chemical structure has specific 
vibration; thus it can be detected by the analysis of its unique IR spectrum (Sibilia, 1996). 
The difference between FTIR and IR is using an interferometer instead of a 
monochromator in FTIR, which measures the spectrum indirectly (Sibilia, 1996). The 
interferometer combines two waves together and due to this combination and 
amplification, it can digitise the data and generate a spectrum (Stuart et al. 1996). In 
comparison with IR spectra, FTIR spectra possess high resolution of the peaks, enhanced 
signal/noise ratio and reduced measuring time, which makes it a very useful and precise 
technique (Schwedt and Haderlie, 1997; Sibilia, 1996).  
In this study, FTIR is an ideal tool to verify the presence of drug and analysis of drug 
conjugation to the surface of synthesised NPs. 
89 
 
3.1.3. Fluorescence spectrometry 
 
Fluorescence spectroscopy (also known as fluorometry or spectrofluorometry) is an 
important investigational technique in many areas of analytical science, due to its 
extremely high sensitivity and selectivity. It is used in a broad range of chemical, 
biochemical and medical research and has become an essential investigational technique in 
the pharmaceutical industry. Fluorescence spectrometry can detect and quantify fluorescent 
chemicals by electromagnetic spectroscopy. 
Compounds which have fluorescent characteristics have rigid molecular structures, such as 
aromatic ring systems, double and triple bonds (Schwedt and Haderlie, 1997). When a 
molecule absorbs a photon of light, the consequential excited electronic state leads to a 
change in the energy of that molecule. But when the molecule returns to its ground state 
the excess electronic energy is released as a photon of light, which is known as 
fluorescence (Hurtubise, 1990; White and Argauer 1970).  
Bisnaphthalimide derivatives are fluorescent compounds due to the presence of aromatic 
rings. This characteristic can help to demonstrate bisnaphthalamide drugs are present (on 
the basis of their excitation and emission properties) within the hybrid nano-formulation by 
fluorescence spectrometry.     
 
3.1.4. High performance liquid chromatography 
 
High performance liquid chromatography (HPLC) is one of the main analytical techniques 
utilised in the pharmaceutical industry. It has been used for a vast range of applications, 
which starts from drug discovery to formulation improvement and beyond. This instrument 
has been used in analytic chemistry to separate, identify, quantify and qualify the 
components in a sample.  
In normal phase HPLC, the separation technique occurs by the transportation of molecules 
through a non-polar mobile phase within a polar stationary phase, a column. This 
transportation relies on a pump that pressurises the liquid solvent containing the sample 
mixture (Kazakevich and LoBrutto, 2007). Each molecule in the solvent interacts with the 
adsorbent material in a different way, which produces different flow rates. Therefore, 
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components can be easily separated as they flow out the column. In reverse phased (RP) 
HPLC the column size is the same but non-polar stationary phase such as modified silica 
(long hydrocarbon chains are attached to its surface) and a polar mobile phase are utilised. 
In this method, compounds are separated due to their differences in hydrophobicity, which 
depends on polarity and size of the molecule (Kazakevich and LoBrutto, 2007). Non-polar 
and larger compounds in the mixture are retained on the column for longer as they tend to 
attach to the hydrocarbon chains in the column due to the van der Waal`s dispersion forces 
but the smaller polar molecules have strong attractions to the solvent and thus are eluted 
first. It means that increasing the polarity of the mobile phase will increases the retention 
time of non-polar molecules in the column. As a result, polar, non-polar and ionisable 
molecules will be separated by this method.  
In this study RP-HPLC with fluorescence detection can help to verify /quantify the drugs 
inside hybrid formulations.  
 
3.1.5. Aims and objectives 
 
The aim of this work is to evaluate the ability of a series of bisnaphthalamide based drugs 
to conjugate onto the surface of HNPs. It is the first time that these drugs conjugated to the 
surface of HNPs to fabricate a thermoresponsive drug delivery system, which will be 
triggered by laser irradiation, enable them to release their cargo in the designated area. 
Different bisnaphthalamide based drugs will be introduced to the HNPs to investigate the 
properties of electrostatic and covalent bonds between the drugs and gold surface. Novel 
formulations will be PEGylated to increase biocompatibility and blood circulation time. 
These nano-formulation will be characterised by PCS, fluorescent spectroscopy, FTIR and 
RP-HPLC. The stability of formulation will be tested at different temperatures and forms 
(dispersed in water or freeze dried) for 4 weeks. Drug release studies will be carried out at 
different temperature, PH and in culturing medium.  
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3.2. Materials and Methods 
3.2.1. Materials used 
 
Table 4. Materials used in synthesis and characterisation of hybrid formulations. 
Materials Suppliers 
Thiolated poly ethylene glycol (PEG-thiol) Sigma-Aldrich Co., UK 
PRMI Medium 1640(1X) Life technologies Co., UK 
HPLC Grade acetonitrile Sigma-Aldrich Co., UK 
Octane sulfonic acid Sigma-Aldrich Co., UK 
Sodium acetate ACROS Organics Co., USA 
HPLC Grade hydrochloric acid Sigma-Aldrich Co., UK 
HPLC Grade dimethyl sulfoxide Sigma-Aldrich Co., UK 
Bis(naphthalimido)-1,20-diaminoicosane (BNIDi) Synthesised by Keele Nanopharmaceutics research 
group 
Bis(naphthalimido)-1,12-diaminododecane (BNIPd) Synthesised by Keele Nanopharmaceutics research 
group 
Bis(naphthalimidopropyl)spermine (BNIPDSpm) Synthesised by Keele Nanopharmaceutics research 
group 
Bis(naphthamimidopropyl)-3,3`-(butane-1,4-
diylbis(sulfanediyl))bis(propan-1-amine) (BNIPds) 
Synthesised by Keele Nanopharmaceutics research 
group 
Hybrid nanoparticles (HNPs) Synthesised in Chapter Two 
 
3.2.2. Methods 
3.2.2.1. Drug conjugation 
 
To a solution of HNPs (1 mgmL
-1
, 5 mL) a certain amount of drug (dissolved in 5 mL 
deionised water) (Table 5) was added (based on the concentration of HNPs used in the 
literature for drug conjugation (Barnett et al. 2013a; Barnett et al. 2013b)). The solution 
was stirred for 3 h (optimum time for drug conjugation as no further attachment was 
achieved over this time) at room temperature (20 ºC) before being magnetically separated 
and extensively washing with deionised water. For the formulations containing 
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O-[2-(3-mercaptopropionyl amino) ethyl]-O′-methylpolyethylene glycol (PEG-thiol), 
25 mg of powdered polymer (based on the concentration used in the literature for 
PEGylation (Barnett et al. 2013a; Barnett et al. 2013b)) was added simultaneously with 
drug (a mixture of drug and PEG was added to the HNP solution) and particles were 
washed after 3 h as previously described. It was postulated that PEG will coat the surface 
of HNPs completely if it was added before the drug, thus no free surface would be 
available for the drug attachment. 
24 formulations (in conjugation with four different bisnaphthalamide derivatives) were 
prepared by this method and half of them were PEGylated by PEG-thiol (Table 5). 
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Table 5.  Table presents the amount of loaded bisnaphthalamide derivatives and PEG-thiol 
(dissolved in 5 mL of water) in each formulation. 
Formulation Type of loaded drug Amount of  loaded 
drug (mg) 
Amount of loaded 
PEG-thiol (mg) 
1 BNIDi 6.25 - 
2 BNIDi 6.25 25 
3 BNIDi 12.5 - 
4 BNIDi 12.5 25 
5 BNIDi 25 - 
6 BNIDi 25 25 
7 BNIPd 6.25 - 
8 BNIPd 6.25 25 
9 BNIPd 12.5 - 
10 BNIPd 12.5 25 
11 BNIPd 25 - 
12 BNIPd 25 25 
13 BNIPDSpm 6.25 - 
14 BNIPDSpm 6.25 25 
15 BNIPDSpm 12.5 - 
16 BNIPDSpm 12.5 25 
17 BNIPDSpm 25 - 
18 BNIPDSpm 25 25 
19 BNIPds 6.25 - 
20 BNIPds 6.25 25 
21 BNIPds 12.5 - 
22 BNIPds 12.5 25 
23 BNIPds 25 - 
24 BNIPds 25 25 
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3.2.2.2. Characterisation of novel formulations 
3.2.2.2.1 Drug quantification 
 
To find the optimal loading concentration of each drug onto the HNPs, the amount of 
attached drug was quantified by RP-HPLC (Prominence, DEGASSER, LC20AD, 
SHIMADZU) using a fluorescence detector at 234 nm (Excitation) and 394 nm (Emission) 
(Jasco, PU-980, Japan; column C18(2), 150×4.60 mm 5 micron, flow rate: 1 mLmin
-1
, 
injection volume: 20 µL). The buffer used in HPLC mobile phase was prepared by adding 
0.432 g octane sulfonic acid (to enhance the retention) and 1.64 g sodium acetate to 
200 mL of deionised water. Then the pH of the solution was reduced to 4.5 by the addition 
of hydrochloric acid (1-2 mL). Mobile phase was prepared by mixing this buffer and 
acetonitrile at a ratio of 70:30, respectively. After drug conjugation the particles were 
separated from the supernatant (waste solution) by using a strong permanent magnet on the 
outside of a glass vial containing the formulation. One mL of the waste solution (in water) 
was diluted with 1 mL of dimethyl sulfoxide (DMSO) and drug concentrations were 
analysed via HPLC. A calibration was run using drug solutions dissolved in 50: 50 H2O: 
DMSO with the concentration of 3.13-50 µgmL
-1
 (R
2 
= 0.999) (Appendix, Figure 7). The 
addition of DMSO helps the drug to be dissolved without sonication. The amount of 
attached drug was calculated from the amount of free drug in waste solution, detected via 
HPLC. All measurements were run in triplicate and recorded as average values. 
 
3.2.2.2.2. Zeta potential measurement  
 
Zeta potential measurements of novel formulations were carried out using a photon 
correlation spectrometer (PCS, Zetasizer Nano-ZS, Malvern Instruments, UK) as described 
in Chapter Two (Section 2.2.2.5.4). 
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3.2.2.2.3. Fourier Transform Infrared Spectroscopy 
 
HNP alone and formulations with the highest drug loading concentrations (5 mL) were 
freeze dried using Heto PowerDry LL3000, Thermo-Fisher UK. The freeze dried samples 
were analysed on the FTIR using a diamond tipped attenuated total reflectance attachment 
(Nicolet iS5 with iD5 ATR, Thermo-Fisher UK) and 64 scans were run at room 
temperature with background subtraction in order to qualitatively verify drug presence. 
 
3.2.2.2.4. Fluorescent spectroscopy 
 
Aqueous solution of free bisnaphthalamide based drugs and their hybrid formulations were 
run at room temperature on the Luminescence spectrometer (Varian, Cary Eclipse 
Fluorescence Spectrophotometer, USA) with Excitation wavelength set at 234 nm. The 
samples were scanned for Emission between 200-600 nm at 400 nmsec
-1
 with the slit 
widths of 5 nm, and the spectra were collected and analysed by the provided software.  
 
3.2.2.2.5. Stability study 
 
The stability of formulations was tested in relation to the amount of released drug from the 
particles in aqueous solution. The formulations were either left suspended in water or dried 
powder. This study was run at both room temperature (20 ˚C) and 4 ˚C over the period of 4 
weeks. For the aqueous formulations, 1 mL of each formulation (drug 
concentration = 0.5 mgmL
-1
) was kept at room temperature or 4 ˚C and the supernatant was 
analysed each week with HPLC to find out the concentration of released drug. For 
studying the stability of powder formulations 1 mL of each formulation with the same 
mentioned concentration was freeze dried. Each week samples were reconstituted in 
deionised water and the concentration of released drug investigated via HPLC as 
previously described in Section 3.2.2.2.1. All samples were sonicated with a sonic bath 
prior the separation of particles from the supernatant. All measurements were run in 
triplicate and recorded as average values. 
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3.2.2.2.6. In vitro drug release study 
 
In vitro drug release study in aqueous environments 
 
Some studies revealed linear correlation model between In vitro drug release in water and 
in vivo absorption (Bose and Wui, 2013; Cardot et al. 2007). Formulations (2 mL, 
0.5 mgmL
-1
) were placed into visking tubing (12-14 KDa) and dialysed against 200 mL 
deionised water at room temperature (20 ˚C) with stirring. The volume of dialysis fluid 
was in excess to mimic the ‘sink’ conditions experienced after injection into the blood 
stream (Barnett et al. 2013a). At selected time points (0.083 h, 0.17 h, 0.33 h, 0.5 h, 1 h, 4 
h, 6 h, 8 h, 24 h, 48 h, 72 h, 144 h, 168 h and 216 h) a sample of the exterior solution 
(1 mL) was removed and replaced with 1 mL deionised water at the specified time points 
previously described. All samples were diluted with 1 mL of DMSO and drug 
concentrations were analysed via HPLC. The experiment was carried out in triplicate and 
the peak area was compared to a calibration of the free drug dissolved in DMSO/H2O 
(50:50) (R
2 
= 0.999) (Appendix, Figure 7). 
 
In vitro drug release at varied temperatures 
 
Drug release study for formulations was performed at different temperatures (20, 30, 40, 
44, 50 & 60 ˚C) and the release of the drugs was monitored by HPLC as described in 
Section 3.2.2.2.1. This test was performed to mimic the temperature change upon the laser 
irradiation. Previously Jelveh and Chithrani used this approach to predict the release of 
drug from gold NPs after laser irradiation (Jelveh and Chithrani, 2011).   
 
In vitro drug release in biological media 
The release of BNIPDSpm drug from PNIPDSpm-HNP and PNIPDSpm-HNP-PEG was 
also tested in serum free culture media (RPMI) at different pH.  RPMI is a form of medium 
used in cell culture and tissue culture to grow different type of human cells. This medium 
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contains a great deal of phosphate and is formulated for use in a 5% carbon dioxide 
atmosphere. Although it is not completely as same as the biological fluid, examining 
release of drug in RPMI may be useful to have better understanding of drug release in 
biological environments. The pH of culture media was 7.5, which was close to the 
intracellular pH (pHi =7.42) of pancreatic cancer cells (Preissler and Williams, 1981). We 
also investigated the drug release pattern at pH=4.6 and pH=3.6 to simulate endosome and 
lysosome environment. pH adjustment was carried out using concentrated hydrochloric 
acid (20 M). The release of the drug was tested by HPLC as described in Section 3.2.2.2.1. 
 
3.3. Results 
3.3.1. Drug conjugation 
 
All four bisnaphthalamide based drugs were characterised using HPLC coupled to a 
fluorescence detector at Excitation 234 nm and Emission 394 wavelengths (Figure 35). 
The retention time for peak observation for all drugs was between 7-11 min, where sharp 
peaks were observed. In order to investigate drug concentration in our experiments, 
calibration curve, obtained from HPLC analysis (samples concentration between 
3.13-50 µgmL
-1
) for each drug was utilised (R
2
 = 0.999) (Appendix, Figure 7).  
 
98 
 
 
 
Figure 35. RP-HPLC analysis of 100 µgmL
-1
 A) BNIDi, B) BNIPd, C) BNIPDSpm and 
D) BNIPds, detected at 394 nm Emission. All drugs were dissolved in DMSO/H2O (50:50 v/v).  
Data from HPLC analysis showed that BNIDi was not capable of conjugation onto the 
surface of HNPs and PEGylated HNPs (HNP-PEG) to form BNIDi-HNP and 
BNIDi-HNP-PEG (Figure 36). This was expected due to the absence of any positively 
charged amine group in BNIDi structure or other driving force for conjugation. The 
remaining drugs (BNIPd, BNIPDSpm, and BNIPds) all successfully conjugated onto the 
surface of HNP and HNP-PEG at varying degrees. Therefore six different formulations 
(BNIPd-HNP, BNIPd-HNP-PEG, BNIPDSpm-HNP, BNIPDSpm-HNP-PEG, 
BNIPds-HNP and BNIPds-HNP-PEG) were fabricated. The optimum loading 
concentration for each drug was investigated by HPLC analysis (Figure 36). 
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Figure 36. Drug loading of bisnaphthalamide based drugs onto HNPs at varied initial drug feed 
concentration (n=3, ave ± SD).  
 
The loading concentrations for each drug were 1.25 mgmL
-1
, 2.5 mgmL
-1
 and 5 mgmL
-1
 
(Figure 36). Higher initial feed concentrations were not investigated due to the lack of 
aqueous solubility of drug compounds over 5 mgmL
-1
. One way to increase the solubility 
of drug is using co-solvent such as DMSO during the formulation process. However, 
DMSO was not used in this study as it increases the cytotoxicity of the final product. In 
general, increasing drug loading concentration of BNIPDSpm resulted in greater drug 
attachment onto the nanoparticle surface. This could be due to the number of amine group 
in BNIPDSpm structure (4 amines), resulted in stronger electrostatic interactions between 
the drug and particle, in comparison with other drugs. As no plateau was observed in the 
graph, it would suggest that further conjugation could be possible and the HNP surface was 
not saturated; however, the physicochemical properties of the drug in solution hindered 
further attachment. For BNIPds the graph did plateau at higher drug feed ratios suggesting 
the particle surface was saturated and no more attachment was possible. Given, the nature 
of the permanent thiol linkage achieved with BNIPds drug (in addition to the electrostatic 
binding opportunities arising from the amines) compared with the sole ability for 
electrostatic attachment of the other drugs, it is postulated that a more rigid binding occurs 
with less flexibility, utilising greater surface area and hence leading to lower binding 
saturation concentrations. 
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The data showed that BNIPDSpm conjugated (with 5 mgmL
-1
 loading concentration) to the 
surface of HNPs at higher concentration to the other drugs (Figure 36). Approximately, 
3.4 mgmL
-1
 and 3.8 mgml
-1
 of BNIPDSpm (from 5 mgmL
-1
 loading concentrations) 
attached to the HNP and HNP-PEG, respectively. This means that the binding efficiency of 
68-76% was achieved. The addition of PEG appeared to increase BNIPd and BNIPDSpm 
loading slightly (Figure 36). This was unexpected given the PEG moiety was in 
competition with the drug for area on the gold surface; however, as evident in the drug 
loading data, the surface was possibly not saturated and also it is possible that small 
quantities of drug molecules could have been physically trapped within the polymer 
framework. At 2.5 mgmL
-1
 loading concentration, BNIPds surpassed BNIPDSpm and 
attached slightly more to the surface of HNPs. However, when the loading concentration 
increased from 2.5 mgmL
-1
 to 5 mgmL
-1
, the concentration of conjugated BNIPds did not 
change significantly (p > 0.05) (Figure 36). 
While BNIDi with no amine group (Figure 34A) did not attached to the HNP and 
HNP-PEG, the loading capacity of bisnphathalamide derivatives increased by increasing 
the number of amine group (from two amines in BNIPd to four amines in BNIPSDpm) 
(Figure 36). In all loading concentrations, BNIPd tended to conjugate to the particles less 
than BNIPDSpm and BNIPds drugs (Figure 36). This could be due to the number of amine 
groups (two amines) presents in its structure (Figure 34B), thus the electrostatic interaction 
between BNIPd and the HNPs is weaker than other formulations. BNIPDSpm possessed 
four amine groups (Figure 34C) , which allowed it to make strong electrostatic interactions 
with negatively charged gold at the surface of HNPs. BNIPds has two amine groups and 
two additional thiol groups (Figure 34D), therefore, it can attach to the particles` surface by 
covalent dative bond via Au-S chemistry and presumably by charge-charge interactions 
through amine groups. However, in 5 mgmL
-1
 loading concentration BNIPds attached to 
the HNPs surface less than BNIPDSpm, which may be due to surface saturation as 
discussed (Figure 36).  
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3.3.2 Characterisation of novel formulations 
3.3.2.1. Zeta potential measurement of novel formulations  
  
Particles conjugated with different drugs were characterised by photon correlation 
spectrometer (Table 6). Zeta potential measurements showed that all the formulations 
possessed positive surface charges, excluding BNIDi-HNP and BNIDi-HNP-PEG. These 
results indicate that drug attachment was achieved as the amine functionalities within the 
majority of the drug molecules would infer positive charge.  
The surface charge of BNIDi-HNP and BNIDi-HNP-PEG formulations was very similar to 
that of the HNP alone, which again confirms that drug conjugation was not achieved 
(Table 6). 
 
Table 6. Zeta potential index of particles measured at 1 mgmL
-1
 (concentration of conjugated drug) 
in deionised water (n=3, Ave ± SD). 
*: Unknown concentration was used due to the lack of drug attachment.  
Particle Zeta Potential 
mV ± SD 
HNP − 4.32±0.03 
*
 BNIDi-HNP − 4.25±0.06 
* 
BNIDi-HNP-PEG − 6.97±0.01 
BNIPDSpm-HNP +28.48±0.14 
BNIPDSpm-HNP-PEG +13.43±0.07 
BNIPd-HNP +26.62±0.05 
BNIPd-HNP-PEG +9.25±0.18 
BNIPds-HNP +10.44±0.12 
BNIPds-HNP-PEG +1.12±0.05 
 
The charge pattern for other unPEGylated formulations was BNIPDSpm-HNP > 
BNIPd-HNP > BNIPds-HNP. The BNIPDSpm-HNP formulation possessed the highest 
zeta potential in this group which is due to the BNIPDSpm molecule possessing the 
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greatest number of amine groups (four amines) compared with other drugs (Figure 34C). 
The surface charge of the BNIPd-HNP formulation was less than BNIPDSpm-HNP as it 
only possesses two amines groups. The reduced surface charge of the BNIPds-HNP (which 
also possesses two amine groups) compared to the BNIPd-HNP formulation is possibly 
due to the presence of the thiol (-SH) group in the drug structure. Thiol groups in water 
surroundings dissociate a proton, which makes the surface less positive 
(Václav et al. 2011). As a result of this, the decrease of zeta potential confirms also the 
binding of thiol groups on gold surface.  
The data shows that all PEGylated formulations possessed lower surface charges, 
compared with unPEGylated formulations conjugated with the same drug, indicating 
further modification of PEG. This could be due to PEG chains shielding surface charge of 
gold coating.  
Although, the absence of BNIDi in the formulations (BNIDi-HNP and BNIDi-HNP-PEG) 
was proposed before, the presence of PEG in BNIDi-HNP-PEG can explain the decrease of 
BNIDi-HNP zeta potential upon the PEGylation. Moreover, the same surface charge 
pattern for PEGylated formulations was achieved, which again proves the presence of 
different drug in each formulation, described before (BNIPDSpm-HNP-PEG > 
BNIPd-HNP- PEG > BNIPds-HNP-PEG) (Table 6). 
 
3.3.2.2. Fourier Transform Infrared Spectroscopy of formulations 
 
FTIR was used to qualitatively confirm the conjugation of drugs onto the HNPs. FTIR 
analysis of the samples (excluding BNIDi formulations) indicated that each drug 
conjugated to the surface of HNPs successfully (Figures 38-40). Before introducing the 
samples to FTIR, background spectrum was collected and subtracted. The series of 
characteristic Infrared (IR) bands for each formulation are summarised in detail in 
Tables 7-9.  
FTIR Spectra of BNIDi-HNP and BNIDi-HNP-PEG indicated that BNIDi did not 
conjugate to the HNP, since there was not any difference between FTIR spectra of HNP 
(Figure 37A) and BNIDi-HNP (Figure 37B). Peaks at 1651 cm
−1
, between 2950-2850 cm
−1
 
and at 3442 cm
−1
 in figures 37A and 37B are associated with N-H bending, alkane C-H 
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stretching and N-H stretching (amine group) vibrations, respectively. These peaks confirm 
the presence of PEI polymer in formulations. Band around 2800 cm
−1 
for 
BNIDi-HNP-PEG is related to C-H stretching vibration (Figure 37C).
 
Other Peaks 
observed at 1660 cm
−1
 (C=O stretching), 1341 cm
−1
 (C–H bending; −CH2 and −CH3) 
confirm the presence of bound PEG within BNIDi-HNP- PEG formulation. 
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Figure 37. FTIR spectra of A) HNP, B) BNIDi-HNP and C) BNIDi-HNP-PEG, between 
1000-4000 cm
−1
. 
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Both FTIR spectra of BNIPd-HNP and BNIPd-HNP-PEG confirmed that the drug 
attachment has been achieved successfully (Figure 38). The series of characteristic IR 
bands for both formulations are summarised in detail in Table 7. The bands at 1260 cm
−1
 
and 1110 cm
−1
 in BNIPd-HNP and BNIPd-HNP-PEG spectra are assigned to aromatic 
in-plane C-H bending vibrations, respectively. Peaks between 800-700 cm
-1
 are associated 
with N-H groups (wagging) in both formulations. Bands between 2920-2900 cm
−1
 and at 
1600 cm
−1
 are due to alkane C-H stretching and C=O stretching vibrations in both 
formulations, respectively; presented within the BNIPd structure (Figures 38A and 38B). 
Peaks observed at 600 cm
−1
 and 2420 cm
−1
 in PEGylated formulation are assigned to C-S 
stretching and S-H stretching vibrations in PEG-thiol molecule, respectively. 
 
 
Table 7. Assignment of FTIR spectra for BNIPd-HNP and BNIPd-HNP-PEG.  
Samples IR bands (cm
−1
) Description 
 
 
 
BNIPd-HNP 
789 
900 
1260 
1600 
1680 
2915 
 
N-H (Wagging) 
Aromatic out-of plane C-H (Bending) 
Aromatic in-plane C-H (Bending) 
Aromatic C=C (Stretching) 
C=O (Stretching) 
C-H (Stretching) 
 
 
 
 
 
BNIPd-HNP-PEG 
600 
780 
900 
1110 
1600 
1646 
2420 
2900 
 
C-S (Stretching) 
N-H (Wagging)  
Aromatic out-of-plane C-H (Bending) 
Aromatic in-plane C-H (Bending) 
Aromatic C=C (Stretching)  
C=O (Stretching) 
S-H (Stretching) 
C-H (Stretching) 
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Figure 38. FTIR spectra of A) BNIPd-HNP and B) BNIPd-HNP-PEG between 500-4000 cm
−1
. 
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The attachment of BNIPDSpm with HNP and HNP-PEG was proved by FTIR spectra 
(Figure 39). The series of characteristic IR bands for both formulations are summarised in 
detail in Tables 8. Bands around 1100 cm
−1
 in BNIPDSpm-HNP and 
BNIPDSpm-HNP-PEG spectra are assigned to aromatic in-plane C-H bending. Peaks 
around 2925 cm
−1
, 1680 cm
−1
 and 1580 cm
−1
 are due to the presence of CH2 (stretching), 
C=O (stretching) and aromatic (C=C stretching) groups in both formulations, respectively; 
presented within the BNIPDSpm structure (Figures 39).  
 
Table 8. Assignment of FTIR spectra for BNIPDSpm-HNP and BNIPDSpm-HNP-PEG. 
Samples IR bands (cm
−1
) Description 
 
BNIPDSpm-HNP 
 
1100 
1580 
1680 
2930 
 
Aromatic in-plane C-H (bending) 
Aromatic C=C stretching 
C=O (Stretching) 
C-H (Stretching) 
 
 
 
BNIPDSpm-HNP-PEG 
 
1110 
1580 
1674 
2920 
 
Aromatic in-plane C-H (Bending) 
Aromatic C=C stretching  
C=O (Stretching)  
C-H (Stretching) 
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Figure 39. FTIR spectra of A) BNIPDSpm-HNP and B) BNIPDSpm-HNP-PEG, between 
1000-4000 cm
−1
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FTIR spectra of BNIPds-HNP and BNIPds-HNP-PEG confirmed the conjugation of the 
drug to the surface of particles (Figure 40). The series of characteristic IR bands for both 
formulations are summarised in detail in Tables 9. Bands at 900cm
-1
 and around 1240 cm
−1
 
in BNIPds-HNP and BNIPds-HNP-PEG spectra are assigned to aromatic out-of-plane and 
aromatic in-plane C-H bending, respectively. Peaks around 760 cm
-1
 are associated with 
N-H groups (wagging) in both formulations. The bands around 2935 cm
−1
 and 1600 cm
−1
 
are due to the presence of CH2 (stretching) and C=O (stretching) groups in both 
formulations, respectively; presented within the BNIPds structure (Figures 40). Small peak 
was observed around 2400 cm
−1
 in PEGylated formulation, which is assigned to S-H bonds 
(stretching), presented within PEG-Thiol structure. 
 
Table 9. Assignment of FTIR spectra for BNIPds-HNP and BNIPds-HNP-PEG. 
Samples IR bands (cm
−1
) Description 
 
 
BNIPds-HNP 
 
742 
900 
1230 
1590 
1680 
2930 
 
N-H (Wagging) 
Aromatic out-of plane C-H (Bending) 
Aromatic in-plane C-H (Bending) 
Aromatic C=C (Stretching) 
C=O (Stretching) 
C-H (Stretching) 
 
 
 
 
BNIPds-HNP-PEG 
 
 
770 
900 
1250 
1600 
1670 
2410 
2940 
 
N-H (Wagging) 
Aromatic out-of plane C-H (Bending) 
Aromatic in-plane C-H (Bending) 
Aromatic C=C (Stretching) 
C=O (Stretching) 
S-H (Stretching) 
C-H (Stretching) 
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Figure 40. FTIR spectra of A) BNIPds-HNP and B) BNIPds-HNP-PEG between 500-4000 cm
−1
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3.3.2.3. Fluorescence spectrometry of formulations 
 
Fluorescence spectrometry was used to confirm the presence of the drug molecules 
attached the surface of the HNPs. The HNPs themselves are not fluorescence; however, the 
aromatic groups in the bisnaphthalimide moieties of the drugs undergo excitation and 
emission allowing them to be detected. The fluorescent spectra for the drugs alone and the 
formulations (excluding BNIDi formulations) confirmed drug attachment to the HNPs 
surface (Figures 42-44).  
Fluorescence spectra of BNIDi formulations were in agreement with HPLC and FTIR 
analysis (Figure 41). While BNIDi alone possessed emission λmax at 508 nm (Figure 41B), 
HNPs alone (Figure 41A) and BNIDi formulations (Figures 41C and 41D) had featureless 
spectra between 200-600 nm, indicating the absence of BNIDi in formulations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41. Fluorescence spectrometry of A) HNP, B) BNIDi, C) BNIDi-HNP and 
D) BNIDi-HNP-PEG (Excitation: 234 nm). Unknown concentration of free drug and conjugated 
drug was analysed at room temperature.  
A B 
C D 
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Fluorescence spectroscopy of BNIPd and its hybrid formulations confirms the presence of 
drug within the formulations. Free BNIPd (Figure 42A), BNIPd-HNP (Figure 42B) and 
BNIPd-HNP-PEG (Figure 42C) showed same peaks around 424 nm and 510 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42. Fluorescence spectrometry of A) BNIPd, B) BNIPd-HNP and C) BNIPd-HNP-PEG 
(Excitation: 234 nm; Emission: 400 nm). Unknown concentration of free drug and conjugated drug 
was analysed at room temperature.  
 
Fluorescence spectrometry also validated the conjugation of  BNIPDSpm to the surface of 
particles (Figure 43). A sharp peak within the same wavelenghth (350 nm) was observed 
for  free BNIPDSpm (Figure 43A), BNIPDSpm-HNP (Figure 43B) and 
BNIPDSpm-HNP-PEG (Figure 43C). 
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Figure 43. Fluorescence spectrometry of A) BNIPDSpm, B) BNIPDSpm-HNP and 
C) BNIPDSpm-HNP-PEG (Excitation: 234 nm). Unknown concentration of free drug and 
conjugated drug was analysed at room temperature.  
 
Figure 44 confirmed the attachment of BNIPds to the surface of HNPs as free BNIPds 
(Figure 44A) and in conjugation with HNP (Figure 44B) and HNP-PEG (Figure 44C) 
possessed the same λmax at 508 nm. 
 
 
 
 
 
A 
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Figure 44. Fluorescence Spectrometry of A) BNIPds, B) BNIPds-HNP and C) BNIPds-HNP-PEG 
(Excitation: 234 nm; Emission: 400 nm). Unknown concentration of free drug and conjugated drug 
was analysed at room temperature.  
 
Following the lack of attachment of BNIDi into the surface of HNP and HNP-PEG, it was 
decided not to continue any further studies with these formulations. 
 
3.3.2.4. Stability tests 
 
The optimal formulations were stored in a dark airtight container at either room 
temperature (20 °C) or under refrigeration (4 °C) and also in two forms; as liquid 
formulations and as freeze dried ‘cakes’ (reconstituted with water and sonicated) for up to 
4 weeks (Figures 45 and 46). Both forms (dried and disperse) were sonicated before 
stability measurement.  
A 
B C 
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Figure 45. Stability test for novel formulations at 20 
ᵒ
C in the form of A) dispersed in water and 
B) freeze dried, over the period of 4 weeks (n=3, ave ± SD).  
 
The data suggested that the form of formulation (aqueous / solid) was a more important 
parameter than the temperature in terms of stability. The samples which were freeze dried 
possessed a higher degree of stability compared to the liquid preparations. This might be 
due to the presence of water in in aqueous formulations, which can increase the risk of 
drug release from the nano-carriers. BNIPd-HNP and BNIPd-HNP-PEG displayed the 
lowest stability, which might be due to the loose electrostatic interactions between the drug 
and HNPs, since this drug only possessed two amine groups within its structure. All 
0
20
40
60
80
100
%
  C
o
n
ju
ga
te
d
 d
ru
g 
in
 2
0 
°C
 
Week 1
Week 2
Week 3
Week 4
A 
0
20
40
60
80
100
%
  C
o
n
ju
ga
te
d
 d
ru
g 
in
 2
0 
ᵒC
  Week 1
Week 2
Week 3
Week 4
B 
116 
 
aqueous form of BNIPd formulations exhibited less than 20 % stability. As the charge 
increased in BNIPDSpm, so too did the stability. Presumably due to the stronger 
electrostatic binding on the HNP surface. Over 80 % and 90 % stability have been 
achieved for aqueous and freeze dried BNIPDSpm formulations after 4 weeks, 
respectively. PEGylated formulations exhibited comparable stability to unPEGylated 
formulations (Figures 45 and 46).  
 
 
  
 
Figure 46. Stability test for novel formulations at 4 
ᵒ
C in the form of A) dispersed in water and 
B) freeze dried, over the period of 4 weeks (n=3, ave ± SD).   
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BNIPds formulations were highly stable in both forms and at both temperatures due to the 
strong covalent binding between the drug and gold at the surface of HNP 
(Figures 45 and 46). In terms of temperature, decreasing temperature from 20 ºC to 4 ºC  
increased the stability of the BNIPd and BNIPDSpm aqueous formulations showing that 
reduced temperature leads to less drug detachment and protects the integrity of the 
electrostatic bonds.  
 
3.3.3. In vitro drug release study 
 
The release of the drugs from the optimal formulations was performed under ‘sink’ 
conditions. We investigated the conditions necessary for drug release in aqueous 
environment and culturing media (at various temperatures and pH). 
 
3.3.3.1. In vitro drug release study in aqueous environments 
 
BNIPd formulations exhibited very low stability (Figures 45 and 46) and the drug attached 
in lower quantity than other drugs to the surface of HNPs (Figure 36). Therefore, it was 
decided to start the drug release experiments at room temperature (20 ºC) in water. As 
expected, the drug release occurred rapidly with 90 % of drug released from PEGylated 
and unPEGylated formulations within 4 h and 6 h, respectively (Figure 47A). This low 
stability and fast drug release could be due to the loose electrostatic interactions between 
the drug and particles, as BNIPd possesses only two amines groups within its structure 
(Figure 34B). It indicates that these formulations are not stable at all and if they are 
injected to the body the drug will be released from the particle before reaching to the 
desired site of action. Following the low stability and fast release of BNIPd from 
formulations, it was decided not to continue any further drug release studies at different 
temperatures and/or in biological media with these formulations. 
BNIPDSpm-HNP and BNIPDSpm-HNP-PEG were analysed in terms of the amount of 
BNIPDSpm release in 20, 30, 40, 50 and 60 ˚C (Figures 47B and 47C). BNIPDSpm 
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release for both formulations measured over 72 h showed a biphasic release profile due to 
an initial burst, which is followed by a constant release.  
 
 
Figure 47. Drug release study of A) BNIPd-HNP and BNIPd-HNP-PEG in 20 ˚C and 
B) BNIPDSpm-HNP in 20 , 30 , 40 , 50 and 60 ˚C, C) BNIPDSpm-HNP-PEG in 20 , 30 , 40 , 50 
and 60 ˚C and D) BNIPds-HNP and BNIPds-HNP-PEG in 60 ˚C. Experiments were performed 
three times, and data were expressed as mean ± standard errors (n=3, ave ± SD). All statistical 
analyses were carried out using t.test analysis within the Microsoft Excel software package.   
 
Release of drug from BNIPDSpm-HNP-PEG (Figure 47C) after 20 min was significantly 
higher than BNIPDSpm-HNP (Figure 47B) in 40, 50 and 60 ˚C (p < 0.05). This might be 
due to the drug position in attachment with the particles. In the absence of PEG 
BNIPDSpm is flattened at the surface of the particles because of the abundance of free 
space, thus establishes strong interactions. In the presence of PEG, drug has to compete 
with the polymer for the particles` surface. As a result this type of interaction is not as 
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robust as unPEGylated formulation. Analysis of data showed no significant difference in 
drug release between 20 and 30 ˚C for formulations (p > 0.05). After 72 h, nearly 40 %, 
50 % and 60 % of drug was released from BNIPDSpm-HNP in 40, 50 and 60 ˚C, 
respectively (Figure 47B). Interestingly, BNIPDSpm-HNP-PEG showed a different 
response in 60 ˚C with about 80 % of drug released after 72 h (Figure 47C).  
BNIPDSpm drug release pattern was investigated at 44 ºC, as this is the optimum 
temperature generated by HNPs upon the laser irradiation, described in Chapter Two 
(Section 2.3.8). BNIPDSpm-HNP and BNIPDSpm-HNP-PEG formulations were able to 
achieve sustained drug release over 264 h and 336 h, respectively (Figure 48). In this 
temperature there was a notable difference in drug release between formulations and the 
amount of drug released from the PEGylated one was significantly higher between 10 min 
and 24 h (p < 0.05). 
 
 
 
Figure 48.  Drug release study for BNIPDSpm-HNP and BNIPDSpm-HNP-PEG at 44 ˚C for the 
period of 336 h. Experiments were performed three times, and data were expressed as 
mean ± standard errors (n=3, ave ± SD). All statistical analyses were carried out using t.test 
analysis within the Microsoft Excel software package.   
 
Due to the permanent covalent binding of BNIPds formulations it was assumed that 
BNIPds may not be release from the particles, thus drug release experiment was 
investigated at high temperature (60 ºC) in water, up to 72 h (Figure 47D). The results 
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showed that less than 1.5 % of drug released from both PEGylated and unPEGylated 
formulations. This could be associated with the strong covalent dative bond between thiol 
group of drug and gold coating at the surface of the HNPs. Therefore, if laser irradiation 
was applied for these formulations, the drug will not be released inside the cells (by the 
temperate increase achieved through laser irradiation in this study (Figure 30)). However, 
some studies showed that adjustment of laser power and ionic strength can cleave Au-S 
bond (Poon et al. 2010). Therefore, this formulation may be considered in the future for 
thermoresposive drug delivery studies. Due to the low release rate of BNIPds from 
formulations, it was decided not to continue any further drug release studies at different 
temperatures and/or in biological media with these formulations. 
 
3.3.3.2. In vitro drug release in biological media 
 
Release of BNIPDSpm from hybrid formulations was tested in culture media at pH= 7.5, 
pH=4.6 and pH=3.6 at 37 ºC and 44 ºC up to 312 h to mimic cytoplasm (pHi =7.42), 
endosome and lysosome environment in pancreatic cancer cells, respectively (Figure 49) 
(Preissler and Williams, 1981). Release of BNIPDSpm from formulations was time, pH 
and temperature dependant. In general, like BNIPDSpm release pattern in water 
(Figures 47B and 47C), formulations showed a biphasic release profile due to an initial 
burst within 6 h, which is followed by a constant release. The highest release rate occurred 
in pH=3.6, at 44 ºC for PEGylated formulation (Figure 49B).  
In 37 ºC, 50 % release from BNIPSDpm-HNP in pH=3.6, 4.6 and 7.5 occurred after 72 h, 
96 h and 144 h, while these amount of drug released from PEGylated formulations after 
6 h , 8 h and 24 h with the same pH mentioned above, respectively (Figure 49A). These 
data suggest that decreasing pH significantly enhanced the release rate of drug from both 
formulations (p < 0.05). Moreover, release rate of BNIPDSpm from PEGylayed 
formulation is significantly higher than the release from unPEGylated formulation 
(p < 0.05) (Figure 49A). After 312 h the drug completely released from both formulations 
at 37 ºC.  
The same pattern was observed in 44 ºC, and again the higher release occurred in lower pH 
(Figure 49B). The release from PEGylated formulations was significantly higher than its 
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unPEGylated counterpart (p < 0.05). Half of the drug (0.5 mg) released from 
BNIPSDpm-HNP in pH=3.6, 4.6 and 7.5 after 24 h, 48 h and 72 h, while these amount of 
drug released from PEGylated formulations after 4 h , 6 h and 8 h with the same pH 
mentioned above, respectively (Figure 49B).  
 
 
 
 
Figure 49. Drug release study for BNIPDSpm-HNP and BNIPDSpm-HNP-PEG at different pH in 
A) 37 ºC and B) 44 ºC for 312 h. All statistical analyses were carried out using t.test analysis within 
the Microsoft Excel software package (n=3, ave ± SD).    
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These data suggest that decreasing pH significantly enhanced the release rate of drug from 
both formulations as electrostatic interactions can be broken faster in lower pH (p < 0.05). 
After 288 h the drug completely released from both formulations at 44 ºC. The results 
confirmed that release of BNIPDSpm from the particles was greater/faster at lower pH and 
PEGylated formulation always possessed faster release compared to the unPEGylated 
formulation. 
By analysing these data we suggest that when the BNIPDSpm-HNP-PEG particles cross 
the pancreatic cancer cell membrane and accumulate inside the lysosome (pH=3.6), at 
44 ºC (achieved by laser irradiation), about 60 % of drug will be released in the first 8 h.  
 
3.4. Discussion 
 
Conjugation of drugs by electrostatic interactions onto the surface of HNPs is a novel 
strategy to deliver therapeutic agents into their site of action and few investigations have 
been performed in this area.  
Recently, Barnett et al. fabricated hybrid iron oxide-gold NPs and a model drug, 
6-Thioguanine (6-TG), was successfully conjugated to the surface of these particles with a 
ratio of 3:1:10 Fe:Au:6-TG. In vitro studies were carried out on human pancreatic 
adenocarcinom (BxPC-3) and differentiated human monocyte cells (U937). The cellular 
uptake increased with a 10-fold decrease in half maximal inhibitory concentration (IC50) 
upon the conjugation of the drug with HNPs, compared with the free drug 
(Barnett et al. 2013a). In another study Barnett and co-workers fabricated and evaluated a 
new class of poly(allylamine) (PAA) polymer conjugated with hydrophobic oxadiazole 
(Ox) pendant group. They suggested that the thiol-containing pendant group can increase 
the attachment of HNPs by dative covalent bonding. Different drugs were conjugated via 
direct conjugation of hydrophilic and encapsulation of hydrophobic drugs. In comparison 
with the free drug, the conjugated drugs had significant higher drug uptake with decreased 
IC50 (Barnett et al. 2013b). 
Wagstaff and colleagues reported the conjugation of cisplatin ({Pt(NH3)2}
2+
) via a 
thiolated polyethylene glycol linker (PEG-thiol) into the surface of iron oxide-gold NPs. 
The thiol groups in PEG-thiol conjugated to the gold surface by dative covalent bond 
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(Au-S chemistry), while attaching cisplatin via its terminal carboxylate groups. This novel 
formulation was up to 110-fold more cytotoxic than the drug alone. Interestingly, they 
explained that this nano-sized formulation could accumulate in specific regions by using an 
external magnetic field, which showed cell growth inhibition area for the treated cells by 
novel formulation (Wagstaff et al. 2012). 
We have demonstrated the ability of our HNPs to conjugate with different 
bisnaphthalamide based drugs onto their surface via electrostatic interactions or covalent 
bonds. Drugs were successfully conjugated to the surface of HNPs and drug content in 
each formulation was analysed using HPLC. Different loading concentrations for each 
drug were used and the optimal loading concentration of them was achieved. In general, 
loading capacity of drugs are affected by a number of factors such as feeding 
concentration, the number of amine group, the presence of thiol group and PEG and the 
type of interaction between drug and HNPs (electrostatic or covalent). Data suggested that 
BNIDi cannot be conjugated to the surface of HNPs (even with the highest loading 
concentration) due to the lack of amine group which is essential for electrostatic interaction 
between bisnaphthalamide derivatives and HNPs. Our results demonstrate that between 
these drugs a significant amount of BNIPDSpm could be loaded on to the HNPs (with 
linear correlation between the drug feeding and attached concentration) (Figure 36), which 
is sufficient to achieve drug release in the range of µg with conservative concentration of 
HNPs. The presence/absence of drug in each formulation has been proved by zeta potential 
measurement (Table 6), FTIR (Figures 37-40) and fluorescent spectroscopy 
(Figures 41-44).  
In general, number of amine group and the presence of thiol group or PEG in formulation 
affected particles surface charge. While the presence of amine groups increased the surface 
charge of the particles (Kardys et al. 2013), thiol group and PEG shifted the zeta potential 
toward negative values (Ku et al. 2010). This result is also indirect evidence demonstrating 
that the amino and thiol group and PEG are conjugated to the surface of HNPs.  
FTIR spectra of BNIDi formulations confirmed the lack of drug inside the formulations 
(Figure 37) which is due to the absence of amine group in this drug discussed before. As a 
result, it was decided not to further study these formulations. 
The conjugation of BNIPd to the HNP is due to the electrostatic interaction of two positive 
amine groups of this drug with the gold coating, as proved by the peak broadening of N-H 
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stretching vibrations of drug-HNPs in FTIR spectra (Figure 38). Previously, Selvaraj and 
colleagues suggested that -NH group of 5-Fluorouracil was involved in binding the drug 
onto the surface of gold NPs (Selvaraj et al. 2007). In another study, Aslam and 
co-workers explained that gold has a strong affinity towards the amino group (Aslam et 
al. 2004). Although the number of amine group is a crucial factor for electrostatic 
interaction of bisnaphthalamide derivatives to the surface of HNPs, the two central amines 
in bisnaphthalmide chain seem to have more affinity to the gold surface as BNIPDSpm 
with four amines attached significantly more than BNIPd and BNIPds to the surface of 
HNPs (p < 0.05) (Figure 36). Moreover, the stability (Figures 45 and 46) and drug release 
pattern (Figure 47) of formulations conjugated with BNIPDSpm and BNIPd confirmed that 
BNIPd formulations were not stable and they possessed fast release pattern.  These results 
associated with the poor interaction of BNIPd with HNPs due to the number of amine 
group discussed before. Instability and fast drug release from BNIPd formulations made 
them unsuitable for drug delivery system. BNIPDSpm (with four amine groups) 
formulations were quite stable for the period of 4 weeks and showed different release 
pattern at different temperature, solutions and pH.  
In general, BNIPDSpm release from formulations in water and culture media showed 
biphasic patterns, which include a sharp release in the first 10 h following by a gradual 
release. For drug release in water, PEGylated formulations showed significant higher drug 
release compared to unPEGylated formulations, especially in 60 ºC, where nearly 73 % of 
BNIPDSpm was released up to 8 h (p < 0.05) (Figure 47C).  
BNIPds is conjugated by covalent dative bond through –SH group of the drug with Au at 
the surface of particles. Au–S bonds are quite strong, approximately 40 kcal mol−1 (Ulman, 
1996), which is nearly half the strength of a C–H or C–C bond. This strong bond resulted 
in high optimal loading concentration (Figure 36) and high stability (Figures 45 and 46). 
But due to this robust interaction, less than 2 % of the drug released in 60 ºC, after 72 h 
(Figure 47D). This means that BNIPds formulations cannot be used in drug delivery 
system as the drug will not be release even in high temperature. 
In cancer therapy, many drugs such as small molecule chemotherapeutic agents, siRNA, 
DNA and proteins have to be delivered by a carrier and released into the particular cellular 
compartments, which is usually cytoplasm or nucleus of cancer cells. Intracellular 
environment-responsive NPs, which possess high extracellular stability while rapidly 
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releasing their cargo inside cancer cells have been enormously investigated for improving 
cancer therapy (Park et al. 2006). The pH of cancer cells in the endo/lysosomal 
compartments is slightly acidic in comparison with normal cells (Figure 50). This naturally 
existing environment has been vigorously exploited as an internal stimulus to trigger drug 
release from NPs inside cancer cells. Particularly, these intracellular pH-responsive NPs 
have shown higher antitumor effects in comparison with non-responsive NPs; as a result of 
quicker and more efficient drug release in cancerous cells (Meng et al. 2009).  
However, these NPs have experienced different levels of success in vitro and in vivo, 
probably due to the diversities in the responsive compartments such as lysosome, 
endosome, cytosol and nucleus. Furthermore, for in vivo studies, these bio-responsive NPs 
have to also present high stability in blood circulation system (Lammersa et al. 2012).  
 
 
 
Figure 50. Schematic diagram of intracellular pH-responsive NPs for “active” drug release inside 
pancreatic cancer cells. The release of drug can be triggered by following two pathways: (i) mildly 
acidic pH (4.5-5.5) induced drug release in endosomal compartments and (ii) low pH (3.5-4.5) 
caused drug release in lysosomes. 
 
pH-sensitive NPs that are susceptible to release at endo/lysosomal pH have been fabricated 
based on formulations possessing protonable amine groups (primary, secondary and 
tertiary amines). Electrostatic interactions that respond to pH variations can be broken at 
lower pH. For example, Bae and colleagues suggested that doxorubicins (Dox)-loaded 
micelles released Dox in a pH-dependent manner and enhanced higher growth inhibition of 
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human colon tumour at acidic than basic pH. They designed pH responsive drug delivery 
system in order to release Dox into the cytoplasm via sensing low pH in endosomes 
(Bae et al. 2005).  
Recently, Nam et al. described a new thermo-pH responsive drug delivery containing 
10 nm gold NPs conjugated with Dox, in vivo. This novel nanocarrier was able to 
aggregate in mild acidic environment such as in tumour tissues. By applying laser 
irradiation, these particles produced heat resulting in Dox release from the particles inside 
the tumour cells. They revealed that Dox accumulated in tumours up to 17 times over the 
control due to the enhanced permeation and retention effect (Nam et al. 2013).  
In our study BNIPDSpm drug release in culture media followed the same pattern of release 
in water; however, decreasing the pH of media and increasing the temperature (from 37 ºC 
to 44 ºC) enhanced the drug release rate (Figure 49). These results also showed that 
BNIPDSpm released in culturing media from HNP-PEG significantly faster than 
unPEGylated formulation (p < 0.05).  
Investigation of drug release pattern in culturing media, in 37 ºC and 44 ºC, was crucial for 
us. Because as described in Chapter Two (Section 2.3.8), 44 ºC would be the temperature 
of the HNPs upon laser irradiation. Therefore, by in vitro drug release investigations in 
culturing media (in body temperature and 44 ºC), the release pattern of the formulations 
inside the pancreatic cancer cells, before and after laser irradiation can be predicted.  
As a result, BNIPDSpm hybrid formulations showed pH and thermoresponsive drug 
delivery properties. Therefore, it is assumed that after accumulation of the NPs in 
endosome and lysosome, the low environmental pH and increasing the temperature 
through laser irradiation, will result in quick drug release from the particles. Then the free 
drug can enter cells` nucleus and interact with DNA for anticancer effect.   
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3.5. Conclusion 
 
It was demonstrated that the type of interaction between bisnaphthalamide derivatives and 
HNPs had a direct impact on conjugation ability, stability and drug release pattern of 
hybrid formulations. BNIPDi with no amine group was not able to conjugate with HNP; 
however, stronger interaction of drug-NPs was achieved by increasing the number of 
amine from BNIPd to BNIPDSpm. Conjugation of BNIPds with HNPs confirmed that 
exploiting Au-S chemistry is possible for conjugation of a molecule possessing thiol group 
to the gold coating surface. This covalent bond resulted in highest stability between 
bisnaphthalamide hybrid formulations and cannot be broken with the produced heat 
achieved by laser irradiation in this study. Within four different bisnphthalamide drugs, 
BNIPDSpm (with four amine groups) formulations possessed the highest loading capacity 
to the surface of HNP, good stability and thermo-pH responsive drug delivery properties. 
Drug release study of BNIPDSpm formulations showed that faster release was obtained by 
increasing the temperature and reducing the pH (close to the pH of intracellular 
organelles). Moreover, PEGylated formulations mostly revealed greater release of drug in 
comparison with their unPEGylated counterparts.  
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 4.1. Introduction 
 
The usual approach in cancer treatment with chemotherapeutic agents comprises of the 
systemic administration of one or more cytotoxic drugs intravenously which do not possess 
tumour specificity (Worns, 2013). This lack of specificity results in the normal cells being 
affected leading to undesirable patient side effects. Various techniques have been reported 
to enhance the efficacy of anticancer agents such as increasing the solubility or uptake rate 
of drugs by cancer cells, targeted delivery to tumour (Jeanbart et al. 2014) and 
mitochondria targeted drugs delivery (Modica-Napolitano and Weissig, 2015); however, 
many of them failed to improve the specific delivery of chemotherapeutic agents. It is 
estimated that 40 % -70 % of all new compounds identified in drug discovery programs are 
insufficiently soluble in aqueous media (Lindenberg et al. 2004). Some of drug carriers 
have side effects on normal tissues and organs. Another drawback is the inability of 
formulation to selectively target tumour cells. Moreover, the resistance of cancer cells to 
the chemotherapeutic agents remains a significant impediment to successful chemotherapy 
(Chakraborty and Rahman, 2012). This is particularly true for pancreatic ductal 
adenocarcinoma (PDAC). PDAC is a deadly disease which is characterised by a dense 
stroma. Studies have shown that the epithelial and stromal compartments interact to 
increase the aggressive nature of this cancer (Rasheed et al. 2012). Therefore, it is crucial 
to develop anticancer therapies targeting the stroma and epithelial cells, which may play a 
prominent role in clinical outcome improvement for patients with this highly lethal disease.  
 
Before a new drug or a novel drug delivery system is deemed clinically suitable and able to 
be marketed, they have to go through rigorous testing and cost-effectiveness analyses, both 
in preclinical and clinical studies. Initial characterisations of new compounds are usually 
followed by in vitro (in Latin means within the glass) investigations, where novel 
formulations are tested on mammalian cells outside their normal biological context. The 
complexity of cells inside the body is a great obstacle to the determination of interactions 
between the drug/formulation and biological compartments and the investigation of their 
basic biological functions. By in vitro analyses, in vivo fate of the drug/formulation can be 
estimated. This can be achieved by in vitro in vivo correlations (IVIVC) that play a key 
role in the drug development and optimisation of formulation (Vignais and Vignais, 2010). 
Therefore, in vitro work (tissue culture) offers the potential of avoiding variations 
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occurring in vivo (Freshney, 2005). However, it might be challenging to generalise from 
the results of in vitro work back to the biology of the living organism and give a true 
representative of in vivo conditions (Rothman, 2002). As such these investigations are 
normally followed by in vivo studies using appropriate models in small animals. 
 
4.1.1. Investigation of bioavailability 
 
It is crucial to verify the biocompatibility or cytotoxicity of a novel formulation in vitro 
before introducing to in vivo environments. In nano drug delivery systems, bioavailability, 
uptake and pharmacokinetics of NPs to organisms are key factors to toxicity. Therefore, 
many in vitro assays have been used, such as cytotoxicity assays and drug uptake analysis. 
These experiments are simple, reproducible and not as expensive or ethically charged as in 
vivo tests. Moreover, NPs as carriers of cytotoxic agents must not be toxic and any increase 
in cytotoxicity must be due to synergistic effects of chemotherapeutic agents. 
 
4.1.1.1. Cytotoxicity assay 
 
4.1.1.1.1. MTT assay 
 
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay is a standard 
colorimetric assay for assessing cell metabolic activity and verifying the cytotoxic effect of 
a new compound or formulation when introduced to the cells. The test is based on treating 
cells in their exponential growth phase with a formulation for a desired period of time 
(usually between 24-72 h) (Lamprecht et al. 2000). Then the formulation is replaced with 
MTT solution. Inside the cells, NAD(P)H-dependent cellular oxidoreductase enzymes can 
reflect the number of viable cells present. As these enzymes can reduce the yellow MTT 
solution to its insoluble formazan, which is identified by a purple colour. Therefore, the 
percentage of cell viability can be calculated and half maximal inhibitory concentration 
(IC50) can be determined. This can be achieved by dissolving the formazan crystal in 
dimethyl sulfoxide (DMSO), following measuring the absorbance formazan solutions by a 
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microplate reader. It has been reported that 4 h is the optimal time for cells to be incubated 
with MTT, in order to achieve accurate viability determination (Carmichael et al. 1987).  
 
In this study MTT assay was utilised to investigate the toxicity of bisnaphthalamide based 
drugs, hybrid nanoparticles (HNPs) and novel formulations and comparing them to 
commercial anticancer drug, gemcitabine.  
 
 
Microplate reader 
Microplate reader (plate readers or microplate photometers) is an instrument which has 
been used for biological and chemical detections of samples in microtiter plates, usually 96 
wells plate (8 by 12 matrixes). They have been enormously utilised in bioassay validation, 
drug discovery, manufacturing processes and quality control tests in the pharmaceutical 
companies and research organisations. The volume of sample in each well is usually 
between 100-200 µL per well. This instrument works by the detection of samples` 
absorbance, fluorescence intensity, time-resolved fluorescence, luminescence, and 
fluorescence polarisation (Mosmann, 1983). 
 
4.1.1.1.2. Trypan blue assay 
 
Trypan blue (TB) exclusion assay is one of the oldest and is still one of the most common 
methods for measuring cell viability. Trypan blue is a vital stain (diazo dye), which is able 
to stain dead cells blue (due to their more permeable cell membrane).  But it cannot colour 
live cells with intact cell membrane as it is not adsorbed by intact live cell membranes. 
Therefore, this assay has the potential to identify and enumerate live (unstained) and dead 
(blue) cells in a given population (Tennant, 1964). The live cells can be counted by an 
automated cell counter or by a microscope. Then the IC50 value can be calculated regarding 
the number of control cells. In this test, cells in their exponential growth phase are 
incubated with formulation for a period of time and then treated cells solution will be 
mixed with trypan blue with the ratio of 1:1 and the number of viable cells is counted.  
 
This assay can be a complimentary test for the MTT results, in order to achieve accurate 
IC50 value.  
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4.1.2. In vitro cellular uptake of formulation   
 
It is important to track a formulation on its cellular journey in order to investigate how the 
NPs enter the cell and to prove that the site of action for payload release is reached. Many 
parameters can affect cellular uptake of particles such as shape, stiffness and charge of NP.  
 
The shape of particles is a crucial factor, which can modify the rate of cellular uptake and 
blood circulation time. Different shapes of NPs have been used in drug delivery systems, 
such as disk-like, spherical, rod-like, and flexible in shape (Petros and DeSimone, 2010). 
However, the influences of shape on cellular uptake have been challenging to analyse 
because most NPs have spherical shape.  
 
The rigidity of NP can also influence distribution and cellular uptake. There are few 
studies to demonstrate that different types of cells have different preferences for NPs 
uptake. As an example, while soft NPs such as polymeric NPs can be taken up better than 
hard NPs (e.g. metalic NPs) by HeLa cells (You and Auguste, 2009), macrophages have 
the ability to uptake hard ones (Beningo and Wang, 2002).  
 
The NP surface charge can influence the particles distribution, tissue retention and cellular 
uptake, which has to be well understood to target the delivery of particles. Many studies 
have been performed to investigate the relation between the surface charge of the particles 
and their cellular uptake. Most of them proposed that in most cell lines, higher uptake can 
be achieved by positively charged NPs, which might be due to the charge-charge 
interaction with the negative cell membrane. However, there are some exceptions for some 
stem cells such as mesenchymal stem cells (due to the differences in 
endocytotic/pinocytotic properties of the cell lines) (Lorenz et al. 2006) and certain 
macrophages (macrophage uptake increases with the surface charge increasing (either 
positive or negative)) (Gratton et al. 2008).  
The effect of particle size and surface charge on cellular uptake and biodistribution of 
polymeric NPs was shown in an interesting study by He et al. Rhodamine B labeled 
carboxymethyl chitosan grafted NPs and chitosan hydrochloride grafted NPs were 
developed as the model negatively and positively charged polymeric NPs, respectively. 
The result revealed that NPs with large particle size and high surface charge were 
phagocytised more efficiently by murine macrophage. In vivo bio-distribution suggested 
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that NPs with slight negative charges (-15 mV) and particle size of 150 nm were tended to 
accumulate in tumour more efficiently. This is positively correlated with in vitro murine 
macrophage uptake assessment. As Rhodamine B labeled carboxymethyl chitosan grafted 
NPs (-15 mV, 150 nm) possessed the lowest distribution percentage in liver and spleen 
(He et al. 2010).  
In this work in vitro cellular uptake assay was used to measure the drug accumulation in 
cells. The concentration of compounds in in vitro assays is usually named as the nominal 
mass dose, which is quoted in units of microgram/picogram of compounds per millilitre 
(µgmL
-1
/ pgmL
-1
) (Lison and Huaux, 2011). Therefore, by knowing the number of the cells 
in each experiment, the concentration of taken up drug in each cell can be calculated.  
  
4.1.3. Atomic Force Microscopy  
 
Atomic force microscopy (AFM) is a kind of scanning probe microscopy (SPM), with very 
high resolution. SPMs are aimed to identify physical properties, for example height, 
magnetism and friction with a specific probe. AFMs work through quantifying force 
between the sample and a probe. Usually, AFMs` probe has a sharp tip, which is like 3-6 
micrometres tall pyramid (Figure 51) (Binnig et al. 1986). Therefore, information is 
generated by "feeling" or "touching" the surface with this probe. AFM is capable to scan 
samples in nanometres and shows the roughness and hardness of a samples surface or cells 
with very high resolution. Piezoelectric elements, which make really small movements 
with high accuracy on (electronic) command, are capable to scan samples very precisely 
(Binnig et al. 1986). By using AFM, researchers can distinguish cancer cells from normal 
cells through the hardness of the cells. Moreover, the interaction between a specific cells 
and the effect of a chemotherapeutic agent on a certain cell line can be analysed.  
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Figure 51. Drawing of basic principle of Atomic Force Microscope (AFM). 
 
Compared to the optical microscope and an electronic microscope, AFM has no lens and 
beam irradiation. Thus, there is no limitation of space resolution due to a diffraction limit. 
Moreover, in this technique, there is no need for staining of the sample.  
 
In this study, AFM topography imaging can help to investigate the surface and morphology 
of the treated cells with different formulations, compared to the control cells.  
 
4.1.4. Arginine-glycine-aspartic acid (RGD) Peptides 
 
In 1999, Buckley and colleagues discovered arginine-glycine-aspartic acid (RGD) peptide 
as cell attachment site in fibronectin. They found that RGD peptides were able to inhibit 
tumour metastasis and induce cell apoptosis (Buckley et al. 1999). After that, RGD 
derivatives have been considerably used in studies of cell migration, adhesion, apoptosis 
and growth by RGD-integrin interactions.  
 
RGD peptides have high affinity to integrin αvβ3, which plays a significant role in tumour 
angiogenesis. Integrin αvβ3, is a receptor for the extracellular matrix proteins with the 
exposed RGD tripeptide sequence (Hwang and Varner, 2004). Integrin avβ3 is expressed 
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on many different types of cancer including pancreatic cancer. However, in this type of 
cancer, integrin avβ3 is expressed both on primary tumours and on metastatic tumours 
(Hosotani et al. 2002) making it an ideal targeting peptide. 
 
Cyclo(-Arg-Gly-Asp-D-Phe-Cys) peptide or c(RGDfC) (Figure 52)  is an RGD 
tumour-targeting peptide, which can bind to αvβ3 receptors. C(RGDfC) can be easily 
attached to drugs or surfaces of NPs (Kilian and Mrksich, 2012; Pattillo et al. 2005).  For 
example, Pattillo and colleagues incorporated combretastatin into long circulating 
liposomes. Then c(RGDfC)  peptide was conjugated to maleimide functional groups  of the 
liposome on the distal end of PEG chains (Pattillo et al. 2005). 
  
In this study, a new approach to link c(RGDfC) peptide to the bis(naphthalimidopropyl) 
spermine PEGylated hybrid formulation (BNIPDSpm-HNP-PEG) is presented with the 
goal of targeting integrin avβ3 to increase drug specific delivery and anticancer activity, 
which will be compared to the formulations without the targeting peptide. This peptide can 
be conjugated to the surface of HNPs via its thiol group (dative covalent bond) in the 
cysteine residue in its structure (Figure 52).   
 
Different bisnaphthalamide based drugs alone and in conjugation with HNPs and 
PEGylated HNPs (HNP-PEG) will be tested in vitro, in case of their cytotoxic effects 
(using MTT assay and trypan blue test). Drug uptake potentials of drug alone and 
drug-loaded formulations will be analysed on human primary pancreatic adenocarcinoma 
(BxPC-3), human epithelial-like pancreatic carcinoma (PANC-1) and human monocyte 
cell line which exhibits macrophage like qualities after differentiation (U937). The latter 
cell line will be used in order to investigate the cytotoxic effect of drugs and different 
formulations on immune cells.  All results will be compared to the cytotoxic effect of 
gemcitabine as a control drug.  
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Figure 52. Chemical structure of c(RGDfC) 
 
C(RGDfC) targeting peptide will be conjugated to BNIPDSpm-HNP-PEG to investigate 
the cytotoxic effects and drug uptake of this novel formulation on all three cell lines, 
mentioned before.  In vitro thermoresponsive drug delivery at various temperatures will be 
carried out to simulate the temperature increase gained upon laser irradiation. AFM 
topography imaging will be performed to visualise cells surface before and after treatment 
with drugs and formulations.  
 
4.1.5. Aims and Objectives 
 
The aim of this work is to determine how effective HNPs are as carriers for cytotoxic 
agents and assess the clinical potential of the bisnaphthalamide formulations in the 
treatment of pancreatic cancer. 
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4.2. Materials and Methods 
4.2.1. Materials used 
Table 10. Materials used in biological investigations. 
Materials Suppliers 
Gemcitabine Sigma-Aldrich Co., UK 
Cyclo(-Arg-Gly-Asp-D-Phe-Cys) peptide Bachem Co., Switzerland  
HPLC Grade ethanol Fisher Scientific, UK 
Thiolated poly ethylene glycol (PEG-thiol) Sigma-Aldrich Co., UK 
PRMI culture medium  Life technologies Co., UK 
DMEM culture medium Life technologies Co., UK 
Trypsin-EDTA 0.05 % Life technologies Co., UK 
Foetal bovine serum Fisher Scientific, UK 
Phorbol-12-myristate 13-acetate (PMA) Sigma-Aldrich Co., UK 
Phosphate buffered saline   Fisher Scientific, UK 
L-glutamine  Sigma-Aldrich Co., UK 
Penicillin streptomycin Life technologies Co., UK 
Cell freezing medium-DMSO Sigma-Aldrich Co., UK 
Highly purified water MillexQ system (UK) 
Acetonitrile Sigma-Aldrich Co., UK 
Octane sulfonic acid Sigma-Aldrich Co., UK 
Sodium acetate ACROS Organics Co., USA 
HPLC Grade hydrochloric acid Sigma-Aldrich Co., UK 
HPLC Grade trifluoroacetic acid Fisher Scientific, UK 
HPLC Grade dimethyl sulfoxide Sigma-Aldrich Co., UK 
Glutaraldehyde Sigma-Aldrich Co., UK 
3-[4,5-dimethylthiazol-2-yl]-2,5- 
diphenyltetrazolium bromide (MTT)  
Sigma-Aldrich Co., UK 
Bis(naphthalimido)-1,12-diaminododecane (BNIPd) Synthesised by Keele Nanopharmaceutics  
Research group 
Bis(naphthalimidopropyl)spermine (BNIPDSpm)  Synthesised by Keele Nanopharmaceutics  
Research group 
Bis(naphthamimidopropyl)-3,3`-(butane-1,4-
diylbis(sulfanediyl))bis(propan-1-amine) (BNIPds) 
Synthesised by Keele Nanopharmaceutics  
Research group 
Hybrid nanoparticles (HNPs) Synthesised in Chapter Two 
BxPC-3 cell line (Passage number:10) LGC Standards Co., UK 
PANC-1 cell line (Passage number:10) LGC Standards Co., UK 
U937 cell line (Passage number:10) LGC Standards Co., UK 
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4.2.2. Methods 
4.2.2.1. Cytotoxicity Assay  
4.2.2.1.1. MTT([3-(4,5-Dimethylthiazol-2-yl)2,5Diphenyltetrazolium 
Bromide]) cytotoxicity assay 
 
BxPC-3, PANC-1 and U937 cells were cultured in their medium (RPMI medium for 
BxPC-3 and U937 and DMEM medium for PANC-1) supplemented with 1 % 
penicillin/streptomycin and 10 % foetal bovine serum (1 % of L-glutamine is also added to 
PANC-1 and U937 cell culture medium). The maximum passage number of 10 was used 
for all cell lines during the biological studies and cells were sub cultured when the 
confluency reached to around 75 %. In order to supply differentiated U937 cell line, 
0.02 % of phorbol-12-myristate 13-acetate (PMA) (50 µgmL
-1
 in PBS) was added to the 
cells suspension. All three different cells (100 μL, 15000 cells/well) in exponential growth 
phases were seeded into 96 well flat bottomed plate and incubated for 24 h at 37 °C with 
5 % CO2. After 24 h, the media was replaced with various concentrations of gemcitabine, 
free bisnaphthalamide based drugs, naked HNPs and novel formulations, diluted in cellular 
growth medium (Table 11). Cells were incubated for further 24 h at the same condition 
discussed before.   
 
A 20 mgmL
-1
 of each free drug solution was prepared using 50:50 of sterile water:DMSO 
as the diluent to form a stock solution. From the stock solution, eight dilutions 
(0.1 - 1×10
-5
 mgmL
-1
) were made using media as the diluent (Table 11).  Media and sterile 
water were the positive and negative controls, respectively (Figure 53). After 24 h, the 
drug solutions were removed and washed with fresh media to remove any excess drug. 
Fresh media was replaced into the wells (100 µL). 3-[4, 5-dimethylthiazole-2-yl]-2, 
5-diphenyl tetrazolium (MTT, 50 μL, 5 mgmL-1 in PBS) was added to the wells and plate 
was incubated (37 °C with 5 % CO2) for 4 h. After this time, the MTT solution was 
removed from the wells. The remaining purple formazan complexes were dissolved in 
DMSO (100 μL) and the absorbance of the plates was read at 570 nm using a microplate 
reader (Tecan, infinite 200 pro, GmbH 5082, Australia). Percentage cell viability and IC50 
was calculated relative to the positive and negative controls (Equation 8) (all biological 
studies were run in triplicate (n=3) and recorded as average values).  
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Table 11. Preparation of anticancer drug solutions for MTT assay (0.1 - 1×10
-5
 mgmL
-1
). 
*: Sample was made from 0.05 mgmL
-1
 concentration as a stock solution.  
 
Drug concentration 
(mgmL
-1
) 
Volume of 20 mgmL
-1
 
drug stock solution (µL) 
Volume of media (mL) 
0.1 22.5 4.5 
0.05 11.5 4.5 
0.025 5.6 4.5 
0.01 2.25 4.5 
0.005 1.125 4.5 
* 0.001 90 4.5 
* 0.0001 9 4.5 
* 0.00001 1 4.5 
 
In order to prepare the same concentration of drug (Table 11) within hybrid formulations, 
the initial hybrid formulations were used as a stock solution and the same concentrations of 
drug discussed in Table 11 were prepared. Moreover, the concentrations made for HNP 
alone (without drug) indicates the concentration of iron oxide in hybrid formulations 
(HNP-drug).  
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Figure 53. Illustration of different concentrations, positive and negative controls in 96-well plate 
for MTT assay. 
 
 
 
 
 
 
 
(8) 
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4.2.2.1.2. Trypan blue cytotoxicity test 
 
BxPC-3, PANC-1 and U937 cells (1 mL, 50000 cells/ well) in exponential growth phase 
were seeded into 12-well flat bottomed plates and incubated for 24 h at 37°C with 5 % 
CO2. The media was replaced with drugs, HNPs and novel formulations at various 
concentrations as previously described. Cells were incubated for 24 h, subsequently the 
media was removed and cells were washed 3 times with PBS. The cells were trypsinised 
and re-suspended in fresh media. A mixture of 50 μL of cells and 50 μL of trypan blue 
solution was placed in an automated cell counter (Invitrogen Countess
®
, UK) and viable 
cells were counted. Percentage cell viability and IC50 were calculated in relation to the 
number of control cells as described in Equation 9. 
 
     
                                                                                                                                    
4.2.2.2. In vitro cellular uptake of formulations   
 
BxPC-3, PANC-1 and U937 cells (3 mL, 150000 cells/ well) in their exponential growth 
phase were seeded into 6-well plates and incubated for 24 h at 37° C with 5 % CO2. The 
media was replaced with 50 μgmL-1 & 100 μgmL-1 of different bisnaphthalamide based 
drugs, their hybrid formulations and gemcitabine and incubated for 1 h and 4 h. The 
medium was removed and each well was washed with 1 mL PBS before the addition of 
185 μL trypsin into each well. Cells re-suspended in 1 mL media and viable cells were 
counted using an automated cell counter (Invitrogen countess
®
, UK). Cells (100,000) were 
transferred into the eppendorf tubes and centrifuged (800 rpm, 5 min). The supernatant was 
removed and cells were resuspended in DMSO:water (1:1) (for samples containing 
bisnaphthalamide derivatives) or water (for samples containing gemcitabine).  
 
The concentration of bisnaphthalamide derivatives and gemcitabine were quantified using 
reverse phase high performance liquid chromatography (HPLC) (cells were transferred 
from 6-well plates into Eppendorf tubes). Characterisation and quantification of 
bisnaphthalamide derivatives were performed by reverse phase HPLC (Prominence, 
(9) 
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Degasser, LC20AD, Shimadzu) using a fluorescent detector at Excitation 234 nm and 
Emission 394 wavelengths, which discussed in Chapter Three (Section 3.2.2.2.1). For 
gemcitabine detection, an HPLC with UV detector (Perkin Elmer, Flexar Autosampler, 
column: SPHERISORB ODS 2 5µm, length 250 mm, internal diameter 4.6 mm) and a 
mobile phase contained H2O and acetonitrile (30:70) were used. The standard solutions of 
gemcitabine were scanned in the range of 200-400 nm against mobile phase as a blank. 
Gemcitabine showed maximum absorbance at 234 nm. Therefore, samples were detected 
at 234 nm with flow rate of 1 mL.  The limit of detection and limit of quantitation were 
0.1498 and 0.4541 μgmL-1, respectively (Rao et al. 2007). A calibration was run using 
gemcitabine solutions, dissolved in H2O with the concentration of 300-18.75 µgmL
-1
 
(R
2
 = 0.999) (Appendix, Figure 7E). All measurements were run in triplicate and recorded 
as average values. 
  
In drug uptake method the concentration of drug accumulated in each cell was calculated 
relative to the total number of cells in each sample (cells were counted by an automated 
cell counter).  
    
4.2.2.3. Peptide conjugation to PEGylated formulation and 
characterisation of the new formulation  
 
To a solution of HNPs (1 mgmL
-1
, 5 mL), 25 mg BNIPDSpm (dissolved in 5 mL deionised 
water), 1 mg c(RGDfC) peptide and 25 mg  PEG-thiol were added. The solution was 
stirred for 3 h before magnetically separating and extensively washing with deionised 
water. The amount of attached drug and peptide was quantified by RP-HPLC (Prominence, 
DEGASSER, LC20AD, SHIMADZU) using the same fluorescence detector with the same 
column discussed in Chapter Three (Section 3.2.2.2.1). c(RGDfC) peptide was detected by 
a mobile phase containing solvents A and B (50:50). Solvent A was water containing 
0.09 % trifluoroacetic acid (TFA) and solvent B was acetonitrile containing 9.91 % H2O 
and 0.09 % TFA (Jin et al. 2007). The Excitation and Emission wavelengths were 250 nm 
and 307 nm, respectively. A flow rate of 1 mLmin
-1 
was employed. The aqueous sample 
(1 mL) was diluted with 1 mL of acetonitrile and 20 µL of the mixture was injected into 
the HPLC. A calibration was run using drug solutions, dissolved in 50:50 H2O: acetonitrile 
with the concentration of 0.312-0.030 µgmL
-1
 (R
2
 = 0.9999). The amount of attached drug 
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was calculated from the amount of free drug in waste solution, detected via HPLC. All 
measurements were run in triplicate and recorded as average values. 
 
4.2.2.4. In vitro thermoresponsive cytotoxicity assay 
 
BxPC-3, PANC-1 and U937 cells (3 mL, 150000 cells/ well) in their exponential growth 
phase were seeded into 6-well plates and incubated for 24 h at 37 °C with 5 % CO2. Cells 
treated with 50 µgmL
-1
 of drugs and formulations and incubated for 1 h. Then, cells were 
further incubated at 25 ºC, 44 ºC and 60 ºC for 0.5 h, in order to investigate the effect of 
temperature on cell cytotoxicity. Then the drug solutions were removed and cells were 
washed with fresh media to remove any excess drug. Fresh media was then added to each 
well. After 24 h incubation (37 °C, 5 % CO2), media was removed and cells were washed 
with PBS. The cells were trypsinised and re-suspended in fresh media. A mixture of 50 μL 
of cells and 50 μL of trypan blue solution was placed in an automated cell counter and 
viable cells were counted. Percentage of cell viability was calculated regarding to the 
number of control cells as discussed before (Equation 9). MTT test was not used in this 
method as the volume (100 µL) in each well (in 96-well plate) was not enough to grow a 
large number of the cells. Therefore, after heating the cells, the number of the cells might 
be lower than the minimum limit number of cells counted by automated cell counter 
( < 1×10 
4
).    
 
4.2.2.5. AFM topography imaging 
 
BxPC-3, PANC-1 and U937 cells (3 mL, 150000 cells/ well) were seeded in 6-well plates 
containing glass coverslips. Cells were incubated for 24 h at 37 °C and 5 % CO2. After 
24 h the media was replaced with gemcitabine, BNIPDSpm, BNIPDSpm-HNP, 
BNIPDSpm-HNP-PEG, BNIPDSpm-HNP-PEG-c(RGDfC) and naked HNPs solution 
(50 µgmL
-1
) and further incubated for 1 h and 4 h. After abundant washing with PBS, cells 
were fixed with 1 mL gluteraldehyde (2.5 % in PBS) for 10 min. Fixed cells were washed 
5 times with PBS and mounted on glass slides. Cell topography was imaged by a Bruker 
Catalyst Atomic Force Microscope (Bruker, Germany) using Peak Force Tapping Mode 
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and a ScanAsyst in contact mode in air (using silicon tip (Bruker, T: 650 nm, L: 115 µm, 
W: 25 µm) on nitride lever). 
 
4.3. Results 
4.3.1. Cytotoxicity of drugs and formulations   
 
Cell viability of BxPC-3, PANC-1 and U937 cells incubated with unloaded HNPs were 
determined by the MTT cytotoxicity test and trypan blue exclusion assay (Figures 54A and 
54B). The concentrations show in the graph for HNP are equal to the concentration of 
hybrid formulations but obviously without drug (the concentrations of Fe in HNP and 
hybrid formulations are the same). Generally, both cytotoxic assays exhibited comparable 
results and the HNPs did not present a remarkable dose responsive effect on cell viability 
(over the concentration range tested). Cytotoxicity of HNPs was slightly different in each 
cell line. No significant reduction in viability was observed over the 24 h period up to 
25 μgmL-1 (p > 0.05). HNPs did not show apparent toxicity to all three cell lines after 24 h 
incubation at concentrations up to 50 μgmL-1 (p > 0.05). However, after 24 h incubation 
with the highest concentration of HNPs (100 μgmL-1) a 19-23 % decrease in viability was 
obtained (p < 0.05). This is much more concentrated than would ever be expected to be 
administered in the drug formulation to a patient in the clinic (Cortajarena et al. 2014). 
Regarding to our biological investigation, which will be discussed in this chapter later, the 
concentration of iron oxide in a formulation with half maximal inhibitory effect is less than 
10 μgmL-1. These findings demonstrated that these particles do not have high toxicity to 
BxPC-3, PANC-1 and U937 cell lines.  
 
MTT cytotoxicity assay and trypan blue exclusion test were utilised to determine the drug 
concentration at which only 50 % of the cells population were viable (IC50). Drugs with 
lower IC50 values have a greater cytotoxic effect. The cytotoxicity of different 
bisnaphthalamide based drugs (BNIPd, BNIPDSpm and BNIPds) was tested against the 
BxPC-3 cells after 24 h (Figure 54C). The IC50 value was analysed by GraphPad Prism 6 
software (Figure 54). In general, all three bisnaphthalamide based drugs a presented dose 
responsive effect on cell viability.  
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BNIPd possessed the highest cytotoxic effect on BxPC-3 cells and no cells were viable 
above the concentration of 0.005 mgmL
-1
 (Figure 54C). Therefore, the treated 
concentrations of BNIPd were modified (0.005 - 1.0 × 10
-5
 mgmL
-1
) in order to investigate 
the IC50 value accurately (Figure 54D). This drug had a significant reduction on cell 
viability from 1 μgmL-1 treating concentration after 24 h (p < 0.05). IC50 was achieved 
around the concentration of 3 μgmL-1 and cells viability reached to less than 10 % at the 
concentration of 5 μgmL-1 after 24 h incubation with BNIPd (Figure 54D).  
 
For BNIPDSpm, no significant reduction in viability was observed after 24 h up to 
5 μgmL-1 (p > 0.05) but the cell viability decreased significantly between the concentration 
of  10 μgmL-1 and 25 μgmL-1 (p < 0.05). IC50 was obtained around the concentration of 
20 μgmL-1. With 50 μgmL-1 incubation concentration of BNIPDSpm, the cell viability 
declined to less than 10 % (Figure 54C). 
 
For BNIPds, the significant reduction in cell viability started from 1 μgmL-1 (p < 0.05). 
IC50 was achieved around the concentration of 18 μgmL
-1 
and at the concentration of 
50 μgmL-1 and 100 μgmL-1 the viability of BxPC3 cells was almost zero (Figure 54C). 
 
The result showed that the additional two amine groups or two thiol groups in BNIPDSpm 
and BNIPds, respectively, decreased their cytotoxic effect in comparison with BNIPd, 
which possesses only two amines groups. These additional functional groups might affect 
the 3D shape of these drugs that made them difficult to cross the cells membrane and 
inhibit DNA replication in cells` nucleus (Ghafoor et al. 2012). 
 
The cytotoxic effect of hybrid formulations (conjugated with different type of 
bisnaphthalamide based drugs) was tested with MTT cytotoxicity test and trypan blue 
exclusion assay on BxPC-3 cells for 24 h and compared with the cytotoxicity of free drugs.  
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Figure 54. Cell cytotoxicity results of HNPs on BxPC-3, PANC-1 and U937 cell lines, after 24 h (0.1 – 1.0 × 10-5 
mgmL-1) characterised by A) MTT and B) Trypan blue cytotoxicity assay, C) Cell cytotoxicity results of BNIPd, 
BNIPDSpm and BNIPds on BxPC-3 cell line by MTT assay, after 24 h (0.1 – 1.0 × 10-5 mgmL-1), D) Cell cytotoxicity 
results of  BNIPd on BxPC-3 cell line by MTT assay with revised concentrations, after 24 h (0.005 – 1.0 × 10-5 mgmL-1) 
and E) IC50 value of drugs and hybrid formulations on BxPC-3 cells obtained by MTT cytotoxicity test and trypan blue 
exclusion assay after 24 h. * denotes significant decrease in IC50 from hybrid formulations compared with drug alone. 
■ denotes significant decrease in IC50 from PEGylated formulation compared with unPEGylated formulation at a similar 
concentration and incubation time (p < 0.05) (n=3, ave ± SD). “>100” means that no IC50 achieved within the 
concentrations tested (0.1 – 1.0 × 10-5 mgmL-1) and an IC50 over 100 µgmL
-1 was given by GraphPad Prism 6 software. 
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In general, both cytotoxic assays exhibited comparable results and the IC50 of free drugs 
obtained by both cytotoxic assays decreased significantly (p < 0.05) upon the conjugation 
to the surface of HNPs. BNIPd-HNP-PEG exhibited the lowest IC50 value within this 
group (0.3 μgmL-1), which was significantly less than the IC50 of its unPEGylated 
counterpart (p < 0.05). The IC50 of hybrid formulations conjugated with BNIPDSpm and 
BNIPds were around 10 times and 5 times less than that of the free drugs, respectively 
(p < 0.05). The IC50 value of BNIPds-HNP decreased significantly from around 5 μgmL
-1
 
to around 3 μgmL-1 after coating with PEG (p < 0.05). Moreover, there was a noticeable 
decrease on IC50 for BNIPDSpm-HNP after PEGylation (p > 0.05). These results confirm 
that the hybrid formulations have significantly higher efficacy compared with free drugs 
(p < 0.05). 
 
The cytotoxic effects of drugs and novel formulations were compared with a commercial 
chemotherapeutic agent, gemcitabine, as a control using the MTT test and trypan blue 
exclusion assay (Figure 54E). Generally, both cytotoxic assays exhibited comparable 
results and gemcitabine presented a dose and time responsive effect on cell viability of 
BxPC-3 cells. Interestingly, no IC50 was observable using both the MTT assay and trypan 
blue cytotoxicity test for gemcitabine after 24 h (IC50 was over the highest incubation 
concentration (100 µgmL
-1
)).  
 
Development of any formulation is a fine balance between physicochemical properties and 
biological activity. The data showed that BNIPd possessed the most potent anticancer 
effects; however, the physicochemical properties and potential use as a triggered system 
were lacking (outlines in Chapter Three). As described in Chapter Three, the most suitable 
formulations regarding drug loading, stability and triggered drug release were the 
BNIPDSpm formulations. Therefore, further cytotoxic studies were focused only on the 
BNIPDSpm formulations.    
 
The cytotoxicity of BNIPDSpm and its hybrid formulations also evaluated on PANC-1 and 
U937 cells by MTT and trypan blue assays (Table 12). Similar results achieved by both 
cytotoxicity tests. U937 cells treated with free BNIPDSpm had lower IC50 values than the 
BxPC-3 and PANC-1 cells, around 6.37 µgmL
-1
, 16.69 µgmL
-1
 and 28.77 µgmL
-1
, 
respectively (achieved by MTT assay). This indicates that free BNIPDSpm is more 
cytotoxic on U937 cells, compared to BxPC-3 and PANC-1 cells (Table 12). This might be 
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due to the changes in cell membrane structure and differences in way/rate at which small 
molecules can be adsorbed by U937 cells in the higher rate, compared with the other cells.   
 
When cells were exposed to BNIPDSpm-HNP formulation, approximately a 9.05-fold and 
1.97-fold increase in cytotoxicity were experienced by BxPC-3 and PANC-1 cell lines, 
respectively (achieved by MTT assay) (Table 12). This indicates that hybrid formulation 
was able to enhance the therapeutic effect of the drug compared with the free BNIPDSpm. 
Moreover, it showed that the cytotoxicity of BNIPDSpm-HNP on BxPC-3 is roughly 5 
times higher than on PANC-1, which might be due to the higher uptake rate of the drug on 
BxPC-3 cells.  
 
Table 12.  IC50 value of BNIPDSpm and hybrid formulations on BxPC-3, PANC-1 and U937 cells 
achieved by MTT and trypan blue assays. Increasing in cytotoxicity of hybrid formulations was 
calculated by comparing with the cytotoxicity of free drug (BNIPDSpm) (n=3, ave ± SD).    
Drug/ Formulation BNIPDSpm BNIPDSpm-HNP BNIPDSpm-HNP-PEG 
IC50 value on BxPC-3 by MTT assay (µgmL-1)  
16.69±1.37 
  
1.84±0.09 
 
1.37±0.07 
Increase in cytotoxicity - 9.05-fold 12.18-fold 
IC50 value on BxPC-3 by Trypan blue assay (µgmL-1)  
23.85±1.89 
 
2.23±0.10 
 
1.81±0.09 
Increase in cytotoxicity - 10.57-fold 13.18-fold 
IC50 value on PANC-1 by MTT assay (µgmL-1)   
28.77±2.69 
 
 
14.58±1.24 
 
12.43±1.40 
Increase in cytotoxicity - 1.97-fold 2.31-fold 
IC50 value on PANC-1 by Trypan blue assay (µgmL-1)  
23.42±2.51 
 
13.95±1.46 
 
11.50±0.96 
Increase in cytotoxicity - 1.68-fold 2.03-fold 
IC50 value on U937 by MTT assay (µgmL-1)  
6.16±0.46 
 
145.50±9.66 
 
150.10±11.01 
Decrease in cytotoxicity - 0.04-fold 0.04-fold 
IC50 value on U937 by Trypan blue assay (µgmL-1)  
7.57±1.23 
 
174.80±15.70 
 
150.60±12.24 
Decrease in cytotoxicity - 0.04-fold 0.05-fold 
 
 
Interestingly, the cytotoxicity of BNIPDSpm on U937 cells decreased significantly; upon 
the conjugation with HNP (IC50 value (by MTT assay) shifted from 6.1 µgmL
-1
 to 
160.1 µgmL
-1
) (p < 0.05). Free BNIPDSpm probably enter to the U937 cells through cell 
membrane pores/ channels and nano-formulations are normally taken up by endocytosis 
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(Park et al. 2006). Therefore, slower proliferation of these cells, in comparison with 
BxPC-3 and PANC-1 cells, resulted in reduced cytotoxic effect of conjugated drug, 
compared to free drug.  
 
4.3.2. Drug uptake investigations 
4.3.2.1. Drug uptake investigations on BxPC-3 Cell line 
 
BxPC-3 cells were incubated with different bisnaphthalamide based drugs, their hybrid 
formulations and gemcitabine, as a control anticancer drug, at 50 μgmL-1 and 100 μgmL-1 
concentrations for 1 h and 4 h (Figure 55). The amount of accumulated free drug was 
quantified by RP-HPLC. In general, cellular uptake appeared to be drug concentration and 
time dependent. However, there is not enough data to show that the drug is released inside 
the cells after it was taken up by the cells.  
 
BNIPd and its hybrid formulations possessed low drug uptake value (less than 9 pg) after 
1 h incubation time (Figure 55). This low uptake value could be due to the instability of 
BNIPd formulations, which discussed in Chapter Three (Section 3.3.2). As a result, BNIPd 
may have been released before the HNPs entered the cells; thus, hindering their uptake. 
However, the PEGylated formulations showed drug internalisation at concentrations 
approximately 17-fold higher than the free drug after only 1 h incubation, which is 
consistent with the use of PEG for transfections, whereby it enables particles to cross the 
cell membrane and accumulate in intracellular spaces. After 4 h incubation, the uptake 
value of free drug (with 100 µgmL
-1
 incubation concentration) increased significantly from 
3 pg to 6 pg and 35 pg upon the conjugation with HNP and HNP-PEG, respectively 
(Figure 55).  
 
For BNIPDSpm and its formulations, after 1 h incubation, less than 1.2 pg of BNIPDSpm 
was taken up from free drug and its formulations. After 4 h incubation, 78 pg and 94 pg of 
BNIPDSpm-HNP and BNIPDSpm-HNP-PEG were taken up, respectively, while uptake 
value of free BNIPDSpm (with 100 µgmL
-1 
incubation concentration) stayed around 
1.2 pg. These results confirmed the ability of our hybrid formulations to accumulate in 
BxPC-3 cells more efficiently compared to the free drug.   
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Figure 55. Drug uptake study on BxPC-3 cell line after 1 h and 4 h exposure with BNIPd, 
BNIPDSpm, BNIPds and their hybrid formulations (n=3, ave ± SD). * denotes significant 
difference in uptake rate between hybrid formulations and free drug at a similar concentration and 
incubation time   (p < 0.05). All statistical analyses were carried out using t.test analysis within the 
Microsoft Excel software package.   
 
In terms of drug uptake value for BNIPds and its formulations, drug was taken up to a 
greater extent than BNIPd formulations at both concentrations and incubation times 
(Figure 55). The initial uptake of BNIPds hybrid formulations after 1 h was significantly 
higher than BNIPd and BNIPDSpm hybrid formulations (p < 0.05). This initial uptake rate 
of BNIPds formulations might be explained by the burst release of the drug seen in 
Chapter Three, Section 3.3.3. However, these values stayed around the same level after 4 h 
incubation with BNIPds hybrid formulations. This could be due to the robust interaction of 
BNIPds with HNPs (discussed in Chapter Three, Section 3.3.2), which resulted in poor 
release inside the BxPC-3 cells. 
 
The drug uptake pattern of the hybrid formulations after 4 h incubation was BNIPDSpm 
formulations > BNIPd formulations > BNIPds formulations. This could be associated with 
the differences of surface charge between formulations. As BNIPDSpm formulations (with 
four amine groups in drug`s chemical structure) were more positive (discussed in Chapter 
Three, Section 3.3.2.2), they were taken up more by BxPC-3 cells which might be 
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associated with the charge-charge interactions of positive formulation with the negative 
cell membrane.  
 
Cells incubating with 50 µgmL
-1
 of gemcitabine for 1 h showed the highest drug uptake 
value within this group (with the same incubation concentration and incubation time) 
(Figure 56). This might be due to the different mechanism of uptake and type and number 
of receptor for different type of drug. By increasing the concentration of gemcitabine, drug 
uptake value after 1 h on BxPC-3 cells did not change significantly and stayed around 
99 pg (p > 0.05). After 4 h incubation with 50 µgmL
-1
 and 100 µgmL
-1
 of gemcitabine with 
BxPC-3 cells, 134 pg and 163 pg of drug was taken up by the cells, respectively. Although 
higher amount of gemcitabine accumulated in BxPC-3 cells compared to the hybrid 
formulations, the cytotoxicity results in Section 4.3.1 confirmed that BNIPDSpm hybrid 
formulations possessed a much lower IC50; therefore, even smaller amount of accumulated 
BNIPDSpm can produce higher cytotoxic effect on BxPC-3 cells, compared with 
conventional drug, gemcitabine.  
 
 
 
Figure 56. Drug uptake study on BxPC-3 cell line after 1 h and 4 h exposure with gemcitabine 
(n=3, ave ±SD). All statistical analyses were carried out using t.test analysis within the Microsoft 
Excel software package.  
  
Due to the poor physicochemical properties and low uptake rate of BNIPd and BNIPds 
hybrid formulations after 4 h (compared with the BNIPDSpm formulations), it was decided 
not to continue any further biological experiments for these formulations. 
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4.3.2.2. Drug uptake investigations on PANC-1 and U937 Cell lines 
 
PANC-1 and U937 cells were incubated with BNIPDSpm, its hybrid formulations and 
gemcitabine at the concentration of 50 μgmL-1 and 100 μgmL-1 for 1 h and 4 h.  
 
A similar trend was detected for PANC-1 cells (Figure 57A) as observed for the BxPC-3 
cells. However, uptake values for all drugs and formulations were less than 30 pg, which 
indicate that this cell line did not internalise the drugs/ hybrid formulations at the same rate 
as BxPC-3 cell line. This could be due to the smaller size of PANC-1 cells (20µm) 
compared to BxPC-3 cells (30µm) resulting smaller capacity of PANC-1 cells to take up 
drugs and formulations (size estimation of the cells achieved by AFM, which will be 
discussed in Section 4.3.7). The data indicates that combination of BNIPDSpm and 
PEGylated HNPs resulted in significantly (p < 0.05) (excluding cells incubated with 
100 µgmL
-1
 of formulation for 4 h) higher drug uptake into PANC-1 cells in comparison 
with BNIPDSpm-HNP, which confirms the ability of PEGylated formulations to act as a 
transfection agent to increase accumulation in cells. 
 
In U937 cells, the drug uptake pattern was completely different from BxPC-3 and PANC-1 
cells, where the highest uptake rates were achieved by the free BNIPDSpm (Figure 57B). 
There was no significant difference in drug uptake between BNIPDSpm-HNP and   
BNIPDSpm-HNP-PEG (p > 0.05). After 4 h incubation of U937 cells with 
BNIPDSpm-HNP and BNIPDSpm-PEG (100 µgmL
-1
) only 2.7 pg and 2.4 pg of drug 
accumulated in each cell, respectively; while this amount for free drug was 32.9 pg, at a 
similar incubation concentration and incubation time, which could be due to the different 
mechanisms of internalisation of drug and NPs. As discussed before, free BNIPDSpm 
enters to cells through cell membrane pores/channels which is not energy dependant but 
particles internalise by endocytosis, thus slower proliferation resulted in less uptake of 
hybrid formulations compared to the free drug (p < 0.05).  
Drug uptake for gemcitabine on U937 cells was around 11 pg at both incubation 
concentrations after 1 h, this amount increased to around 17 pg after 4 h incubation with 
the same incubation concentrations of gemcitabine. It seems that gemcitabine uptake 
pattern on U937 cells is more time dependant (p < 0.05), rather than concentration 
dependant (p > 0.05) (Figure 57B). 
 
153 
 
   
 
 
Figure 57. Drug uptake study on A) PANC-1 and B) U937 cell lines after 1 h and 4 h exposure 
with BNIPDSpm, BNIPDSpm-HNP, BNIPDSpm-HNP-PEG, (n=3, ave ± SD). * denotes 
significant difference between BNIPDSpm uptake from formulations compared with free 
BNIPDSpm at a similar concentration and incubation time (p < 0.05). All statistical analyses were 
carried out using t.test analysis within the Microsoft Excel software package.   
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4.3.3. Cojugation of targeting peptide onto the optimal formulation 
 
The c(RGDfC) peptide, BNIPDSpm and thiolated PEG were simultaneously and 
successfully conjugated to the HNP and the amount of drug and targeting peptide were 
analysed by RP-HPLC. The peaks for BNIPDSpm observed at the same time described in 
Chapter Three (Section 3.3.1). The c(RGDfC) peptide was very sensitive to the HPLC 
fluorescence detector and a very sharp peak was detected around 17 min at the 
concentration of 0.156 µgmL
-1
 of c(RGDfC) (Figure 58).    
 
 
 
Figure 58. Reverse phase HPLC analysis (with fluorescence detector) of 0.156 µgmL
-1
 c(RGDfC) 
peptide. Mobile phase contained solvents A and B (50:50). Solvent A was water containing 0.09 % 
trifluoroacetic acid (TFA) and solvent B was acetonitrile containing 9.91 % H2O and 0.09 % TFA, 
Excitation: 250 nm, Emission: 307 nm, flow rate: 1 mLmin
-1
.  
 
The concentration of the BNIPDSpm and c(RGDfC) peptide in BNIPDSpm-HNP-PEG-
c(RGDfC) formulation characterised by HPLC were 3.2 ± 0.0465 mgmL
-1 
(R2 = 0.9998) 
and 0.0968± 0.0075 mgmL
-1
 (R2 = 0.9999), respectively. 48 % of the initial amount of 
peptide was able to conjugate to the surface of HNPs.   
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4.3.4. Cytotoxicity of optimal formulation incorporating targeting 
moieties. 
 
The MTT cytotoxicity test and trypan blue exclusion assay were carried out on 
BNIPDSpm-HNP-PEG-c(RGDfC) to determine whether this formulations was capable of 
delivering BNIPDSpm into the BxPC-3 and PANC-1 cancer cells and enhancing the 
cytotoxic effect of this drug in comparison with non-targeted hybrid formulations. The 
cytotoxicity of this formulation was also tested on U937 cells to compare the response of 
the formulation on immune like cells (Figure 59).   
 
After 24 h incubation of BxPC-3 cells with BNIPDSpm-HNP-PEG-c(RGDfC), the IC50 
was 1.15 µgmL
-1
 and 1.05 µgmL
-1
 achieved by MTT and trypan blue cytotoxicity test, 
respectively. This was slightly less (but not significantly) than the IC50 of PEGylated 
non-targeted formulation (1.37 µgmL
-1
 and 1.81 µgmL
-1
, obtained by MTT and trypan 
blue cytotoxicity test, respectively) (p > 0.05). The same result was obtained from PANC-1 
cells and notable drop in IC50 of targeted formulation was attained, compared with 
BNIPDSpm-HNP-PEG (p > 0.05) (Figure 59). The slight decrease in IC50 observed 
between the targeted and untargeted formulations could to be due to the presence of 
peptide, which can facilitate the entrance of hybrid formulation inside the pancreatic 
cancer cells. These results suggest that the BNIPDSpm-HNP-PEG-c(RGDfC) was a more 
effective delivery vehicle for the delivery of BNIPDSpm to BxPC-3 and PANC-1 cells 
(although it was not statistically significant (p > 0.05)). 
Interestingly, while BNIPDSpm-HNP-PEG possessed no IC50 on U937 cells after 24 h, the 
IC50 value for targeted formulation was around 57.72 µgmL
-1
 (p < 0.05). This shows that 
U937 cells can recognise targeted formulation better than non-targeted formulations, which 
could be due the presence of targeting peptide. However, this IC50 value is around 10 times 
higher than the IC50 of free BNIPDSpm on U937 cells (Table 12), indicating that targeted 
formulations appear to be less toxic than the free drug on these cells.   
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Figure 59. IC50 value of BNIPDSpm-HNP-PEG and BNIPDSpm-HNP-PEG-c(RGDfC) achieved 
by MTT cytotoxicity assay and trypan blue exclusion test on BxPC-3, PANC-1 and U937 cell 
lines, after 24 h (n=3, ave ± SD). “>100” means that no IC50 achieved within the concentrations 
tested (0.1 – 1.0 × 10-5 mgmL-1) and an IC50 over 100 µgmL
-1 
was given by GraphPad Prism 6 
software.  
 
4.3.5. Drug uptake of optimal formulation incorporating targeting 
moieties 
 
BxPC-3, PANC-1 and U937 cells were incubated with 50 µgmL
-1
 & 100 µgmL
-1
 of 
BNIPDSpm-HNP-PEG-c(RGDfC) for 1 h and 4 h and the results were compared with the 
uptake rate of BNIPDSpm-HNP-PEG on these cells. In general, the uptake rate of 
BNIPDSpm increased significantly in all cell lines upon the addition of targeting agent (at 
both concentrations and incubation times) (p < 0.05).  The greatest uptake rate was 
achieved by BxPC-3 cells.  
 
After 1 h incubation, while less than 2 pg of BNIPDSpm-HNP-PEG was taken up by these 
cells, BNIPDSpm-HNP-PEG-c(RGDfC) had uptake value around 109 pg at 100 μgmL-1 
incubation concentrations (Figure 60). These amounts after 4 h incubation with the same 
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concentration were 94 pg and 123 pg, respectively (p < 0.05).  This indicates that the 
targeted formulation can be taken up faster than non-targeted formulation (especially 
within 1 h, since the difference of the cellular uptake between formulations was higher 
after 1 h incubation). The same pattern was observed for PANC-1 and U937 cells. 
However, the uptake rate of targeted formulation for these cell lines was around five times 
less than BxPC-3 cells, which was in line with the previous uptake results (Section 4.3.2).  
 
On PANC-1 cells, after 4 h incubation with 100 μgmL-1 of hybrid formulations, drug 
uptake for BNIPDSpm-HNP-PEG-c(RGDfC) reached to 22.5 pg, which was 5 times 
higher than uptake value of BNIPDSpm-HNP-PEG at a similar concentration and 
incubation time (p < 0.05). This indicates that combination of targeting peptide and 
PEGylated formulation caused higher uptake rate on PANC-1 cells in comparison with 
BNIPDSpm-HNP-PEG.     
 
Although, non-targeted formulation showed negligible uptake rate, compared with free 
drug on U937 cell line (Figure 57B), BNIPDSpm-HNP-PEG-c(RGDfC) possessed 
comparable uptake rate to BNIPDSpm, since 33 pg and 22 pg of free drug and 
BNIPDSpm-HNP-PEG-c(RGDfC) accumulated in U937 after 4 h, respectively (incubation 
concentration: 100 µgmL
-1
) (Figures 57B and 60). This again indicates that the presence of 
the targeting ligand can increase the accumulation of the formulations in cells. 
 
 
 
 
 
158 
 
 
 
Figure 60. Cellular uptake analysis of BNIPDSpm-HNP-PEG and BNIPDSpm-HNP-PEG-
c(RGDfC) after 1 h and 4 h incubation with BxPC-3, PANC-1 and U937 cell lines (n=3, ave ± SD).  
* denotes significant decrease in IC50 from BNIPDSpm-HNP-PEG-c(RGDfC)compared with 
BNIPDSpm-HNP-PEG in different cell lines (p < 0.05). 
 
4.3.6. In vitro thermoresponsive cytotoxicity assay  
 
In order to investigate the effect of heat on drug release and overall cytotoxicity of the 
hybrid formulations, BxPC-3, PANC-1 and U937 cells were treated with 50 µgmL
-1
 of 
hybrid formulations for 0.5 h at 25 ºC, 44 ºC and 60 ºC (and compared with the free drug 
and HNPs controls). Treating concentration of 100 µgmL
-1
 was not used as it would be 
more toxic and a great number of the cells will be killed; thus treated cells cannot be 
counted by the automated cell counter. In general, the result revealed that increasing the 
temperature had no remarkable impact on cytotoxicity of HNPs (p > 0.05) and the viability 
of all three types of cells treated with HNPs was more than 80 % at all different incubation 
temperatures (Figure 61). Increasing the temperature from 25 ºC to 44 ºC decreased the 
viability of the cells treated with free BNIPDSpm significantly (p < 0.05) in all cell lines, 
which suggests that incubation at 44 ºC increases the action of this anticancer agent. 
However, upon the incubation of PANC-1 and U937 cells with free drug at 60 ºC, the 
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viability of the cells increased and changed from 42 % and 14 %  viability, respectively 
(at 44 ºC) to 55 % and 32 % viability, respectively (at 60 ºC) (Figures 61B and 61C). It 
was postulated that in 60 ºC, the physiochemical properties of BNIPDSpm might be 
changed (chemical degradation), thus the cytotoxicity of this drug was decreased for 
PANC-1 and U937 cells. Although this result was observed in triplicate, further 
investigation is required in order to fully understand if this finding is reliable.  
Cytotoxicity of hybrid formulations on BxPC-3 cells significantly increased upon the 
temperature increase (from 25 ºC to 44 ºC and 60 ºC), compared with free BNIPDSpm 
(p < 0.05), which was more prominent for PEGylated formulations. The viability of 
BxPC-3 cells treated with BNIPDSpm-HNP at 25 ºC, 44 ºC and 60 ºC were 24 %, 14 % 
and 9 %, respectively (Figure 61A). These amounts for cells incubated with 
BNIPDSpm-HNP-PEG at 25 ºC, 44 ºC and 60 ºC were 11 %, 5 % and 3 %, respectively. 
The results indicate that the PEGylated formulation is significantly more cytotoxic than 
unPEGylated formulation on BxPC-3 cells, at all temperatures (p < 0.05). This could be 
due to the higher uptake rate of PEGylated formulation discussed before. There was an 
increase in cell cytotoxicity on BxPC-3 cells treated with BNIPDSpm-HNP-PEG-
c(RGDfC) compared with BNIPDSpm-HNP-PEG at different incubation temperatures, 
though it was not significant (p > 0.05) (Figure 61A and Table 13).  
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Figure 61. In vitro thermoresponsive cytotoxicity test on A) BxPC-3, B) PANC-1 and C) U937 
cell lines at 25, 44 and 60 ºC (n=3, ave ± SD). 
 
The same cytotoxicity pattern was observed in PANC-1 cells treated with hybrid 
formulations (Figure 61B). However, the viability of these treated cells was higher than 
BxPC-3, with the same incubation temperature and treating agent. This again confirms the 
cytotoxicity results achieved by MTT and trypan blue cytotoxicity tests whereby the drug 
and hybrid formulations are more cytotoxic on BxPC-3 cells, in comparison with PANC-1 
cells (Table 12).  
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Table 13. Comparative thermoresponsive cytotoxicity of hybrid formulations at different 
temperature in comparison with free BNIPDSpm on BxPC-3, PANC-1 and U937 cell lines.   
     
Cell line 
 
Incubation 
temperature 
BNIPDSpm-HNP BNIPDSpm-HNP-
PEG 
BNIPDSpm-HNP-
PEG-c(RGDfC) 
Cytotoxicity increase from free BNIPDSpm 
 
BxPC-3 
25 ºC 1.50-fold 3.14-fold 5.43-fold 
44 ºC 1.84-fold 4.54-fold 5.31-fold 
60 ºC 1.89-fold 4.77-fold 5.99-fold 
 
PANC-1 
25 ºC 1.11-fold 2.15-fold 3.00-fold 
44 ºC 1.17-fold 2.84-fold 3.08-fold 
60 ºC 1.69-fold 2.83-fold 4.22-fold 
 
U937 
25 ºC 0.71-fold 0.71-fold 0.70-fold 
44 ºC 0.34-fold 0.55-fold 0.64-fold 
60 ºC 3.31-fold 2.19-fold 3.95-fold 
 
 
Slight increase (p > 0.05) in toxicity achieved upon the treating of U937 with targeted 
formulations at 25 ºC and 44 ºC in comparison with BNIPDSpm-HNP-PEG. This 
enhanced cytotoxic effect for cells incubated at 60 ºC was significant (p > 0.05). The 
highest cytotoxic effect on U937 cells received for cells treated with hybrid formulations at 
60 ºC (Figure 61C). Cell viability of U937 treated with BNIPDSpm-HNP and 
BNIPDSpm-HNP-PEG decreased significantly upon incubating at 60 ºC (p < 0.05), which 
might be due to the higher amount of BNIPDSpm being released from the particles at this 
temperature (Figure 61C).  
 
Table 13 illustrates the increasing cytotoxic effects of drugs upon the conjugation with 
HNP, HNP-PEG and HNP-PEG-c(RGDfC) with increasing of incubation temperature on 
BxPC-3 and PANC-1 cell lines. However, this enhanced cytotoxic effect was not observed 
in U937 cells and increase in toxicity was only achieved for cells treated with hybrid 
formulations. As it was mentioned before, these cells responded to hybrid formulation at 
60 ºC in a different way and an increase in cytotoxicity was attained for cells incubated 
with hybrid formulation, especially with targeted formulation (4-fold) (Table 13).   
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While no significant increase in cytotoxicity was observed between U937 cells incubated 
with BNIPDSpm-HNP at 25 ºC and 44 ºC (p > 0.05), the viability of U937 cells treated 
with BNIPDSpm-HNP-PEG decreased significantly from 45 % (25 ºC) to 26 % (44 ºC) 
(Figure 61C). U937 cells treated with BNIPDSpm-HNP-PEG-c(RGDfC) showed the same 
response as PEGylated formulation, however an increase in cell cytotoxicity was observed 
for the cells incubated with formulation containing targeting peptide in 60 ºC, in 
comparison with BNIPDSpm-HNP-PEG (p < 0.05) (Figure 61C and Table 13).  
 
These results confirm that the cytotoxicity of hybrid formulations on BxPC-3 and PANC-1 
cells was significantly enhanced by increasing the incubation temperature in vitro, 
compared with the free drug (p < 0.05). Here we used control cells which were not exposed 
to any formulation, only the temperature increase, as such it may have been more 
appropriate to compare to cells incubated at physiological temperature for example. In this 
work it is assumed (in relation to the drug release studies) that by increasing the particles` 
temperature (accumulated inside the pancreatic cancer cells) via laser irradiation, drug will 
be released from HNP inside the cells; thus the hybrid formulations are able to kill 
pancreatic cancer cells in a more efficient way. Therefore, to further investigate this 
potential in a more appropriate manner future in vitro studies are required using laser 
irradiation as the heating source.  
 
4.3.7. AFM topography imaging 
 
The AFM images were in agreement with the drug uptake study after 1 h and 4 h 
incubation. In All cell lines, morphological changes appear to have a time dependent 
manner (Figures 62-64).  There was not any remarkable morphological difference between 
BxPC-3, PANC-1 and U937 control cells and cells incubated with gemcitabine and HNPs, 
after 1 h and 4 h incubation. This confirms the low cytotoxicity of HNPs and gemcitabine 
on these cell lines, which was explained before (Section 4.3.1). In BxPC-3 cells, while 
cells incubated with BNIPDSpm after 1 h were quite healthy (Figure 62D1), after 4 h their 
cellular structures were relatively damaged (Figure 62D2). Interestingly, treating these cells 
with BNIPDSpm-HNP, BNIPDSpm-HNP-PEG and BNIPDSpm-HNP-PEG-c(RGDfC) 
changed the structure and morphology of BxPC-3 cells completely after 1 h (Figures 62E1, 
62F1 and 62G1) and 4 h incubation (Figures, 62E2, 62F2 and 62G2). 
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Figure 62. AFM image of BxPC-3 cells: A) Control cells, cells with 50 μgmL-1 of B) gemcitabine, 
C) HNP, D) BNIPDSpm, E) BNIPDSpm-HNP, F) BNIPDSpm-HNP-PEG and G) BNIPDSpm-
HNP-PEG-c(RGDfC). All incubated for 1) 1 h & 2) 4 h. 
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AFM images of PANC-1 cells showed the same result. There was not any significant 
morphological difference between control cells and cells incubated with gemcitabine and 
HNPs, after 1 h and 4 h incubation. The circular shape of these cells and the smooth 
surface of them changed completely upon treating with hybrid formulations (Figures 63E1, 
63E2, 63F1, 63F2, 63G1 and 63G2). However, these morphological changes on BxPC-3 
cells were more noticeable (Figure 62), confirming the previous biological studies 
(cytotoxicity tests and drug uptake analyses) on hybrid formulations; where it was 
suggested that BNIPDSpm and its hybrid formulations possess higher cytotoxic effect and 
uptake rate on BxPC-3 cells, in comparison with PANC-1 cells.    
 
 
 
 
 
165 
 
 
 
Figure 63. AFM image of PANC-1 cells: A) Control cells, cells with 50 μgmL-1 of 
B) Gemcitabine, C) HNP, D) BNIPDSpm, E) BNIPDSpm-HNP, F) BNIPDSpm-HNP-PEG and 
G) BNIPDSpm-HNP-PEG-c(RGDfC). All incubated for 1) 1 h & 2) 4 h. 
166 
 
Again in U937 cells, there was not any notable morphological difference between control 
cells and cells incubated with gemcitabine, HNPs and formulations after 1 h and 4 h 
incubation. This confirms the low cytotoxicity of HNPs, gemcitabine and formulations on 
this cell line, which was explained before (Section 4.3.1). U937 AFM images revealed that 
only free BNIPDSpm resulted morphological changes on U937 cells after 4 h 
(Figure 64D2) and other treated U937 cells look similar to the control cells after 1 h and 
4 h. These results were in agreement with our cytotoxicity tests and drug uptake analyses; 
where higher cytotoxicity and drug uptake achieved by U937 cells treated with free 
BNIPDSpm, compared with cells incubated with hybrid formulations (Table 12 and Figure 
57B, respectively).     
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Figure 64. AFM image of U937 cells: A) Control cells, cells with 50 μgmL-1 of B) gemcitabine, 
C) HNP, D) BNIPDSpm, E) BNIPDSpm-HNP, F) BNIPDSpm-HNP-PEG and G) BNIPDSpm-
HNP-PEG-c(RGDfC). All incubated for 1) 1 h & 2) 4 h. 
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4.4. Discussion 
 
Pancreatic cancers are often diagnosed when they have metastasised. Usual treatments for 
the advanced disease state comprise of radiotherapy and/or chemotherapy approaches. The 
use of radiotherapy is highly toxic and chemotherapies using gemcitabine and 
5-fluorouracil (5-FU) are often ineffective or only effective over short periods. 
Gemcitabine has been suggested to improve the quality of life in patients (Mignotte and 
Vayssiere, 1998); however, this drug alone and in combination chemotherapy has failed to 
achieve great success, which might be explained by the high level of intrinsic resistance of 
pancreatic cancer tumours to currently available anticancer therapies (Von Wichert et al. 
2008). 
 
In vitro cytotoxicity tests and basic biological analyses of any drug or formulation are 
essential before introducing them to animals for in vivo studies. General toxicity tests, such 
as MTT cytotoxicity assay and trypan blue exclusion cytotoxicity test are utilised mainly to 
detect the biological activity of drugs and formulations, which can be carried out on many 
cell types.  
 
Possessing high cytotoxicity and specific delivery are essential characteristics of any 
anticancer drug or formulation. In this study the fabricated HNPs had limited cytotoxic 
impact on BxPC-3, PANC-1 and differentiated U937 cell lines, over the concentration 
range tested (0.1 – 1.0 × 10-5 mgmL-1) with less than 30 % cytotoxic activity observed for 
high HNP concentrations (Figures 54A and 54B). These findings were consistent with 
other reports of HNP and provide increased confidence for the long term in vivo effects of 
these particles (Barnett et al. 2013a; Hoskins et al. 2010; Hoskins et al. 2012a; 
Hoskins et al. 2012c and Roach et al. 2013). Reports have proposed that coating layer of 
gold protects and shields the iron oxide core from enzymatic degradation, which may result 
in free radical production. Barnett and colleagues reported no free radical (ROS or LPO) 
production was detected above basal levels after 72 h incubation of HNPs with both 
BxPC-3 and differentiated U937 cells. Moreover, there was no significant cytotoxic effect 
for cells incubated with the high concentration of HNPs (100 µg mL
-1
) for up to 1 week 
(Barnett et al. 2013a). Hoskins et al. also proposed the same cytotoxic effect of HNPs on 
different cell lines. They reported that after 24 h incubation of iron oxide NPs coated with 
polyethyleneimine (Fe3O4-PEI) (100 µgmL
-1
) with neuroblast cells (SH-SY5Y), breast 
adenocarcinoma cells (MCF-7) and U937 cells, up to 30 %, 50 % and 20 % reduction in 
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viability was detected, respectively. Additionally, they showed that PEGylated Fe3O4-PEI 
experienced only a maximum of 5 % viability reduction across the three cell lines 
(Hoskins et al. 2012a). Moreover, Roach et al. investigated cytotoxic effect of HNPs on 
mouse osteoblast cells (7F2) over 72 h. They found over 80 % of cell viability on 7F2 
treated cells with HNP at the highest incubation concentration (100 µg mL
−1
) 
(Roach et al. 2013). 
 
Recently, a series of bisnaphthalimide polyamine derivatives were synthesised and 
characterised in vitro (Hoskins. 2010; Ralton et al. 2009 and Wu et al. 2009a). In this 
study, three different types of bisnaphthalamide based drugs were used (BNIPd, 
BNIPDSpm and BNIPds). The cytotoxic effects of these bisnaphthalamide derivatives on 
BxPC-3 cells were characterised. IC50 values for BNIPd, BNIPDSpm and BNIPds, 
achieved by MTT and trypan blue cytotoxicity assays after 24 h, were around 3 µgmL
-1
, 
20 µgmL
-1
 and 19 µgmL
-1
, respectively (Figure 54C). The high cytotoxicity of BNIPd 
could be due to its chemical structure and number/ position of amine group (two lateral 
amines) (Chapter Three, Figure 34) that enables this drug to interact with the DNA of 
BxPC-3 cells more efficiently. The cytotoxicity results of the hybrid formulations (in 
conjugation with bisnaphthalamide derivatives) on BxPC-3 cell line revealed significant 
reduction of cell viability after 24 h (compared with the free drugs), especially for 
PEGylated formulations, where the cytotoxic effect of PEGylated formulation of BNIPd, 
BNIPDSpm and BNIPds were about 7, 13 and 6 times greater than the cytotoxicity of free 
drugs, respectively (Figure 54E). These findings confirm the high efficacy of the hybrid 
formulations which could be associated with the higher uptake rate of the novel 
formulations by cells, in comparison with the drugs alone. Cytotoxicity analyses were in 
agreement with previous study on hybrid formulations. 
 
Previously, Barnett and colleagues conjugated 6-Thioguanine (6-TG) onto the HNPs` 
surface and incubated with BxPC-3 cells. A 10-fold decrease in IC50 was reported with the 
6-TG-conjugated with HNPs, in comparison with free drug (Barnett et al. 2013b). 
Wagstaff and co-workers introduced cisplatin conjugated with HNP to ovarian cancer cell 
lines (A2780 and A2780/cp70). They found that their novel hybrid formulation is up to 
110-fold more cytotoxic than free cisplatin on ovarian carcinoma cells (Wagstaff et al. 
2012). 
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All cytotoxicity results from the bisnaphthalamide derivatives and their hybrid 
formulations were compared with commercial anticancer drug, gemcitabine. No IC50 
achieved for BxPC-3, PANC-1 and differentiated U937 cells treating with gemcitabine 
within 24 h (Figure 54E). Around 60 %, 80 % and 70 % of cell viability was achieved for 
BxPC-3, PANC-1 and differentiated U937 cells treated with the highest treating 
concentration of gemcitabine (100 µgmL
-1
) after 24 h, respectively. This result confirms 
that the fabricated formulations were highly cytotoxic to pancreatic cancer cells, in 
comparison with gemcitabine. These findings were consistent with other report of 
cytotoxicity of gemcitabine on BxPC-3, human pancreas cells (AsPC-1), homo sapiens 
pancreatic carcinoma (MiaPaCa-2) and PANC-1 as no IC50 was observed after 24 h on 
these cells (Wu et al. 2009b).  In another study Wang and colleagues, treated BxPC-3, 
PANC-1, MiaPaCa-2, AsPC-1 and epithelial ductal adenocarcinoma (PL-45) with 
gemcitabine over the period of 48 h. They reported over 75 % cell viability analysed with 
MTT cytotoxicity test over the range of 1 µm (Wang et al. 2011). As such, perhaps this 
study could have benefited from longer incubation times for comparison. 
 
Exploiting targeting peptides for efficient delivery of different materials into cells has a 
relatively recent history. Integrin αvβ3 receptor is expressed on many different types of 
cancer cells as for pancreatic cancer cells. This receptor plays key role in tumour 
development and metastasis. Therefore, by targeting the integrin αvβ3 receptor on 
pancreatic cancer cells, the efficacy of targeted therapy can be increased with reduced 
unwanted side effects. Previously, Ji et al. conjugated a novel arginine-glycine-aspartic 
acid (RGD) peptide to bovine serum albumin nanoparticles (BSANPs) to increase the 
intracellular uptake of gemcitabine into the pancreatic cancer cells (BxPC-3) by 
receptor-mediated endocytosis. They found that BSANPs accumulate into BxPC3 cells in a 
time and concentration dependent manner and cellular uptake of gemcitabine for 
RGD-conjugated BSANPs in BxPC-3 cells was higher than formulation without RGD 
peptide (Ji et al. 2012). In another study, Zuo and colleagues conjugated iRGD peptide 
(CRGDK/RGPD/EC) to the surface of super paramagnetic iron oxide nanoparticles 
(SPIONs) to improve labelling of PANC-1 cells in cancer imaging.  They proposed that 
SPIONs with iRGD peptide can increase the uptake and labelling rate of PANC-1 
(Zuo et al. 2014).  
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As described in Chapter Three (Section 3.2.2.2) BNIPDSpm formulations showed higher 
conjugation ability, stability and sustained drug release pattern, thus these formulations 
were used for further conjugation by c(RGDfC) peptide. In this study, c(RGDfC) peptide 
was successfully conjugated to the surface of BNIPDSpm-HNP-PEG (PEGylated 
formulation was used in order to increase biocompatibility) and the amount of  attached 
BNIPDSpm and peptide were analysed by RP-HPLC. Table 12 indicates that the 
cytotoxicity pattern of free BNIPDSpm was U937 cells > BxPC-3 > PANC-1.  
Interestingly, the pattern for hybrid formulation was BxPC-3 > PANC-1 > U937, where the 
cytotoxicity of BNIPDSpm on U937 significantly decreased (p < 0.05) upon the 
conjugation to the surface of HNPs. This indicates that U937 cells internalised the 
conjugated BNIPDSpm much less than the free drug, which might be due to the difference 
between drug mechanism of entry (through cell membrane pores/ channels), and hybrid 
formulations mechanism of entry (endocytosis) as described before. But the IC50 of 
BNIPDSpm-HNP-PEG-c(RGDfC) added to these cells was around half of the IC50 
achieved by BNIPDSpm-HNP and BNIPDSpm-HNP-PEG. This could be due to the 
presence of peptide, which can be recognised by the U937 cells.  
 
Cytotoxicity of BNIPDSpm-HNP-PEG-c(RGDfC) (by MTT assay) were 14.51 and 12.4 
times higher than free BNIPDSpm on BxPC-3 and PANC-1 cells, respectively; while the 
increased cytotoxic effect for BNIPDSpm-HNP-PEG was 12.2 and 12.4 times, 
respectively. It is assumed that a higher toxicity would be experienced with the formulation 
containing targeting peptide. However, this is not what was observed. The slight (but not 
significant) increase of cytotoxicity upon the conjugation of targeting peptide could be due 
to the 2D in vitro cytotoxicity analysis (in vitro cell culture) and higher cytotoxic effect 
may be achieved by 3D in vitro culturing or in vivo. 
 
Drug uptake study of bisnaphthalamide derivatives on BxPC-3 cells showed that hybrid 
formulations were taken up significantly higher than free drugs (p < 0.05) (Figure 55). 
Within this group BNIPDSpm hybrid formulations, especially the one containing targeting 
peptide, possessed the highest uptake rate after 4 h incubation (incubation concentration: 
100 µgmL
-1
). Moreover, the presence of targeting peptide within the formulations resulted 
in comparable uptake rate to gemcitabine. Due to low stability of BNIPd hybrid 
formulations and robust interaction of BNIPds with HNPs that resulted poor drug release 
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in vitro (Chapter Three, Section 3.2.2), hence no further investigation of these formulations 
on PANC-1 and U937 cell lines was carried out. 
 
Drug uptake results for gemcitabine on BxPC-3 and PANC-1 cell lines were in the range 
of the drug uptake data previously reported by Paproski et al (Paproski et al. 2010). 
Although gemcitabine was taken up mostly in the highest level at all concentration and 
incubation time by pancreatic cancer cells (Figures 56 and 57A), the cytotoxicity result 
from gemcitabine showed that this drug did not possess IC50 after 24 h. This means that 
novel BNIPDSpm hybrid formulations are faster acting at killing pancreatic cancer cells, 
compared with gemcitabine. BNIPDSpm and its hybrid formulations uptake pattern from 
PANC-1 cells (Figure 57A) were comparable to BxPC-3 cells (Figure 55). However, the 
uptake rate of drugs (gemcitabine and BNIPDSpm) and hybrid formulations from BxPC-3 
cells was around 5 times higher than PANC-1 cells (Figure 57). This might be due to the 
differences in proliferation of these cells, volume of the cells and/or binding sites for drugs 
per cell in pancreatic cancer cell lines. In U937 cell line, free BNIPDSpm was accumulated 
in cells more than hybrid formulations indicating that our hybrid formulations were not 
recognised by these cells as much as free drug (Figure 57B). The presence of targeting 
peptide increased uptake rate of BNIPDSpm from the formulations, which means that this 
formulation was recognised by U937 cells more than other formulations (Figure 60).   
 
In vitro thermoresponsive cytotoxicity result from BxPC-3, PANC-1 and U937 cell lines 
showed that the viability of treated cells with BNIPDSpm and hybrid formulations mostly 
decreased by increasing the temperature (Figure 61).  Many in vitro and in vivo studies 
suggested that the combination of hyperthermia and anticancer drugs has synergistic effect 
(Hahn, 1982). In vivo investigations on animal tumour systems demonstrated by Urano at 
al. showed that some drugs such as cisplatin and bleomycin are more cytotoxic between 
40 ºC-45 ºC as the drugs are more active within these temperatures (Urano et al. 1999). 
This is in agreement with BNIPDSpm thermoresponsive cytotoxicity result. Greater 
cytotoxic effects on BxPC-3, PANC-1 and U937 cells achieved by hybrid formulations 
incubated in higher temperature could be due to the higher amount of drug being released 
from the formulations (Figure 61).  
 
AFM topography images of treated cells after 1 h and 4 h were in agreement with drug 
uptake results, which confirmed the higher cytotoxic effect of hybrid formulations 
comparing with free BNIPDSpm, especially the PEGylated and targeted formulations  
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(BNIPDSpm-HNP-PEG-c(RGDfC)) on BxPC-3 and PANC-1 cells (Figures 62 and 63). 
The enhanced cytotoxic effect of BNIPDSpm hybrid formulations was more prominent on 
BxPC-3 cells (Figure 62), in comparison with PANC-1 cells (Figure 63), which 
strengthened our previous results suggesting higher cytotoxic effect (Table 12) and drug 
uptake rate for our novel formulations on BxPC-3 cells (Figure 55), compared with 
PANC-1 cells (Figure 57A). Except cells treated with BNIPDSpm for 4 h (Figure 64D2), 
no significant changes in U937 cells morphology was observed upon the incubation with 
drug and hybrid formulations (Figure 64).  This is again in line with the low cytotoxicity 
(Table 12) and uptake rate (Figure 57B) of BNIPDSpm formulations on these cells. Our 
results provide evidence that BNIPDSpm delivery with HNPs is highly more efficient 
compared to the conventional anticancer drug gemcitabine. 
 
4.5. Conclusion 
 
This study shows the ability of BNIPDSpm novel formulations to accumulate and kill 
pancreatic cancer cells more effectively, compared to the free BNIPDSpm and 
conventional drug, gemcitabine. The HNPs as carriers showed negligible cytotoxic effect 
on pancreatic and microphage-like cells over the concentrations tested. The novel hybrid 
formulations (conjugated bisnaphthalamide derivatives to the surface of HNPs) were 
capable of increasing cytotoxic effect of free bisnaphthalmides in two pancreatic cancer 
cell lines (BxPC-3 and PANC-1). In vitro drug uptake study also validated that hybrid 
formulations internalise and accumulate inside pancreatic cancer cells significantly higher 
than free drugs. The data suggested that the presence of PEG enhances the property of the 
formulations to internalise inside the BxPC-3 and PANC-1 cells in an efficient way. 
Moreover, the presence of targeting peptide increased the cytotoxicity and uptake value of 
the hybrid formulations on pancreatic cancer cells. BNIPDSpm hybrid formulations 
possessed thermoresponsive drug release potentials in vitro. Further research has to be 
performed in vitro and in vivo to fully exploit the properties of these nanoparticles for 
image guided thermally triggered drug delivery. 
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Chapter Five 
General Conclusions 
and Future Work 
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5.1. General conclusion 
 
Hybrid iron oxide-gold core shell nanoparticles (HNPs) were successfully synthesised. The 
physiochemical properties of fabricated particles were characterised by different 
techniques. Powder x-ray diffraction (PXRD) analysis showed that the diffraction peaks of 
synthesised iron oxide nanoparticles are closely matched with the reference sample, 
indicating that our particles have a cubic crystal system with no specific impurities. The 
ratio of iron: gold within the formulation was around 4: 1, achieved by inductively coupled 
plasma-optical emission spectroscopy (ICP-OES). UV/Visible spectroscopy, photon 
correlation spectroscopy and zeta potential measurement confirmed the coating process of 
particles with polyethylenimine (PEI) and subsequently gold seeding and gold coating 
steps. HNPs were coated using thiolated poly (ethylene glycol) (PEG-thiol) to increase 
biocompatibility. The size of HNPs by transmission electron microscopy (TEM) was 
approximately 40 nm. These HNPs had fairly similar transverse relaxivities (r2) with 
previously clinically administered Feridex
®
, indicating the ability of synthesised HNPs to 
be used in MRI imaging. Iron oxide core of the HNPs was highly crystalline and 
magnetically ordered at room temperature analysed by superconducting quantum 
interference device (SQUID). These results suggest that the magnetic characteristics of 
HNPs after gold coating process are in agreement with clinical standards and therefore 
have the capacity to be used as contrast agents. These fabricated particles can also act as 
thermo-seeds due to the presence of gold, since upon laser irradiation for 60 s, HNPs 
showed a time and concentration dependant heating effect.  
 
Four different bisnaphthalamide derivatives conjugated to the surface of HNP and 
PEGylated HNP (HNP-PEG) with varied feeding concentrations. As a result, 24 different 
formulations were synthesised. The difference between these drugs was the number of 
amine groups presented in carbon chain (between naphthalmaide moieties) and  the 
presence of thiol group, started from bis(naphthalimido)-1,20-diaminoicosane (BNIDi) 
without any amine to bis(naphthalimido)-1,12-diaminododecane (BNIPd) with two amines, 
bis(naphthalimidopropyl)spermine (BNIPDSpm) with four amines and 
bis(naphthamimidopropyl)- 3,3`-(butane-1,4-diylbis(sulfanediyl))bis(propan-1-amine) 
(BNIPds) with two amines and two additional thiol groups. Our study aimed to investigate 
the potential of electrostatic interaction of drugs and HNPs (through cationic drug and 
negatively charged HNPs) as stimuli responsive systems for drug release.  
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The maximum loading concentration for all drugs was 5 mgmL
-1
 and higher initial feed 
concentrations were not investigated due to the lack of aqueous solubility of drug 
compounds over this concentration. Results from high performance liquid chromatography 
(HPLC) analysis, Fourier Transform Infrared Spectroscopy (FTIR) and fluorescence 
spectroscopy indicated that BNIDi (without any amine) could not conjugate to the surface 
of HNP and HNP-PEG at any feeding concentration (Figure 65A). Binding concentration 
of BNIPd was very low as this drug only possesses two amines in its structure 
(Figure 65B). BNIPDSpm with the highest number of amine (four amines) conjugated 
significantly more than other drugs into the particles (p < 0.05) (Figure 65C). Although 
BNIPds was able to conjugate by both electrostatic interactions (through two amines) and 
dative covalent bond (via two thiols) to the surface of HNP, it did not conjugate as much as 
BNIPDSpm (Figure 65D). It is proposed that a more rigid binding occurs with less 
flexibility, utilising greater surface area and hence leading to lower binding concentrations. 
Increased drug loading feed concentration of BNIPd and specially BNIPDSpm resulted in 
greater drug attachment onto the HNPs surface. However, the physicochemical properties 
of the drug in solution hindered further attachment. By increasing the loading 
concentration of BNIPds from 2.5 mgmL 
-1 
to 5 mgmL 
-1
 the binding concentration of this 
drug to the surface of HNPs did not change significantly (p > 0.05), indicating 
 
that  the 
particle surface was saturated and no more attachment was possible 
 
 
 
Figure 65. Schematic diagram illustrates conjugation ability of A) BNIDi, B) BNIPd, 
C) BNIPDSpm and D) BNIPds to the surface of HNP.   
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PEGylated formulations possessed comparable amount of drugs to unPEGylated 
formulations; however, slight increase in binding concentration of BNIPd and BNIPDSpm 
in PEGylated formulations was achieved. We assume that small quantities of drug 
molecules could have been physically trapped within the polymer framework. The 
presence of drugs in formulations was also proved by zeta potential measurement, FTIR 
and fluorescence spectroscopy. Following the lack of attachment of BNIDi into the surface 
of HNP and HNP-PEG, it was decided not to continue any further studies with these 
formulations.  
 
Stability studies of the formulations at room temperature (20 ºC) and 4 ºC (in aqueous 
environment and for freeze dried samples) were in agreement with the conjugation theory 
since BNIPd formulations with two amines presented very low stability. BNIPDSpm 
formulations also showed satisfying stability as over 80 % stability was achieved at both 
temperatures and forms (aqueous and freeze dried forms). BNIPds in conjugation by both 
covalent (via two thiols) and electrostatic (via two amines) bonds with HNP and HNP-PEG 
presented the highest stability over the period of four weeks.  Moreover, the stability of all 
formulations increased when samples were kept as a freeze dried powder at both 
temperatures, indicating that less drug detachment was occurred in the form of powder and 
liquid environment would increase the risk of drug release from the formulations.    
 
Drug release studies were in line with the conjugation theory (Figure 66). The data showed 
that the release of BNIPd from formulations in aqueous environment at 20 ºC was very 
quick due to the loose electrostatic interaction of the drug with HNPs. Around 90 % of 
BNIPd released from PEGylated and unPEGylated formulations within 4 h and 6 h, 
respectively. Release of BNIPDSpm from formulations in water showed biphasic patterns, 
which includes a sharp release in the first 10 h, following by a gradual release. Increasing 
the temperature had an impact on release of BNIPDSpm from formulations and the highest 
release rate occurred in 60 ºC, where around 78 % and 57 % of drug released from 
PEGylated and unPEGylated formulation within 72 h, respectively. Release of BNIPDSpm 
from PEGylated formulation was higher than unPEGylated formulation which might be 
due to the small amount of free drug being trapped inside the polymer chain. Release of 
BNIPds from the formulations in 60 ºC was almost zero which could be due to the robust 
interaction of the drug with gold at the surface of HNPs.  
178 
 
Release of BNIPDSpm from the formulations was also investigated in culturing medium. 
Drug release was performed at 37 ºC and 44 ºC with different pH; pH 7.5 as it was close to 
cytoplasm pH and pH 4.6 and 3.6, which were in the range of endosomal and lysosomal 
pH, respectively. Drug release in culturing media followed the same pattern; however, 
decreasing the pH of media and increasing the temperature (from 37 ºC to 44 ºC) enhanced 
the drug release rate. Results showed that BNIPDSpm released in culturing media from 
HNP-PEG significantly faster than unPEGylated formulation (p < 0.05).  
 
 
 
Figure 66. Diagram illustrates drug release pattern from A) BNIPd, B) BNIPDSpm and C) BNIPds 
formulations.  
Drug release rate in culturing media, in 37 ºC and 44 ºC, was important for this study. 
Because 44 ºC would be the obtained temperature of HNPs upon laser irradiation. 
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Therefore, by in vitro drug release investigations in culturing media (in body temperature 
and 44 ºC), the release pattern of the formulations inside the pancreatic cancer cells, before 
and after laser irradiation can be predicted. These novel formulations demonstrated pH and 
thermoresponsive drug delivery properties. Therefore, it is suggested that when HNPs were 
taken up by endosome and lysosome, the low environmental pH and increasing the 
temperature via laser irradiation, would lead to quick drug release from the particles. Then 
the free drug can enter cells` nucleus and interact with DNA for anticancer effect.   
Biological investigations of HNPs, bisnaphthalamide based drugs and their optimal 
formulations were performed on human primary pancreatic adenocarcinoma (BxPC-3), 
human epithelial-like pancreatic carcinoma (PANC-1) and human monocyte cell line, 
which possess macrophage like qualities after differentiation (U937). U937 cell line was 
applied in order to examine the cytotoxic effect of drugs and different formulations on 
immune cells. For cytotoxicity evaluation, MTT assay and trypan blue exclusion test were 
used. Fabricated HNPs incubated with BxPC-3, PANC-1 and U937 cells for 24 h, did not 
show apparent toxicity, indicating that these particles are not toxic as drug carriers. The 
cytotoxicity pattern of bisnaphthalamide derivatives was BNIPd > BNIPDSpm ≥ BNIPds. 
The high cytotoxicity of BNIPd might be associated with its chemical structure and 
number/ position of amine group (two lateral amines) that enables this drug to interact with 
the DNA of BxPC-3 cells more efficiently. The cytotoxicity results of hybrid formulations 
(in conjugation with bisnaphthalamide derivatives) on BxPC-3 cell line revealed 
significant reduction of cell viability after 24 h (compared with the free drugs), especially 
for PEGylated formulations. As an example, the cytotoxicity of BNIPDSpm-HNP and 
BNIPDSpm-HNP-PEG were 9-fold and 12-fold higher than the cytotoxicity of free drug, 
respectively. These findings confirm the high efficacy of hybrid formulations, compared to 
the drugs alone, which could be due to the higher uptake rate of the novel formulations by 
the cells. The cytotoxicity results from bisnaphthalamide derivatives and their hybrid 
formulations were compared with the conventional anticancer drug, gemcitabine. 
Interestingly, no IC50 achieved for BxPC-3, PANC-1 and differentiated U937 cells treating 
with gemcitabine within 24 h, which confirms that fabricated formulations were highly 
cytotoxic on pancreatic cancer cells, in comparison with gemcitabine. Although BNIPd, 
BNIPds and their formulations possessed potent anticancer effects, their physicochemical 
properties and potential use as a triggered system were lacking and the most suitable 
formulations regarding drug loading, stability and triggered drug release were the 
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BNIPDSpm formulations. Therefore, further cytotoxic studies were focused on 
BNIPDSpm formulations. The cytotoxicity of BNIPDSpm and its hybrid formulations on 
PANC-1 followed the same pattern. However, BNIPDSpm-HNP and 
BNIPDSpm-HNP-PEG were 8 times and 9 times more cytotoxic on BxPC-3 cells, 
respectively, in comparison with PANC-1 cells. The drug appeared to be more cytotoxic 
on U937, compared to hybrid formulations, indicating that conjugated BNIPDSpm cannot 
internalise into U937 cells as much as free drug. Free BNIPDSpm probably enter to the 
U937 cells through cell membrane pores/channels and nanoformulations are taken up by 
endocytosis. Therefore, slower proliferation of these cells, in comparison with BxPC-3 and 
PANC-1 cells resulted in reduced cytotoxic effect of conjugated drug, compared to free 
drug. 
 
Drug uptake study was investigated for bisnaphthalamide based drugs, their hybrid 
formulations and gemcitabine within 1 h and 4 h incubation time, which was drug 
concentration and time dependent. Hybrid formulations possessed significant higher drug 
uptake (p < 0.05), especially PEGylated formulations, on BxPC-3 cells, at all incubation 
concentrations and times. Gemcitabine showed the highest uptake rate in this group, but 
the cytotoxicity result from gemcitabine showed that this drug did not possess IC50 after 
24 h. This means that novel BNIPDSpm hybrid formulations are more efficient to kill 
pancreatic cancer cells, compared with gemcitabine. Due to the poor physicochemical 
properties and low uptake rate of BNIPd and BNIPds hybrid formulations after 4 h 
(compared with the BNIPDSpm formulations), it was decided not to continue any further 
biological experiments for these formulations. Cellular uptake pattern from PANC-1 cells 
were comparable to BxPC-3 cells. However, the uptake rate from BxPC-3 cells was around 
5 times higher than PANC-1 cells, which might be due to the differences in proliferation of 
these cells, volume of  the cells and/or binding sites for drugs per cell in pancreatic cancer 
cell lines. In U937 cell line, free BNIPDSpm was accumulated in cells more than hybrid 
formulations which showed again that hybrid formulations were not recognised by these 
cells as much as free drug. This could be due to the differences of uptake mechanisms for 
free drug and particles discussed before.  
 
A c(RGDfC) peptide as a targeting agent was successfully incorporated to 
BNIPDSpm-HNP-PEG with the goal of targeting integrin avβ3 (receptor for the 
extracellular matrix proteins with the exposed arginine-glycine-aspartic (RGD) tripeptide 
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sequence) to increase drug specific delivery and anticancer activity of the hybrid 
formulation. The cytotoxic effect of PEGylated formulation on all three cell lines increased 
upon the addition of targeting peptide but this enhanced cytotoxic effect was insignificant 
on BxPC-3 and PANC-1 cells (p > 0.05). It is postulated that this slight increase of 
cytotoxicity upon the conjugation of targeting peptide could be associated with the 2D in 
vitro cytotoxicity analysis and higher cytotoxic effect may be achieved by 3D in vitro 
culturing or in vivo analysis. Targeted formulation was taken up by all cell lines 
significantly higher than BNIPDSpm-HNP-PEG at all concentrations and incubation times 
(p < 0.05), which confirms that the presence of targeting peptide resulted in higher 
accumulation of drug in cells.   
 
In vitro thermoresponsive cytotoxicity test at different temperature was performed on 
BxPC-3, PANC-1 and U937 cell lines to investigate the heating effect on cytotoxicity of 
the formulations. This experiment was performed to mimic the particles` temperature 
increase upon the laser irradiation (up to 44 ºC). Our result showed that the viability of 
treated cells with hybrid formulations mostly decreased by increasing the temperature. This 
could be due to the higher amount of drug being released from the formulations in higher 
temperature. Moreover, the targeted formulation possessed comparable cytotoxic effect to 
BNIPDSpm-HNP-PEG at different temperatures.   
 
Control and treated cells with different drugs and formulations (all three cell lines), were 
imaged by atomic force microscopy (AFM), after 1 h and 4 h incubation. The results were 
in agreement with drug uptake results, confirming higher cytotoxic effect of hybrid 
formulations comparing with free BNIPDSpm, especially the PEGylated formulation and 
targeted formulation, on BxPC-3 and PANC-1 cells as these formulations changed the 
structure and morphology of the cells significantly, after 1 h and 4 h. Except cells treated 
with BNIPDSpm for 4 h, no significant changes in the morphology of U937 cells was 
observed upon the incubation with drug and hybrid formulations, which is in line with the 
low cytotoxicity and uptake rate of BNIPDSpm formulations from these cells. These 
results provide evidence that BNIPDSpm delivery with HNPs is highly more efficient 
compared to the conventional anticancer drug, gemcitabine. 
 
In conclusion, this is the first time novel HNPs, conjugated with bisnaphthalamaide 
derivatives, have been shown for pancreatic cancer therapy. BNIPDSpm novel 
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formulations possessed interesting potential to act as thermoresponsive drug carriers. The 
data suggested that the presence of PEG and RGD targeting peptide enhances the ability of 
the BNIPDSpm-HNP to act as biocompatible multimodal platforms with higher affinity to 
pancreatic cancer cells as an anticancer formulation.  
 
5.2. Future work 
 
The work describes the synthesis and evaluation of novel HNPs. These particles are 
designed such that they can produce heat on laser irradiation and load cytotoxic drugs to 
treat pancreatic cancer. Upon the gold coating of iron oxide core and incorporation of 
different bisnaphthalamide based drugs, multifunctional hybrid formulations have shown 
their superb application capability in diagnosis and therapeutics. Several hybrid 
nanoparticles have already exhibited promising application potential during clinical trials 
(Min et al. 2015). For example, functionalised iron oxide NPs such as dextran-coated iron 
oxide NPs (Sienna+
®
) for the detection of sentinel lymph nodes, aminosilane-coated iron 
oxide NPs (MFL AS1
®
) for hyperthermia therapy, and siloxane-coated iron oxide NPs 
(Ferumoxsil
®
) as efficient oral MRI contrast agents have presented clinical utility (Nguyen 
and Zhao, 2015). These encouraging results are driving the research field forward quickly. 
In view of the significant research efforts being dedicated to the field, it could be expected 
that humanity will greatly benefit from nanomedicine in the near future. 
Despite all of the advantages of NP-based systems discussed in this account, there is 
always room for further improvements in this field. For example, in this study, laser 
irradiation was only performed in agar gel and raw chicken breast. It would be beneficial to 
study the actual temperature increase in cells in vitro and in vivo. Determination of surface 
temperature upon laser irradiation by fluorescent markers would also be useful to achieve 
better understanding about the actual temperature changes. 
We investigated physiochemical and biological effect of four bisnaphthalamide derivatives 
in conjugation with HNPs. Further modification of the bisnapthalamide chain to increase 
drug loading capacity would be desirable. We performed a short term stability test 
(4 weeks) by storing liquid and freeze-dried preparations of the formulations. Long term 
stability testing of BNIPDSpm hybrid formulations in the future would be advantageous in 
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order to evaluate their potential as pharmaceutical formulations. More drug release studies 
involving laser irradiation at appropriate wavelength, i.e. closer wavelength to lambda max 
of HNP would also be beneficial. 
Further cytotoxicity test is required on normal pancreatic cell lines, in order to compare 
with our cytotoxicity results on pancreatic cancer cells. It would also be beneficial to 
perform further in vitro intracellular trafficking to analyse the mechanism of cellular 
uptake in pancreatic cancer cells and to visualise exactly where particles reside, which can 
be carried out by staining the organelles in the cell e.g. cell membrane, nucleus, 
mitochondria, etc. (Savic et al. 2003). It would also be desirable to utilise different 
inhibitors such as cytochalasin D (endocytosis inhibitor) or sodium azide (metabolic 
inhibitor) to verify the mechanism of cellular uptake and fate of the particles such as active 
transport, endocytosis or a different type of transport (Maysinger et al. 2007).  
It would be beneficial to image treated cells with fluorescent microscopy to show the 
accumulation of BNIPDSpm inside pancreatic cancer cells as the bisnaphthalamide 
derivatives are fluorescent chemicals. TEM imaging of accumulated particles inside the 
pancreatic cancer cells would also be desirable. Moreover, it may be valuable to repeat the 
AFM topography imaging of the formulations in cells, as the images could be improved 
upon.   
In vivo study is also required to inject the formulation into the pancreatic tumour and 
investigate reduced growth in xenograft mice over longer time periods to validate the 
potential of the novel formulation for pharmaceutical therapies. All these studies must be 
carried out with the aim of bringing the work forward before being considered for clinical 
investigation. 
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1.0. Standard calibration curves in ICP-OES analysis 
 
 
 
 
 
Figure 1. Standard calibration curve of A) Standard Iron and B) standard Gold, analysed by 
ICP-OES. 
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1.1. Histogram of frequency distribution (temperature increase by laser irradiation) 
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Figure 2. Histogram of frequency distribution of temperature increase for A) 50 µgmL-1 and 
B) 100 µgmL-1 of HNPs upon laser irradiation for 60 s at room temperature.  
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1.2. NMR spectra of bisnaphthalamide based drugs 
 
 
Figure 3. NMR spectrum of BNIDi.  
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 Figure 4. NMR spectrum of BNIPd.  
 
 
 
 
 
222 
 
 Figure 5. NMR spectrum of BNIPDSpm. 
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Figure 6. NMR spectrum of BNIPds. 
 
 
 
 
224 
 
1.3. Calibration graphs of bisnaphthalamide based drugs and gemcitabine 
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Figure 7.  Calibration graph of A) BNIDi, B) BNIPd, C) BNIPDSpm, D) BNIPd and 
E) Gemcitabine by RP-HPLC analysis detected at 394 nm and 234 nm Emission for 
bisnaphthalamide based drug and gemcitabine, respectively. Binaphthalamide derivatives were 
dissolved in DMSO/H2O (50:50 v/v) and gemcitabine was dissolved in water.  
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